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In 1981, the first cases of the acquired immunodeficiency syndrome (AIDS) were ob-
served in San Francisco, US1. At that time AIDS had not yet been recognized as a result of 
a viral infection. Two years later, it was found that a new retrovirus, now known as the 
human immunodeficiency virus (HIV), was the causative agent of AIDS2. 
Since the early 1980s, the pandemic of HIV has had an enormous impact. Until now, 
more than 30 million people have died from HIV/AIDS and currently 34 million people are 
estimated to be living with HIV3. The southern part of Africa is the region most severely 
affected, and it accounts for 68% of the global total living with HIV. In contrast to most 
other regions, where particular groups, such as men who have sex with men or injectable 
drug users, are most at risk, the epidemic in Sub-Saharan Africa has substantially affected 
women in the general population. Since the prevalence is high in women of reproductive 
age, transmission of HIV from mother to child (MTCT) is also common in the region. In 
2011, 330.000 children acquired HIV infection (90% due to MTCT) and more than 90% 
of those live in Sub-Saharan Africa3. 
The total number of people living with HIV still continues to rise, but the overall growth 
appears to have stabilized, as the number of people newly infected globally each year is 
continuing to fall and fewer people are dying from AIDS-related causes worldwide, since 
the introduction of combination antiretroviral therapy (cART). Despite the progress made 
in the fight against HIV/AIDS during the last decade, the HIV pandemic remains one of 
the most seri ous challenges to global health.
Prior to 1987, no antiretroviral drugs were available and therapy consisted of treating com-
plications from HIV/AIDS. Zidovudine was the first approved drug for HIV treatment and 
is still used in current regimens. However, it took almost 10 years before viral replication 
could be adequately suppressed. In 1996, the non-nucleoside reverse transcriptase inhibi-
tors (NNRTIs) and protease inhibitors (PIs) became available, resulting in major advances. 
Rather than monotherapy, more potent, so called combination ART, which consists of a 
combination of three or more antiretroviral drugs from at least two different classes, was 
introduced leading to a significant decrease of the AIDS mortality rates and a dramatic in-
crease in the life-expectancy of HIV-infected people4. HIV has become eventually more of a 
chronic disease rather than a fatal one – at least for those able to access drugs.
At present, six different classes containing a total of 24 drugs with varied mechanisms to 
inhibit HIV replication are approved by the Food and Drug Authorization (FDA) for HIV 
treatment. An overview of those is presented in Table 1.
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Table 1  Antiretroviral drugs in HIV treatment
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Unfortunately, ART is still not universally accessible. Since the turn of the millennium, a 
massive scale-up of access to ART in low-income countries, especially in Africa, has been 
realized with political commitments5-7 and extensive international financial support. To 
further scale-up access to ART in resource-limited countries, the Western approach of 
individualized patient care using advanced laboratory monitoring, such as viral load tes-
ting, resistance genotyping and routine high-technology therapeutic drug monitoring, 
and the full range of antiretroviral drugs, is not feasible8. In resource-limited settings, 
doctors are scarce, laboratory infrastructure is lacking and not all antiretroviral drugs are 
available. Therefore, the World Health Organisation’s (WHO) approach to rapid scale-up 
of universal ART access is a population-based strategy using standardized antiretroviral 
treatment protocols, such as simplified drug regimens and appropriate fixed-dose combi-
nation (FDC) drug formulations. 
Major gains have been achieved in scaling-up ART. By the end of 2011, 8 million HIV-in-
fected adults and children were taking cART, a 20-fold increase since 20033. For the first 
time the majority (54%) of people eligible for cART in low- and middle-income countries 
were receiving it. Despite these remarkable achievements, the global coverage for the 
most vulnerable population in need for ART is still low to moderately low; only 28% of 
children 0-14 years of age in need for ART and 50% of pregnant women and infant pairs 
in need of antiretroviral prophylaxis for the prevention of MTCT (pMTCT) are currently 
receiving the life-saving medicines3.
ART in the prevention of MTCT in Africa
Since 2010, HIV-infected pregnant women with CD4 counts ≤350 cells/mm3 or WHO 
stage 3 or 4 disease are recommended to start on combination therapy for life for their 
own health as well as for the prevention of infant HIV infection. 
For pregnant women with CD4 counts >350 cells/mm3, who do not require treatment 
according to current criteria, pMTCT guidelines recommend starting antiretroviral pro-
phylaxis early in preg nancy and the use of antiretroviral drugs by either the mother or 
child during the peripartum period. Since 2000, WHO recommended a simple, affordable 
and effective intervention of a single-dose of nevirapine at labour onset for pMTCT of 
HIV9. This has reduced MTCT by 40% and has saved thousands of babies from HIV infec-
tion. However, a major disadvantage is the development of nevirapine resistance in mo-
thers (1-69%) and infants10. Single-dose nevirapine alone is therefore no longer endorsed 
as a preferred option, but is recommended only as part of a longer prophylactic regimen 
(zidovudine pre-delivery, single-dose nevirapine and zidovudine/lamivudine at delivery, 
zidovudine/lamivudine for 7 days post-delivery). This (option A) and other more complex 
regimens (option B/B+) have been shown to be more effective in preventing MTCT with 
less occurrence of nevirapine resistance11. 
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It is estimated that 18-64% of women living in Sub-Saharan Africa with HIV are receiving 
cART for pMTCT, as now recommended by WHO (Option B+). The simple single-dose 
nevirapine at labour is a fading concept, but in practice it is still widely used by thousands 
of women in resource-limited settings, particularly in more rural areas where access to 
cART is more limited.
ART in children in resource-limited settings
Over the past years, uniform and simple first-line regimens, generally comprising two 
NRTIs and one NNRTI (nevirapine or efavirenz), have been developed for children in 
line with WHO’s population-based strategy for the scale-up of ART access in resource- 
limited settings12,13. Also access to second-line therapy, which includes two NRTIs and 
one ritonavir-boosted PI (lopinavir), has  been promoted. cART has become more and 
more available as generic inexpensive fixed-dose combination (FDC) formulations in 
low-income countries. However, many of these formulations have been developed for 
adults. Appropriate and affordable antiretroviral formulations for children are still lacking. 
Scarcity has restricted roll-out in resource-limited settings (that is why coverage is only 
28%), but a number of FDC tablets with dose ratios correct for children have and are 
being developed in order to simplify first- and second-line treatment and increase the 
number of children on cART14. Generic pharmaceutical manufacturing companies are 
leading many of these initiatives and trying to fill the gap in resources for the unmet 
need of ART in the paediatric population in Africa. 
The overall aim of this thesis was to optimize HIV treatment in HIV-infected pregnant 
women and children in Africa by studying clinical pharmacology of antiretroviral drugs in 
the most vulnerable populations in resource-limited settings.
The research objectives of this thesis were:
 To investigate simple, accessible and affordable strategies for the prevention and the 
 reduction of MTCT of HIV in Sub-Saharan Africa using enzyme inducers for the 
 elimination of nevirapine resistance after single-dose nevirapine as part of the anti- 
 retroviral prophylaxis for MTCT.
 To optimize paediatric antiretroviral regimens for the scale-up of HIV treatment in 
 resource-limited settings, where new appropriate antiretroviral drug formulations 
 were evaluated and newly developed WHO weight-band based dosing recommen- 
 dations were validated for the use in resource constraint settings.
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Clinical pharmacology emphasizes the pharmacokinetic and pharmacodynamics of drugs 
in humans. Pharmacokinetics describes the effect of the human body on the drug, which 
includes absorption, distribution, metabolism and excretion. Pharmacodynamics is the 
study of the relationship of drug concentration and effect on the human body. 
Part I: Clinical pharmacology studies in HIV-infected pregnant women
The first part of this thesis deals with clinical pharmacology studies in pregnant women 
using single-dose nevirapine as part of antiretroviral prophylaxis for pMTCT.  
Notably, single-dose nevirapine is still being used globally in pMTCT, with a risk of 1-76% 
of development resistance against nevirapine from just this single dose10. Development of 
nevirapine resistance is most likely due to its long elimination half-life (61 hours15), leading 
to several days to weeks of subtherapeutic plasma concentrations, coupled with its low 
genetic barrier to resistance. Newly emergent resistant HIV may be transmitted to the 
infant or to others, limiting their treatment options, and may also reduce future combina- 
tion antiretroviral therapy (cART) efficacy in the mother16. Chapter 2 of this thesis includes 
a systematic review of data on the different interventions, which have been investigated 
until now, for reducing nevirapine resistance. Most interventions are antiretroviral-based, 
but a totally different approach is a pharmacological strategy of adding a CYP3A4 enzyme 
inducer to the single-dose of nevirapine. Nevirapine is extensively metabolized in the 
liver by cytochrome P450 (CYP) isoenzymes 3A4 and 2B617 and other drugs which affect 
these enzymes have been shown to decrease nevirapine elimination half-life in healthy 
women18, with greatest reductions from carbamazepine and phenytoin. In this thesis a 
clinical trial investigating the effect of a single-dose of carbamazepine (Chapter 3; VITA-1 
trial) and a pilot study investigating the effect of seven days phenytoin (Chapter 4; VITA-2 
trial) on nevirapine pharmacokinetics and the development of nevirapine resistance in 
HIV-infected pregnant women in Tanzania and Zambia are presented.
Part II: Clinical pharmacology studies in HIV-infected children
The second part of this thesis focuses on the clinical pharmacology of cART in HIV- 
infected children in Africa. Adequate drug exposure is essential in HIV treatment of 
children, who generally start treatment earlier and will need to take it for far longer than 
adults: it is therefore a major goal in the development of appropriate paediatric FDCs. 
However, obtaining optimal drug exposure in children is challenging, as they cannot 
simply be regarded as small adults19. Pharmacokinetics of antiretroviral drugs are highly 
variable in the paediatric population as children mature and grow rapidly20. In an open 
randomized trial, called CHAPAS-1 (Children with HIV in Africa-Pharmacokinetics and 
Adherence of Simple antiretroviral regimens), appropriate dosing of FDC tablets, approved 
based on early pharmacokinetic data generated within the trial, was assessed. The 
tablets have higher nevirapine to lamivudine/stavudine dose ratio compared to adults 
FDCs. It is known that children, particularly the youngest, metabolize nevirapine more 
rapidly than adults21, 22. Chapter 5 (substudy of CHAPAS-1) reports the exposure to nevira- 
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pine in African, HIV-infected infants weighing 3-6 kg taking these paediatric FDC 
tablets. WHO guidelines recommend nevirapine dose escalation (half dose for the first 14 
days) when initiating ART to avoid toxicity from high initial nevirapine levels. Since young 
children metabolize nevirapine more rapidly, there is the potential for inadequate 
nevirapine plasma levels during dose escalation, which could result in slower viral load 
suppression or increased risk of later virological failure. In the subsequent chapter 
(Chapter 6; also a substudy of CHAPAS-1) the pharmacokinetics of nevirapine at 
week 2 after nevirapine initiation with and without dose escalation strategy was 
evaluated in Zambian HIV-infected infants/children and its relationship with safety and 
efficacy was assessed.
Furthermore, paediatric dosing has not only been standardized with FDC formulations, but 
also by using simplified weight-bands based dosing recommendations. However, these 
have typically been determined using extrapolation from licensed mg/kg or mg/m2 doses, 
and require validation for optimal HIV treatment. Chapter 7 describes actual efavirenz 
plasma exposure in children treated following the 2006 efavirenz weight-band based 
dosing recommendations of WHO using full pharmacokinetic information. This was a 
substudy of the ARROW trial, an open-label randomized trial comparing routine labo-
ratory (toxicity, CD4) versus clinically driven monitoring strategies, and also comparing 
three different first-line ART strategies in HIV-infected infants and children in Uganda and 
Zimbabwe (www.arrowtrial.org)23.
There are numerous factors which may lead to interindividual variability in pharma-
cokinetics, such as gender, age, body weight, non-compliance, and genetic factors24, 
25. Chapter 8 evaluates mid-dosing interval efavirenz plasma concentrations and the 
influence of CYP2B6 polymorphisms in relation to efficacy, tolerability, and adherence in 
Rwandan HIV-infected children.
In Chapter 9 (again a pharmacokinetic substudy of ARROW) we evaluated a different 
weight-band based dosing recommendation from WHO, for twice-daily zidovudine, 
which has not been studied before, to investigate whether this provides optimal exposure 
in Ugandan, HIV-infected children.
The final chapter before the General Discussion expands on the scale-up of second- 
line ART access. ART formulations suitable for children should ideally be pleasant- 
tasting, with no food restrictions, be heat-stable and require administration no more 
than twice-daily. The present accessible antiretroviral drug for second-line in resource-
limited settings is ritonavir-boosted lopinavir. This drug is currently only available as syrup, 
which tastes bad, requires a stable cold chain and has a relatively short shelf-life, or as 
tablets, which are very hard, relatively large, unscored and cannot be cut into pieces 
(as this significantly reduces bioavailability). tablets cannot typically therefore be taken 
by children younger than 5-6 years old – in contrast to many of the FDCs discussed 
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above which can be taken by young children, and are generally preferred by carers26. A 
randomised pharmacokinetic bio-equivalence phase Ib trial (CHAPAS-2) was designed 
(Chapter 10) to assess the pharmacokinetics and acceptability of ritonavir-boosted 
lopinavir in sprinkle and tablet formulations for treatment of HIV infected children in Africa.
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Objectives 
To assess the effectiveness of different drug interventions to prevent nevirapine 
resistance development after use of single-dose nevirapine as part of antiretroviral 
prophylaxis for prevention of HIV mother-to-child transmission (pMTCT).
Design
A systematic review including meta-analyses.
Methods
Systematic search of electronic databases (MEDLINE, EMBASE and Cochrane) was 
performed. Studies included HIV-infected, pregnant women, who were adminis- 
tered single-dose nevirapine for pMTCT and who were receiving a drug intervention 
to reduce nevirapine resistance. Primary outcome was the proportion of nevirapine 
resistance detected in plasma samples collected ≤3 months postpartum. The reducing 
effect of drug interventions on nevirapine resistance was assessed in meta-analyses 
using random effects models and the GRADE approach for quality of evidence.
Results
In a total of 18 eligible studies included, the estimated pooled proportion for the 
detection of nevirapine resistance mutations upon single-dose nevirapine at labor 
was 31% (95% CI 7.6-54); this was reduced to 21% (95% CI 8.6-33) with addition 
of antepartum zidovudine. A combination of antepartum zidovudine, single-dose 
nevirapine and a short (<8 days) postpartum regimen resulted in a major reduction 
in the emergence of nevirapine resistance conferring mutations to 0.011% (95% CI 
-0.11-0.13). The summary effect of 20-30 days of postpartum drug regimens com-
bined with antepartum zidovudine and single-dose nevirapine was associated not 
different with a 0.003% (95% CI -0.054-0.060) incidence of nevirapine resistance 
conferring mutations. 
Conclusions 
Addition of antepartum zidovudine plus antiretroviral drugs postpartum to single-
dose nevirapine for pMTCT has shown to nearly eliminate the emergence muta-
tions associated with reduced susceptibility to nevirapine. The effect of longer (20-30 
days) post partum regimens was similar compared with a short (<8 days) postpartum 
regimen. The WHO guideline option A (antepartum zidovudine, single-dose nevira-
pine and one week of lamivudine/zidovudine postpartum) seems to be a rational 
approach to  effectively reduce the risk of emerging nevirapine resistance in regions 
where single-dose nevirapine is still being used.
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Without antiretroviral drugs, the overall cumulative risk of mother-to-child transmission 
(MTCT) of HIV-1 is 30-45% in the breastfeeding population1. Nearly half of the risk of 
MTCT occurs around the time of delivery1 and hence, it has become a major focus in the 
prevention of MTCT (pMTCT). In 2000, a single-dose of nevirapine administered to the 
mother at onset of labor was introduced as a simple and affordable strategy for prevention 
of perinatal HIV transmission in resource-limited settings. It reduces MTCT by ~50% and 
has benefited thousands of babies.
A major disadvantage of single-dose nevirapine is the rapid emergence of mutations in 
the HIV-1 reverse transcriptase gene (RT) that confer reduced susceptibility to nevirapine. 
These mutations may be selected in both the mothers and the infants2. A major factor 
contribution to the rapid selection of these variants is the long elimination half-life of nevi- 
rapine (61 hours3) resulting in several days to weeks of subtherapeutic nevirapine plasma 
concentrations4. Secondly, the genetic barrier to resistance for nevirapine is considered to 
be low, which means that only one or two mutations in HIV-1 RT are sufficient to render 
the virus resistant to antiviral treatment with nevirapine. HIV-1 variants harbouring nevi-
rapine resistance mutations may be transmitted to the infant or to other individuals, limi-
ting their future treatment options. It may also reduce efficacy in the mother with future 
combination antiretroviral therapy (cART) containing non-nucleoside reverse transcriptase 
in-hibitors, such as nevirapine5. In a previous meta-analysis, published in 2007, the pre-
valence of nevirapine resistance mutations upon a single-dose nevirapine at labour onset 
with or without antepartum antiretroviral drugs was estimated to be 36% between four 
to eight weeks postpartum2. Given that since then more effective options have become 
available, this simple and single time point intervention has faded from current state of the 
ART clinical practice in developed countries, but single-dose nevirapine in the absence of 
additional antiretroviral agents is still widely administered to thousands of women in re-
source-constrained settings, particularly in more rural areas where access to cART is limited. 
In order to reduce the emergence of nevirapine resistance, co-interventions, such as short-
course antiretroviral regimens in combination with single-dose nevirapine, have been 
evaluated. Addition of a short (4-7 days) postpartum course of lamivudine/zidovudine 
to single-dose nevirapine and antepartum zidovudine reduced viral resistance mutations 
tremendously6 and is currently recommended by WHO (Option A) for situations where 
long-term cART (WHO Option B/B+7, 8) is not available or unfeasible. Many other ap- 
proaches, such as extension of the duration of the abovementioned course or the use 
of other drugs, have been studied since the introduction of single-dose nevirapine. Until 
now, evaluation studies on the efficacy of  co-interventions to reduce the emergence of 
nevirapine drug resistance mutations (DRMs) has not yet been conducted. We therefore 
performed a systematic review and meta-analyses to assess the effect of different drug 
interventions and duration, on nevirapine resistance development after use of a single-
dose nevirapine as part of antiretroviral prophylaxis for pMTCT. 
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Search strategy
A literature search was performed in the MEDLINE database, the Cochrane Library and 
the EMBASE database until March 20, 2013. Combinations of the following free key-
words and medical subject heading terms and variations on these words were used in the 
search strategy: ‘pregnancy’, ‘prevention-of-mother-to-child-transmission’, ‘nevirapine’, 
‘viral drug resistance’ (detailed search strategy can be found in Supplementary Materials 
S1). For additional studies, the ISI Web of Knowledge citation index and the reference lists 
of included studies were searched.
Inclusion criteria
Titles and abstracts of all included studies identified by the search strategy were indepen-
dently screened for eligibility by two reviewers (QF, BB). Subsequently, a second screening 
session by two reviewers (QF, BB) was assessed on full texts of the primarily eligible 
studies. Discrepancies were resolved by consensus. Studies were eligible for inclusion if 
they met the following selection criteria: HIV-infected pregnant women, who received 
a single-dose of nevirapine for pMTCT were enrolled; a drug intervention aiming at re-
ducing nevirapine resistance development and resistance incidence was determined <3 
months after intake of single-dose nevirapine. No design, place or language restrictions 
were set, but full-text publications were required to be available. Conference abstracts 
were excluded.
Data extraction
Data for each study were extracted by a single author (QF) on: authors’ name, title, jour-
nal, year of publication, inclusion criteria, study location, study design, study population, 
study intervention, time of genotypic assessment after intake of single-dose nevira- 
pine and type of genotypic assessment (consensus or sensitive), number of samples with 
nevirapine resistance as per intervention arm, total number of measured samples as per 
intervention arm. Data duplicated in different papers were only extracted once. A second 
reviewer (BB) randomly checked the data extraction sheet on appropriate data entry by 
the first reviewer (QF).
Primary and secondary outcomes
The primary outcome of interest was the proportion of nevirapine resistant viral muta-
tions (primary nevirapine mutations L100I, K101P, K103N/S, V106A/M, V108I, Y181C/I, 
Y188C/L/H, G190A9) per drug intervention detected in plasma samples collected <3 
months postpartum using population sequencing).
Secondary outcomes were: 1) the effect of adding antepartum zidovudine on the pro-
portion of nevirapine resistant viral mutations after single-dose nevirapine alone, 2) the 
effect of adding antepartum zidovudine on the reducing effect of postpartum interventions 
to reduce nevirapine resistance after single-dose nevirapine, 3) the effect of short-course 
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postpartum interventions on the proportion of nevirapine resistance after single-dose 
nevirapine, 4) the effect of the duration of postpartum interventions on the proportion of 
resistance after single-dose nevirapine, measured using population sequencing. 
Data analysis
The effect of drug interventions on the reduction of nevirapine resistance was assessed 
in a meta-analysis using random effects models. The proportion of nevirapine resistance 
and its 95% confidence interval (CI) of each eligible study arm was graphically presented 
in a forest plot. The summary effect per type of intervention to the development of nevira- 
pine resistance and its 95% CI were calculated using Microsoft Excel (Microsoft, 2007. 
Computer Software; Redmond, Washington10). The presence of statistically significant 
heterogeneity among studies was assessed by Q (significant when p-value <0.05) and 
the extent of the observed heterogeneity was assessed by I2 (ranging from 0-100%)11. 
Quality of evidence
The GRADE approach was used as a transparent and structured system of rating 
quality of evidence of research questions and grading strength of recommendations 
in our systematic review. The quality of evidence was considered high (three points), 
moderate (two points), low (one point) or very low (no points) based on five predefined 
GRADE criteria12-16, including risk of bias, inconsistency, imprecision, indirectness and 
publication bias. An overview of the five predefined GRADE criteria and the system used 
to establish rating of the quality of evidence for these criteria are shown in Table 1. For 
each outcome measure, all criteria were scored independently by two reviewers (QF and 
BB). Discrepancies were resolved by consensus. 
For quality assessment of randomised clinical trials (RCTs) the guidelines for systematic 
reviews of the Cochrane Collaboration Back Review Group were used17, 18. The criteria 
according to the STROBE guidelines were used to assess the quality of observational 
studies (Table 2)12-16, 19, 20. The initial quality of evidence for RCTs was considered as high 
(i.e. 3 points) and for observational studies as low (i.e. 1 point)21.
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TABLE 1  Schematic overview for scoring GRADE criterions per outcome measure
G
R
A
D
E-
cr
it
er
io
n
Method Quality indicator
Cut off quality 
indicator for each 
individual study
Score 
R
is
k 
o
f 
b
ia
s Quality 
assessment 
of individual 
studies (Table 2):
Inappropriate selection 
of groups
Failure to control for 
confounding (obser-
vational studies only)
Selective outcome 
reporting
Lack of blinding (RCTs only)
High loss to follow up
Lack of allocation 
concealment (RCTs only)
Intention-to-treat principle 
violated (RCTs only)
-1: >75% of the 
prioritized items 
are not adequately 
described and 
>50% of the non-
prioritized items 
are not adequately 
described 
(Table 2)
-1: >50% of the 
study participants has 
scored -1
In
-
co
n
si
st
en
cy Forest plot Extent of CI overlap -1: p<0.05 (and CIs of 
the different studies 
have little or no 
overlap)
Test for 
heterogeneity (Q)
 P-value 
Im
p
re
ci
si
o
n
Quality assess-
ment of indivi-
dual studies 
(Table 2)
Description of power 
analysis
-1: no power analysis 
described
-1: no power ana-lysis 
described in >25% of 
the study participants 
or >50% of study 
participants in studies 
with a non-acceptable 
drop-out rate (i.e. 
>30%) or if upper/
lower range of the CI 
of any study represents 
the risk difference
Forest plot
Drop-out rate
-1: non-acceptable 
drop-out rate (i.e. 
>30%)
Width of CI
In
d
ir
ec
tn
es
s
Quality 
assessment 
individual 
studies (Table 2)
Description of setting, 
patient selection, 
outcome measures
-1: >50% of the 
scoring items are not 
adequately described
-1: majority of study 
participants is a 
‘between’ studies 
comparison (and 
<50% of the scoring 
items are adequately 
described)
Comparison 
within or 
between studies
Comparison within or 
between studies
Pu
b
lic
at
io
n
 b
ia
s Quality 
assessment 
individual 
studies (Table 2)
Funding
-1: Industry 
sponsoring described 
-1: >75% of studies 
sponsored and/or
(if ≥5 studies) 
asymmetrical 
distribution of funnel 
plot 
Funnel plot Symmetry of the plot
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TABLE 2  Schematic overview for scoring GRADE criterions per outcome measure
Item quality assessment GRADE criterion
Study type
RCT
Observational 
study
Setting/generalizability Indirectness + + 
Patient selection
Eligibility criteria specified Indirectness + +
Methods of inclusion/selection Risk of bias + +
Treatment allocation and concealment Risk of bias + -
Matched controls, matching criteria Risk of bias - +
Similarity of groups at baseline Risk of bias + +
Potential confounders Risk of bias - +
Report number of individuals at each stage 
of study Risk of bias + +
Reasons for non-participation Risk of bias + +
Intervention
Explicit description of exposure Indirectness + +
Blinding of care provider Risk of bias + -
Avoidance of co-interventions Risk of bias, indirectness + +
Define effect modifiers Risk of bias - +
Acceptable compliance Risk of bias + +
Blinding of patient Risk of bias + -
Outcome measurement
Blinding of outcome assessor Risk of bias + -
Relevance of outcome measures Indirectness + +
Description of adverse effects Risk of bias + +
Description of withdrawal/drop-out rate Risk of bias + +
Acceptable drop-out rate Risk of bias + +
Timing follow-up measurement correct Indirectness + +
Timing of outcome measurement in both 
groups comparable
Indirectness + +
Statistics 
Power analysis Imprecision + +
Intention-to-treat analysis included Risk of bias + -
Presentation of point estimated and 
measures of variability
Imprecision + +
Loss to follow up Risk of bias + +
Sensitivity analysis Risk of bias - +
Effort to address potential sources of bias Risk of bias - +
Funding Publication bias + +
Note 1: ‘+’ item is required to be scored for the type of study, ‘-‘ item is not applicable for type of study.  
Note 2: Bold values are the prioritized items for the quality assessment of GRADE criteria (Table 1).
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Database Search
Embase, Medline and Cochrane Library
Citations identified
n=823
(n=242 (Medline) + n=485 (Embase) + n=96 
(Cochrane)) 
Duplicates: n=249
Excluded: n=501
Excluded: n=51
n=1 no full text available
n=4 congress presentation
n=11 no single-dose nevirapine
n=31 no intervention (or not clear)
n=4 >3 months/ no resistance 
measured
Excluded: n=4
n=4 duplicated data
Review of titles and abstracts
n=574
Review of full texts
n=73
Review for duplicated data
n=22
Included in Systematic Review
n=18
n=0 NVP resistance with consensus strategy 
n=7 NVP resistance with sensitive strategy
n=1 NVP resistance with both consensus and 
sensitive strategy
FIGURE 1  Flow chart of literature search and selection procedure
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Literature search
Through our literature search strategy 823 articles were identified. Two-hundred and 
forty-nine duplicates were removed. Based on the inclusion and exclusion criteria a total 
of 556 (501+51+4) studies were excluded resulting in 18 eligible studies for our systematic 
review (Flowchart, see Figure 1). Nine were RCTs, one was a random subset of an RCT and 
eight were observational studies. 
One study presented nevirapine resistance data measured both by a population sequen-
cing based drug resistance mutation detection assay and by more sensitive drug geno-
typic techniques. Eleven (24 study arms) of the 18 studies contained nevirapine resistance 
data measured by a population sequencing based drug resistance mutation detection 
assay and eight (18 study arms) by more sensitive drug genotypic techniques. Eleven 
studies were conducted in Sub-Saharan Africa, one in West Africa, four in Asia and two 
studies had sites in both Asia and Africa. Of the 18 included studies, five had one eligible 
arm, seven studies had two, three studies had three, two had four eligible arms and one 
study had six eligible arms available for analysis. In total, 3,726 patients from 42 study 
arms were included in our analyses (Table 3).
Effect of antepartum zidovudine
Since only studies with a drug intervention aiming at reducing nevirapine resistance were 
included in our systematic review, no more than three study arms provided a single- 
dose nevirapine alone. The summary proportion of the emergence of nevirapine resistance 
mutations was 31% (95% CI: 7.6-54); Figure 2), but statistically significant heterogeneity 
was observed between these three study arms (p<0.005, I²=88%). 
1,218 HIV-infected pregnant women from 11 different study arms (six population and 
five sensitive sequencing) were on antepartum zidovudine from 28-36 weeks of gestation 
combined with single-dose nevirapine at delivery. Hundred sixty-seven of 698 women 
(summary effect 21% (95% CI: 8.6-33)) had nevirapine resistance mutations (Figure 2) 
measured by population genotypic assessments. However, also here a significant differen-
ce (p<0.005, I²=97%) was found on the effect of antepartum zidovudine on nevirapine 
resistance. Hence, antepartum zidovudine combined with a single-dose of nevirapine 
shows a relative decrease of 32% in the proportion of nevirapine resistance compared 
to single-dose nevirapine alone. The quality of evidence for this research question was, 
however, very low (0 points in the GRADE range of 0-3).
Effect of antepartum zidovudine on the effect of postpartum interventions
In total, there were eleven short-course interventions postpartum, including two 
single-dose drug interventions; four were without antepartum zidovudine and seven inter- 
ventions were with the addition of antepartum zidovudine (Figure 2). Evaluating the 
effect of antepartum zidovudine on nevirapine resistance, five study arms were selected 
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with the same postpartum interventions: three intervention arms without antepartum 
zidovudine and two with antepartum zidovudine as part of their pMTCT prophylaxis. 
All women in these selected study arms received a short (<8 days) postpartum course of 
lamivudine/zidovudine. The summary effect of the proportion of nevirapine resistance 
without antepartum zidovudine was 11% (95% CI: 5.5-17). However, the effect of no 
antepartum zidovudine on nevirapine resistance differed between these three studies 
(p<0.005, I²=75%). The effect summary of the proportion of nevirapine resistance of the 
two studies using antepartum zidovudine was 1.2% (95% CI: -0.48-2.9) with no clear 
statistical presence of heterogeneity (p>0.05, I²=0%). Therefore, antepartum zidovudine 
shows a ten times lower prevalence of nevirapine resistance compared to postpartum 
interventions where antepartum zidovudine was not provided. However, quality of 
evidence for this question was low (1 point in the GRADE range of 0-3).
Effects of short-course postpartum drug interventions 
The effectiveness of three different short (<8 days) postpartum drug interventions on 
the occurrence of nevirapine resistance mutations was tested in women who received 
single-dose of nevirapine combined with antepartum zidovudine (Figure 2 and 3). Three 
of the six study arms used emtricitabine/tenofovir for 7 days, one used 7 days of ritonavir- 
boosted lopinavir and two arms used lamivudine/zidovudine either 3 or 7 days. The 
overall estimated proportion of nevirapine resistance in patients who received a short 
postpartum drug intervention using the random effects model was 0.011% (95% CI: 
-0.11-0.13) with no significant difference (p>0.05, I²=0%) between the five studies, 
although the GRADE score for quality of evidence for these studies was very low (0 points 
in the range of 0-3). This shows a >2800 times lower incidence compared to women 
receiving a single-dose nevirapine alone.
Duration of long-course postpartum drug interventions
In four study arms postpartum drugs were provided for a longer time period (Figure 2 
and 3): one study arm provided 21 days of lamivudine/zidovudine, or ritonavir/boosted 
lopinavir, or tenofovir/emtricitabine and one study provided didanosine/zidovudine to 
the women for 30 days. The estimated pooled proportion of nevirapine resistance was 
0.0030% (95% CI: -0.054-0.060) with no clear evidence (p>0.05, I²=0%) that these four 
studies differed. Comparing these data to short postpartum drug interventions (0.011%), 
nevirapine resistance of longer postpartum drug regimen appeared to be slightly 
lower with moderate quality of evidence (2 points in the GRADE range of 0-3). Ritonavir- 
boosted lopinavir appeared to be less effective, since it has shown higher nevirapine 
resistance upon both short and long postpartum courses compared to other regimens, 
but this could not be statistically confirmed.
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FIGURE 2  Forest plot of nevirapine resistance in each intervention arm
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FIGURE 3  Forest plot of nevirapine resistance in short and long postpartum antiretroviral
  strategies
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The present systematic review shows that the summary effect of nevirapine resistance 
through postpartum drug regimens combined with antepartum zidovudine and intra-
partum nevirapine has been estimated to be <1%. A postpartum regimen of 20-30 days 
might be slightly more effective compared to a short (<8 days) postpartum regimen with 
a prevalence of nevirapine resistance of 0.003% versus 0.011%, respectively.
Nevirapine resistance was estimated to be 31% after single-dose exposure of nevirapine 
alone. However, the number of study arms for this pooled estimate was small, as we 
included only studies containing drug interventions to reduce nevirapine resistance after 
single-dose exposure in our systematic review. Nevirapine resistance of single-dose nevira- 
pine combined with antepartum zidovudine was ~30% lower at 21% compared to the 
incidence in women receiving single-dose nevirapine alone. Despite small numbers, these 
values are consistent with previous studies showing 20-69% nevirapine resistance and 
an estimated pooled value of 36% in mothers exposed to single-dose with or without 
antepartum zidovudine2, 22-27. Addition of only a seven-day course of antiretroviral drugs 
to antepartum zidovudine and single-dose of nevirapine has shown an extensive effect 
in decreasing nevirapine resistance from 21% to 0.011%, probably due to the effect in 
suppressing viral replication of the seven-day postpartum antiretroviral course. Almost all 
strategies evaluated in this systematic review were supplemental postpartum anti-retroviral 
therapies intending to suppress viral replication until nevirapine concentrations are no longer 
sufficient to select for resistant strains, since the lengthy duration of low and sub- 
therapeutic levels of nevirapine in blood are plausibly associated with increases in nevirapine 
resistance. The estimated pooled effect was nearly 0% and most effective by protecting the 
subtherapeutic nevirapine ‘tail’ when single-dose nevirapine was combined with antepartum 
zidovudine and a long course postpartum regimen. This is consistent with the findings of 
McMahon et al evaluating long versus short course antiretroviral strategies. Noteworthy, their 
findings showed that 21-day regimens were significantly better than seven-day regimens28.
The estimated pooled effects in many of the evaluated interventions of our systematic review 
have shown high heterogeneity. An important reason for this could be a difference in base-
line plasma HIV-1 RNA viral load. Previous studies have shown that higher baseline plasma 
HIV-1 RNA viral load was associated with increase in the proportion of nevirapine resistance2, 
29, probably due to higher level of viral replication when single-dose nevirapine is used.
A limitation in our systematic review is that the number of studies was small, especially 
for the quantification of effect summaries, but our data were consistent compared with 
previous reviews1, 2. We also did not statistically assess potential sources of between-
study heterogeneity. Variability between studies was high and factors of heterogeneity 
have been evaluated in an earlier study2. A strength of our study was our validated 
analysis using the GRADE approach to determine the quality of evidence, which was 
generally low, at evaluating our research questions.
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Simple and standardized pMTCT regimens (Option B/B+) need widespread implemen-
tation in resource limited settings. Due to the challenges in the scale-up of pMTCT 
programs, thousands of women are still using a single-dose nevirapine alone in pMTCT 
of HIV30. Ideally, based on our findings, each HIV-infected pregnant woman living in a 
resource-limited region on single-dose nevirapine at labor onset should combine this 
with antepartum zidovudine plus a postpartum antiretroviral strategy of preferably two 
nucleoside reverse transcriptase inhibitors, which have shown to nearly eliminate nevira-
pine resistance. A major disadvantage of these long-course drug regimens, however, 
is its complexity and consequently risk to non-adherence, but also the emergence of 
lamivudine resistance (due to long intracellular elimination half-life), which is associated 
with virological and clinical failure in women starting lamivudine-containing cART for 
their own health31, 32. The use of shorter postpartum regimens (WHO option A8) will 
therefore still be advocated, but might need to be intensified by adding other drugs 
to achieve the maximal effect on preventing the emergence of nevirapine resistance 
(i.e. elimination). A single-dose33 or a seven-day course of an enzyme inducer34 at labour 
onset might have significant additional benefits in reducing selection of nevirapine resis-
tance mutations, even on top of the current antiretroviral prophylaxis “tail”. These and 
other regimens need urgent evaluation. 
Our findings have shown that the optimal management to nearly eliminate nevirapine 
resistance after single-dose exposure for pMTCT is the addition of antepartum zidovudine 
plus a 20-30 days course of antiretroviral drugs postpartum, while a seven-day postpartum 
course already have shown a low prevalence of nevirapine resistance <1%. Given its com-
plexity and the current challenge in the scale-up of pMTCT programs, the WHO guideline 
of option A should be followed to reach the overarching goal of the WHO to strongly 
reduce or eliminate MTCT. Intensification of the current postpartum courses or alternative 
regimens need to be evaluated to achieve the best feasible minimum risk of nevirapine 
resistance to emerge in regions where single-dose nevirapine is still being used.
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Search strategies for the MEDLINE (PubMed) database, the Embase database and the 
Cochrane library:
Search strategy for the MEDLINE (PubMed) database:
("Pregnancy"[Mesh] OR "Pregnant Women"[Mesh] OR pregnancy[tiab] OR pregnant[tiab] 
OR labor[tiab] OR labour[tiab] OR intrapartum[tiab] OR delivery[tiab] OR "Infectious 
Disease Transmission, Vertical"[Mesh] OR Vertical Infectious Disease Transmission[tiab] OR 
Vertical Infection Transmission[tiab] OR Vertical Transmission of Infectious Disease[tiab] OR 
Maternal-Fetal Infection Transmission[tiab] OR Maternal Fetal Infection Transmission[tiab] 
OR mother-to-child transmission[tiab] OR mother-to-child-transmission[tiab] OR 
PMTCT[tiab] OR mtct[tiab] OR Mother To Child Transmission[tiab] OR prevention-of-
mother-to-child-transmission[tiab]) AND ("Nevirapine"[Mesh] OR Nevirapine[tiab] OR 
viramune[tiab] OR nvp[tiab] OR sdnvp[tiab]) AND ("Drug Resistance, Viral"[Mesh] OR 
Resistance[tiab] OR resistant[tiab])
Search strategy for the Embase database:
exp pregnancy/ or labor onset/ or labor onset/or (pregnancy or pregnant or labor or 
labour or intrapartum).ti,ab. or delivery.ti,ab. Or exp vertical transmission/or(Vertical 
Infectious Disease Transmission or Vertical Infection Transmission or Vertical Transmission 
of Infectious Disease or Maternal-Fetal Infection Transmission or Maternal Fetal Infection 
Transmission or mother-to-child transmission or mother-to-child-transmission or PMTCT 
or mtct or Mother To Child Transmission or prevention-of-mother-to-child-transmission).
ti,ab. Or vertical transmission.ti,ab. And exp nevirapine/ or (Nevirapine or viramune or nvp 
or sdnvp).ti,ab. And exp antiviral resistance/ resistance.ti,ab. resistant.ti,ab.
Search strategy for the Cochrane library:
MeSH descriptor: [Nevirapine] explode all trees or nevirapine or viramune:ti,ab,kw (Word 
variations have been searched) NVP:ti,ab,kw (Word variations have been searched) 
or sdnvp:ti,ab,kw (Word variations have been searched) and  MeSH descriptor: [Drug 
Resistance, Viral] explode all trees or resistance or resistant:ti,ab,kw (Word variations have 
been searched)
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Background
WHO guidelines recommend zidovudine+lamivudine for seven days from labor 
onset in HIV-infected women receiving single-dose nevirapine to cover prolonged 
subtherapeutic nevirapine concentrations. Although effective, this is complicated 
and does not eliminate resistance; alternative strategies could add benefit.
Methods
Antiretroviral-naive, HIV-infected, pregnant women aged 18-40 years, with CD4 
>200 cells/mm3, able to regularly attend the antenatal clinics in Moshi, Tanzania 
were enrolled 1:1 by alternate allocation to receive 200 mg single-dose nevirapine 
alone (sdNVP), or in combination with open-label 400 mg single-dose carbama-
zepine (sdNVP/CBZ) at delivery (ClinicalTrials.gov NCT00294892). The co-prima-
ry outcomes were nevirapine plasma concentrations one week and nevirapine 
resistance mutations six weeks post-partum. Analyses were based on those still 
eligible at delivery. 
Results
Ninety-seven women were assigned to sdNVP and 95 to sdNVP/CBZ during preg-
nancy, of whom 75 sdNVP and 83 sdNVP/CBZ were still eligible at delivery at 
study sites. The median (IQR) nevirapine plasma concentration was 1.55 (0.88-
1.84) mg/L in sdNVP (n=61) and 1.40 (0.93-1.97) mg/L in sdNVP/CBZ (n=72) at 
delivery (p=0.91), but 1 week later was significantly lower in sdNVP/CBZ (n=63; 
0.09 (0.05-0.20) mg/L) than in sdNVP (n=52; 0.20 (0.09-0.31) mg/L; rank-sum: 
p=0.004) (GMR: 0.64, 95% CI: 0.43-0.96; p=0.03). Six weeks postpartum, nevira- 
pine mutations were observed in 11/52 (21%) in sdNVP and 6/55 (11%) in sdNVP/
CBZ (odds ratio=0.46, 95% CI: 0.16-1.34; p=0.15).
Conclusions
Addition of single-dose carbamazepine to single-dose nevirapine at labor onset in 
HIV-infected, pregnant women did not affect nevirapine plasma concentration at 
delivery, but significantly reduced it one week postpartum, with a trend towards 
fewer nevirapine resistance mutations. 
qf_offerte154258_binnenwerk_zw_1-1_01.indd   50 7-7-2013   19:05:17
 Clinical Pharmacology Studies in HIV-Infected Pregnant Women - PART I 51
Without intervention, the risk of mother-to-child HIV transmission in the breastfed popula-
tion is 35-40%1,2. Single-dose nevirapine to the mother at onset of labour and single-dose 
nevirapine to the newborn within 24-72 hours after birth remains part of treatment for 
prevention of mother-to-child HIV transmission (pMTCT) in most resource-limited coun-
tries2,3. This simple and affordable intervention reduces MTCT by 40% and has benefited 
thousands of babies since its introduction in 2000. 
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with potent antiviral 
activity, but a low genetic barrier, with one mutation causing high-level resistance. It is 
rapidly absorbed when given orally and passes quickly through the placenta. The primary 
elimination pathway for nevirapine is oxidative metabolism by cytochrome P-450 3A4 and 
2B6 enzymes4. The drug has a long elimination half-life in pregnant women using a single 
200 mg dose at labor (median 61-66h). This leads to persisting subtherapeutic plasma con-
centrations, which, given its low genetic barrier to resistance5,6, means a single dose can 
lead to primary nevirapine resistance in 15-75% mothers7-9. 
Clinically, nevirapine resistance has three major implications. Firstly, the efficacy of nevira-
pine or other NNRTIs in combination antiretroviral therapy (ART) may be diminished when 
a patient harbours resistant virus. Indeed, studies in sub-Saharan Africa suggest that recent 
exposure to single-dose nevirapine (<6 months) is associated with increased risk for viro-
logical and clinical failure7,10-13. Secondly, nevirapine-resistant strains may be transmitted 
to others, limiting their treatment options. Thirdly, nevirapine resistance could reduce the 
efficacy of single-dose nevirapine in subsequent pregnancies14,15, although data suggest 
nevirapine resistance fades in these women over time  and single-dose nevirapine remains 
effective for prophylaxis in subsequent pregnancies16,17. 
Updated World Health Organisation (WHO) guidelines therefore now recommend adding 
zidovudine+lamivudine for seven days postpartum to cover the prolonged presence of 
subtherapeutic nevirapine concentrations after single-dose nevirapine at labor onset18-20. 
Recent studies show adding single-dose tenofovir+emtricitabine to single-dose nevirapine 
and short-course zidovudine further reduces NNRTI resistance21-23. Of note, none of these 
interventions fully eradicated nevirapine resistance19, which therefore remains a serious and 
growing concern. 
A different approach to limit nevirapine resistance development would be a pharma- 
cological intervention to reduce nevirapine elimination half-life. Carbamazepine is a low 
cost widely available anticonvulsant, an inducer of cytochrome P-450 3A4 enzymes, which 
passes into breast milk, and might decrease nevirapine elimination half-life and resistance 
development in the mother. A pilot study comparing eight different CYP3A induction stra-
tegies with different drugs demonstrated that elimination half-life of single-dose nevirapine 
was reduced most (by 35%) by adding single-dose carbamazepine in healthy volunteers4.
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In this phase II trial, we therefore investigated whether the addition of single-dose 
carbamazepine, as CYP3A4 enzyme inducer, would diminish nevirapine resistance devel-
opment by reducing elimination half-life after exposure to single-dose nevirapine at onset 
of labor in HIV-infected, pregnant, Tanzanian women.
Study participants 
HIV-1-infected, pregnant women attending antenatal clinics in Moshi, Tanzania were 
recruited from Kilimanjaro Christian Medical Centre (KCMC) as the consultant hospital, 
three primary and one tertiary antenatal care units. Counseling and voluntary HIV testing 
(by the dual rapid-test algorithm) was offered routinely to all pregnant women atten-
ding antenatal services in these clinics as part of the national pMTCT program. Women 
testing positive received post-test counseling and were informed about the trial. Eligible 
HIV-infected women were: aged 18-40 years, CD4 count >200 cells/mm3 (i.e. did not 
qualify for ART at the time), antiretroviral (ARV) naïve, living within the catchment 
area, not intending to relocate during study participation, willing to adhere to the follow- 
up schedule, able and willing to give informed consent and to regularly attend the 
antenatal clinic. Exclusion criteria were: previously treated with ARVs including single-dose 
nevirapine in a previous pregnancy and serious illness that required systemic treatment/ 
hospitalization. Women who qualified for ART (i.e. CD4<200 cells/mm3) were referred for 
care and not enrolled. Written consent was obtained where possible; for eligible women 
who could not read, consent was obtained orally and documented by a witness. The study 
was approved by institutional review boards of KCMC, Moshi, Tanzania and Radboud 
University Nijmegen Medical Centre (RUNMC), The Netherlands. The study is registered with 
ClinicalTrials.gov, number NCT00294892.
After 28 weeks gestation, eligible women who had provided informed consent were 
allocated 1:1 to receive either the national standard care at the time of single-dose nevira-
pine (200 mg) or single-dose nevirapine plus single-dose carbamazepine (400 mg) orally 
at onset of labor (open-label). Nevirapine (and carbamazepine if allocated) was handed 
to the woman at enrolment following standard antenatal policy, ideally at 28 weeks of 
pregnancy at her routine checkup visit and at the latest just before delivery following 
standard antenatal policy. In both groups single-dose nevirapine suspension was admin-
istered to the baby within 24-72 hours after birth. The randomization list was generated 
as alternate allocations by the study pharmacist (i.e. was quasi-randomized), and was 
held centrally at the KCMC pharmacy. Allocations were made by local medical officers at 
antenatal clinics phoning the pharmacist; as there were four local antenatal clinics, the 
next allocation was concealed to study teams until it was made. Participants were asked 
to take study drugs at onset of labor pain and to come to the labor ward for delivery. If the 
woman vomited within 30 minutes of study drug(s) administration or did not deliver 
within 48 hours a second single-dose of nevirapine (not carbamazepine) was given. When 
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the women presented in labor, a study nurse confirmed study drug(s) ingestion by direct 
observation of intake at the clinic or by asking the women when they had taken study 
drug(s) already at home. Replacement drugs were provided for those who had not taken 
them. The time of ingestion of study drugs was recorded in the Case Report Form. As 
the national guidelines recommended, all women (100%) in the trial opted to exclusively 
breastfeed for six months and then wean rapidly.
Objectives, outcomes and follow-up
The primary objectives were to determine the effect of adding single dose carbamazepine 
on single-dose nevirapine pharmacokinetics and nevirapine resistance development in 
the women. The first co-primary outcome was therefore nevirapine plasma concentra-
tion one week postpartum. Blood samples were taken one week post-partum (and at 
delivery) for pharmacokinetic evaluation. The second co-primary outcome was the pro-
portion of women with any of the following major nevirapine resistance mutations L100I, 
K101P, K103N, V106A/M, V108I, Y181C/I, Y188C/L/H, G190A9,24 on majority sequencing 
six weeks post-partum. Secondary outcomes were any positive HIV RNA PCR test of the 
newborn and adverse events (including any grade of toxicity in laboratory safety tests 
taken one week post-partum) possibly/probably/definitely related to study drugs. 
Hematology and biochemistry tests were determined at enrolment and one week post-
partum. CD4 cell counts and quantitative plasma HIV-1 RNA were assayed just after deli-
very. Infants were tested just after birth, week 6 and month 4 by HIV-1 RNA PCR assays. 
Blood was taken at delivery and one week post-partum, and plasma stored for bioana-
lysis of nevirapine plasma concentrations, done in the Department of Clinical Pharmacy, 
RUNMC, Nijmegen, The Netherlands using high performance liquid chromatography 
(lower limit of quantification 0.05 mg/L)25. Resistance was assayed in plasma stored from 
samples with >500 copies/ml at delivery and the 6 week antenatal visit at the Department 
of Virology of the University Medical Centre Utrecht, The Netherlands (samples <500 
copies/ml, the lower limit of quantification of the resistance assay, were assumed to have 
no important resistance mutations). 
The intended sample size of 100 women per group provided >80% power to detect a 
two-fold reduction in the proportion with resistance (from 36% to 18%) with 2-sided 
alpha=0.05. Statistical analysis of nevirapine plasma concentrations and mutations was 
undertaken using SPSS, version 13.0 (SPSS Inc.). Categorical variables were analyzed with 
chi-squared tests (or exact tests for expected cell frequency <5), and continuous variables 
with rank-sum tests. Analyses were based on women still eligible at delivery (Figure 1). 
As the primary outcome measures were based on batched laboratory measures, analyses 
also excluded women who had evidence of non-compliance (carbamazepine detected 
by HPLC in sdNVP group or no carbamazepine detected by HPLC in sdNVP/CBZ group).
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Excluded (162):
not meeting inclusion 
criteria or declined to 
participate
Quasi-randomized (192)
Lost to follow up 
after delivery (8)
Attended at week 1 and/or 
week 6 (71)
• 63 attended at week 1 (8 
missed visit)
• 57 attended at week 6 (14 
missed visit)
Lost to follow up 
after delivery (12)
Attended at week 1 and/or 
week 6 (67)
• 52 attended at week 1 (15 
missed visit)
• 53 attended at week 6 (14 
missed visit)
Assessed for 
eligibility (354)
Allocated to control (97)
Gave birth and received 
study drugs (75)
Excluded from the 
analysis prior to delivery 
(22)
• CD4 <200 cells/mm3 
and referred for ART 
(4)a
• absconded before 
delivery (12) 
• delivered at non study 
site (5)
• withdrew at delivery (1)
Allocated to intervention (95)
Gave birth and received 
study drugs (83)
Excluded from the 
analysis prior to
delivery (12)
• absconded before 
delivery (9)
• home deliveries 
(2)
• withdrew before 
delivery (1)
CBZ detected in 
delivery sample (1): 
excluded from 
analysis
FIGURE 1  Trial profile
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We screened 354 HIV-infected, ARV-naïve, pregnant women between February 2006 
and April 2009 (Figure 1). 192 (54%) were eligible; the remainder were not eligible 
(mostly CD4 <200 cells/mm3) or declined to participate. The study was terminated in April 
2009 after 192 patients had been enrolled when the new WHO pMTCT regimen (with 
zidovudine+lamivudine tail) was introduced in Moshi. Groups were reasonably balanced 
for age, BMI, weight, CD4 count, hematology and biochemistry parameters at enrolment 
and delivery (Table 1). 
Thirty-four women were randomized but did not take study drugs at delivery. Four (all 
sdNVP) had CD4 declines to <200 cells/mm3 and were referred for ART. 21 (12 sdNVP, 9 
sdNVP/CBZ) did not return after enrolment for subsequent antenatal visits or delivery, 7 
(5 sdNVP, 2 sdNVP/CBZ) delivered at home or at non-study sites, and 2 (1 sdNVP, 1 sdNVP/
CBZ) withdrew or did not want study participation disclosed before or at delivery. Thus 75 
sdNVP and 83 sdNVP/CBZ women remained in the study at delivery. 133/158 (84%) delivery 
samples were available (62/75 (83%) sdNVP, 72/83 (87%) sdNVP/CBZ). Missing samples 
were not taken or had insufficient volume or clotted prior to analysis. One woman in the 
control group had detectable carbamazepine levels, and was excluded from analyses
Pharmacokinetics
The median (IQR) nevirapine plasma concentrations immediately after delivery were 1.55 
(0.88-1.84) mg/L for the sdNVP group and 1.40 (0.93-1.97) mg/L for the sdNVP/CBZ 
group (Table 2) (ranksum p=0.91) (GMR: 1.17, 95% CI 0.76-1.81; p=0.48). As expected 
nevirapine plasma concentrations were significantly reduced in both groups one week 
after delivery (based on matched pairs of measurements, sdNVP GMR (1 week:delivery, 
n=44)=0.18, 95% CI: 0.12-0.26; sdNVP/CBZ GMR (1 week:delivery, n=54)=0.10, 95% CI 
0.07-0.14): results similar using unmatched data). In the sdNVP/CBZ group, week 1 nevira-
pine plasma concentrations were significantly lower compared to the sdNVP group (GMR: 
0.64, 95% CI 0.43-0.96; p=0.03; Table 2) with median (IQR) nevirapine concentration 
0.09 (0.05-0.20) mg/L in the sdNVP/CBZ group vs. 0.20 (0.09-0.31) mg/L in the sdNVP 
group (rank-sum: p=0.004). Moreover, there was a trend to a greater proportion with 
undetectable nevirapine levels (<0.05 mg/L) in sdNVP/CBZ than sdNVP groups; 15/63 
(24%) vs. 6/52 (12%), respectively (chi-squared p=0.09). 
Nevirapine resistance
At week 6, 110 (53 sdNVP, 57 sdNVP/CBZ) samples were available for HIV genotyping. 
For 3 women, plasma volumes were too limited, leaving 107 with valid genotypes. 
Eleven (21%) of the 52 women in the sdNVP group had one or more nevirapine- 
associated resistance mutations, compared to 6/55 (11%) in the sdNVP/CBZ group (odds 
ratio=0.46, 95% CI 0.16-1.34, chi-squared p=0.15). Eight women in the sdNVP group 
had one nevirapine mutation and three had two mutations (Figure 2), compared to five 
and one, respectively in the sdNVP/CBZ group (poisson incidence rate ratio for number of 
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TABLE 1  Characteristics of women at enrolment, delivery and one week after delivery
 sdNVP sdNVP/CBZ
At enrolment n=97 n=95
Age (years) 29 (25-32) 29 (25-31)
Weight (kg) 63 (57-73) 65 (56-71)
BMI (kgm2) 25.7 (23.4-28.5) 26.0 (23.1-29.6)
Alkaline phosphatase (U/L) 117 (76-180) 140 (88-185)
Bilirubin (µmol/L) 8.6 (<8.6-12.6) <8.6 (<8.6-12.1)
Creatinine (µmol/L) 51.7 (<44.2- 62.1) 51.9 (<44.2-58.9)
AST (U/L) 9.4 (7.9-12.1) 9.5 (8.3-11.2)
ALT (U/L) 4.4 (3.4-7.5) 4.7 (3.5-6.4)
Hemoglobin (g/L) 98 (57-109) 97 (53-105)
Platelets(U/L) 261 (220-347) 234 (180-311)
Leukocytes (U/L) 6.7 (5.2-8.0) 6.3 (5.1-7.4)
Neutrophils (U/L) 4.1 (3.3-5.1) 3.6 (2.8-4.4)
At delivery n=75 n=83
CD4 (cells/µL) 353 (212-466) 296 (200-531)
HIV-1 RNA (copies/mL) 8533 (3290-48768) 6339 (1311-48865)
Birth weight (kg) 3.01 (2.80-3.30) 3.20 (2.90-3.40)
Hours from nevirapine ingestion to delivery 5.02 (3.08-15.50) 3.58 (2.00-8.67)
One week after delivery n=52 n=63
Alkaline phosphatase (U/L) 134 (112-173) 125 (100-185)
Bilirubin (µmol/L) 9.1 (<8.6-13.6) 8.8 (<8.6-13.4)
Creatinine (µmol/L) 62.8 (46.5-75.0) 56.3 (47.1-69.3)
AST (U/L) 11.5 (9.6-14.6) 10.8 (8.3-17.4)
ALT (U/L) 9.7 (6.6-12.3) 9.8 (6.7-14.7)
Hemoglobin (g/L) 111 (89-122) 108 (96-122)
Platelets (U/L) 401 (277-534) 382 (300-422)
Leukocytes (U/L) 7.2 (6.3-10.1) 6.4 (5.5-7.8)
Neutrophils (U/L) 4.5 (3.6-6.4) 3.9 (3.1-5.2)
Note: Values are median (IQR). BMI, body mass index; IQR, interquartile range. 
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TABLE 2   Maternal nevirapine plasma concentrations at delivery and one week after delivery
sdNVP sdNVP/CBZ p
 Geometric Mean 
Ratio (95% CI)
At delivery
Samples taken (n) 61 72
NVP plasma conc.  
(mg/L; median (IQR))
1.55 
(0.88-1.84)
1.40 
(0.93-1.97)
0.91
 NVP plasma conc. (mg/L; 
geometric mean (95% CI))
0.89  
(0.63-1.26)
1.04
 (0.79-1.38) 
0.48
1.17 
(0.76-1.81)
<0.05 mg/L NVP (n (%)) 6 (10%) 4 (6%) 0.51
One week after delivery
Samples taken (n) 52 63
NVP plasma conc.  
(mg/L; median (IQR))
0.20 
(0.09-0.31)
0.09 
(0.05-0.20)
0.004
 NVP plasma conc.  
(mg/L; geometric mean  
(95% CI))
0.16  
(0.12-0.21)
0.10 
(0.08-0.14)
0.03
0.64 
(0.43-0.96)
<0.05 mg/L NVP (n(%)) 6 (12%) 15 (24% ) 0.09
NVP plasma conc. 1 
week:delivery (number 
of paired measurements; 
GMR (95% CI))
n= 44; 
0.18 (0.12-0.26)
n=54; 
0.10 (0.07-0.14)
Note: p-values from rank-sum tests for plasma concentration, exact and chi-squared tests for <0.05 mg/L at 
delivery and week 1, respectively.
mutations in sdNVP/CBZ vs sdNVP=0.47 (95% CI 0.19-1.17) p=0.11). All but two of the 
mutations were detected as mixtures with wild-type nucleotide sequence. Only one of 
two mutations in one woman in the sdNVP group was already present in a sample stored 
at the enrolment visit. None of the other nevirapine mutations were already present in 
enrolment samples. Figure 3 shows the distribution of the nevirapine mutations six weeks 
after delivery. K103N, Y181C/I and G190A were the most frequently observed nevirapine 
mutations. The most common mutation was K103N, present in nine women, alone in 
eight women and with G190A in one. 
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Combined pharmacokinetic–resistance analysis
Nevirapine plasma concentrations one week postpartum were available from 14/17 
(82%) women with mutations vs. 71/90 (79%) without mutations. Median week 1 nevi-
rapine plasma concentrations were similar in women with (median (IQR) 0.12 (0.09-0.29) 
mg/L) and without (0.11 (0.06-0.22) mg/L) mutations (p=0.36). However, none of the 
15 women with undetectable nevirapine levels at week 1 developed nevirapine resis-
tance compared to 14/70 (20%) of those with detectable nevirapine at week 1 (exact 
p=0.07). Thus, irrespective of group assignment, women with undetectable plasma 
concentrations at week 1 were less likely to develop nevirapine-associated mutations 
after single-dose nevirapine for pMTCT.
Safety
Samples were available for viral load testing from 102 newborns (93%), of which 3 were 
of insufficient quantity or clotted. The overall HIV-1 transmission rate was 6/50 (12%) in 
the sdNVP/CBZ group and 3/49 (6%) in sdNVP group (exact p=0.49). Although not all 
infants were tested at delivery, 1/6 (17%) and 0/3 (0%) infected babies in the sdNVP/CBZ 
and sdNVP groups respectively were known to have been infected during the intrauterine 
period. Three babies (1 sdNVP, 2 sdNVP/CBZ) died at delivery, one (sdNVP/CBZ) died in the 
first 6 weeks after delivery and one (sdNVP/CBZ) after 4 months of delivery. There were 
no adverse events in the infants possibly/probably/definitely related to study medication(s).
Women were similar in all laboratory safety parameters at enrolment (p=0.06 to p=0.80) 
(Table 1). Forty-two adverse events were reported in the sdNVP group and 40 in the 
sdNVP/CBZ group between enrolment and delivery (i.e. before trial intervention), mostly 
grade 1 (31 sdNVP, 29 sdNVP/CBZ). Only seven were grade 4 (3 sdNVP, 4 sdNVP/CBZ); six 
women had grade 4 anemia (Hb<6.5 g/dl) and one had AST>10.0*upper limit of normal. 
 
One week after delivery women were also comparable in hematology and biochemistry 
parameters (p>0.26) except for leucocytes (p=0.002) and neutrophils (p=0.009, Table 1). 
However, nearly all values (27/27 (100%) sdNVP, 37/38 (97%) sdNVP/CBZ) were in the 
normal range for neutrophils (>1.3*109/L) and for leucocytes (27/27 (100%) sdNVP; 
38/39 (97%) sdNVP/CBZ) (>2.5*109/L). After delivery, six adverse events were reported in 
the sdNVP group and 21 in the sdNVP/CBZ group. Most events were grade 1 (2 sdNVP;13 
sdNVP/CBZ); of the remaining events seven were grade 2 (3 sdNVP; 4 sdNVP/CBZ), three 
grade 3 (1 sdNVP; 2 sdNVP/CBZ) and only two were grade 4 (2 sdNVP/CBZ), both anemia 
(Hb<6.5 g/dl). None of the adverse events (including the grade 4 anemias) were 
considered possibly/probably/definitely drug-related. 
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FIGURE 2  Percentage of women with nevirapine mutations. Tested for nevirapine resistance at 
      week 6: 107 women (52 sdNVP and 55 sdNVP/CBZ).
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FIGURE 3  Number of mutations related to nevirapine resistance.
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This trial provides the first data on adding a single-dose of an enzyme inducer (carba-
mazepine) to single-dose nevirapine for pMTCT in HIV-infected, pregnant women. Single 
dose carbamazepine significantly reduced nevirapine plasma concentrations one week 
after delivery, with a trend towards fewer resistance mutations. We also found a trend 
towards lower rates of nevirapine resistance in women with undetectable nevirapine con-
centrations across the whole population, supporting the validity of this approach.
Nevirapine plasma concentrations were determined in samples obtained immediately after 
delivery and one week postpartum. Overall, these plasma concentrations were com-para-
ble to previous studies6,26,27. Adding single-dose carbamazepine did not affect nevirapine 
plasma concentrations immediately after delivery, similarly to to the study of L’homme et 
al. in healthy women4. A delay in effect on enzyme induction by single-dose carbamaze-
pine would be expected, because increased protein synthesis is required, which takes a 
few days for maximum impact4. This is important as the addition of an enzyme inducer 
should not negatively influence the protective effect of single-dose nevira-pine on HIV 
MTCT. The delay in enzyme induction, and the low concentrations of carbamazepine 
in breast-milk, mean that reductions in infant nevirapine levels are unlikely28. Indeed, 
perinatal HIV-1 transmission rates were similar to rates reported in previous studies of 
women using single-dose nevirapine for the first time2,15,29-31. 
One week after delivery, nevirapine concentrations were 36% lower in the sdNVP/CBZ 
group, with a trend towards a higher proportion with undetectable plasma concentra-
tions in this group. Plasma concentrations one week post-partum are determined by nevira-
pine elimination half-life, and therefore significantly lower concentrations in the sdNVP/
CBZ group directly translate into significantly higher elimination half-life. In a previous pilot 
study4 in healthy, Dutch, female volunteers, the nevirapine elimination half-life declined 
by 35% with additional single-dose carbamazepine and the median time to undetectable 
levels was reduced by 23%. Our study differed in study design (single sample only) and 
subject population, but single-dose carbamazepine seems to reduce nevirapine elimination 
half-life at least as effectively in HIV-infected, pregnant, Tanzanian women. As our sample 
size was determined by the (binary) nevirapine resistance co-primary endpoint, our power 
to detect changes in nevirapine concentrations was higher, with even 50 patients per group 
providing at least 80% power to detect a 50% relative decrease in 1-week nevirapine con-
centration based on standard deviations observed in the pilot study4.
To reduce the emergence of nevirapine resistance after single-dose nevirapine, several 
studies have investigated the addition of other ARVs after delivery. A meta-analysis reported 
36% average nevirapine resistance prevalence for women using single-dose nevirapine 
(with or without other ARVs)32. For those women receiving ARVs postpartum, this fell to 
4.5%. Whilst nevirapine resistance drops dramatically with these new strategies including 
combination "tail" ARVs, the major disadvantages are their complexity and the emergence 
of lamivudine resistance (due to long intracellular elimination half-life), which is associated 
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with virological and clinical failure in women starting lamivudine-containing ART for 
their own health11,33. To preserve its simplicity, Chi et al22 administered a single dose of 
emtricitabine+tenofovir with single dose nevirapine in 400 women, which also halved nevira- 
pine resistance; 25% vs. 12%. As it targets a different mechanism, the pharmacologic 
approach described here might have an additive effect and also maintains simplicity.
Our study has several limitations. Firstly, we had high loss to follow-up. This is unfortu-
nately not uncommon in pMTCT programs in sub-Saharan Africa34,35. Traditions, stigma-
tization and fear of harassment and rejection accounted for most of our loss to follow-up. 
More intensive counseling for women using  pMTCT prophylaxis and more aggressive 
methods to identify and locate those not returning for appointments should reduce loss to 
follow-up rates in future studies. Secondly, the randomization list was generated as alter-
nate allocations (i.e. was only quasi-randomized) by the study-pharmacist, who assigned 
groups centrally and did not include patients herself; previous allocations were concealed 
from the local medical officers enrolling patients. This together with the open-label 
allocation, could have led to bias, although not in the direct assessment of co-primary 
outcomes (pharmacokinetics and resistance) which were measured on batched stored 
samples blinded to allocation. The third limitation was the far smaller sample size for 
resistance testing than designed, which limited our power to detect differences in 
resistance between the groups. Finally, the standard HIV genotyping assays could only 
detect viral mutations found in >20% of the overall HIV population and not sub-popula-
tions of mutants. Deep sequencing is planned for future projects.
The original pilot study in healthy, Dutch, female volunteers, was performed to identify 
enzyme inducers that could reduce nevirapine half-life. The mechanisms by which the 
CYP3A4 enzyme are induced involves the activation of the transcription factors pregnane 
X receptor (PXR) and the constitutive androstane receptor (CAR)36. Nevirapine is a drug 
that binds to those receptors, whereafter activation of the CYP3A4 enzyme starts. From 
the eight interventions, single-dose carbamazepine and phenytoin for 3 or 7 days were 
shown to decrease the nevirapine half-life significantly5. We therefore chose single-dose 
carbamazepine as our study intervention because of its simplicity. Single-dose carba-
mazepine could lead to greater adherence compared to the current national and WHO 
guidelines, and is highly likely to reduce emergence of NNRTI resistance even further. Mo-
reover, single-dose carbamazepine is a very low-cost intervention and even when NRTIs 
turn out not to be available, carbamazepine is in almost every clinic in resource-limited 
countries. The current national and WHO guidelines for pMTCT recommend new and 
more effective, but also more complex and expensive regimens than single-dose nevira-
pine alone; their widespread implementation is challenging. A second pharmacokinetic 
trial (VITA-2; ClinicalTrial.gov ID: NCT01187719) has consequently started to evaluate the 
effect of seven days of phenytoin, a different course of an enzyme inducer, also shown to 
be effective in the previous pilot study, on the pharmacokinetics and resistance of sdNVP 
in HIV-infected pregnant women in combination with the new recommended WHO and 
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national guidelines. Studies, as the VITA-2 trial, with different enzyme inducers given for 
an extended period will be in addition to the new WHO pMTCT guidelines combining 
single-dose nevirapine at delivery with zidovudine from the second trimester of gestation 
and zidovudine+lamivudine labor for seven days post-partum. The fact that nevirapine 
resistance is still observed using these approaches suggests pharmacologic interventions 
such as evaluated in this study may still add benefit.
In conclusion, our study demonstrates that a simple intervention of single-dose carba-
mazepine in addition to single-dose nevirapine alone for antiretroviral prophylaxis for 
pMTCT considerably reduces the nevirapine plasma concentrations and likely reduces 
emergence of nevirapine resistance mutations. Enzyme inducers, such as carbamazepine, 
show new possibilities for pMTCT programs to reduce the development of nevirapine 
resistance in settings where other options are limited.
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Objectives
To confirm whether 7-days phenytoin, an enzyme inducer, decreases the elimina-
tion half-life of single-dose nevirapine and to investigate its effect on nevirapine 
resistance development in pregnant, HIV-infected women.
Methods
In a pharmacokinetic pilot trial (NCT01187719), Zambian/Tanzanian HIV-infected, 
antiretroviral (ARV)-naive pregnant women ≥18 years with CD4 >350 cells/mm3 
were randomized 1:1 to control (zidovudine pre-delivery, single-dose nevirapine/
zidovudine/lamivudine at delivery, zidovudine/lamivudine for 7 days post-delivery) 
or intervention (control plus 184 mg phenytoin once-daily for 7 days post-delive-
ry) groups. Primary endpoints were nevirapine pharmacokinetics and resistance.
Results
35/37 women were allocated to control/intervention groups with median (IQR) 
age of 27 (23-31) and 27 (23-33) years, respectively. 23/23 had detectable nevi-
rapine levels at delivery and subsequent samples in control/intervention groups, 
respectively. Geometric mean (95% CI) nevirapine plasma levels at delivery were 
1.02 (0.58-1.78) mg/L and 1.14 (0.70-1.86) mg/L in control/intervention groups 
(p=0.76). One week after delivery, 0/23 (0%) and 15/22 (68%) control/interven-
tion mothers had undetectable levels (<0.05 mg/L; p<0.001). One week later, this 
was 10/21 (48%) and 18/19 (95%), respectively (p=0.002). GM (95% CI) nevi-
rapine half-lives were 63.2 (52.8-75.7) versus 25.5 (21.6-30.1) hours in control 
versus intervention groups (p<0.001). New nevirapine mutations were found in 
0/20 (0%) intervention vs. 1/21 (5%) control mothers. There was no difference in 
adverse events (p>0.28).
Conclusions
Adding 7-days of an enzyme inducer to single-dose nevirapine to prevent mother-
to-child transmission significantly reduced subtherapeutic nevirapine levels by 
shortening nevirapine half-life. As prolonged subtherapeutic nevirapine leads to 
resistance emergence, a single-dose nevirapine could be used with phenytoin as 
an alternative if other ARVs are unavailable.
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While the risk of HIV mother-to-child transmission (MTCT) is 20-40% without treatment,1, 2 
a simple cheap intervention, single-dose nevirapine at labour onset, reduces MTCT by 
~50%.1, 3 Its major disadvantage is development of nevirapine resistance in mothers (1-
69%) and infants,4 most likely due to its long elimination half-life (61 hours),5-7 leading 
to several days to weeks of subtherapeutic plasma concentrations, coupled with its low 
genetic barrier to resistance8. Newly emergent resistant HIV may be transmitted to the 
infant or to others, limiting their treatment options, and may also reduce future combina-
tion antiretroviral therapy (cART) efficacy in the mother.9 
Given its simplicity and efficacy, single-dose nevirapine is nevertheless still endorsed 
by the WHO as part of the regimen for preventing MTCT (pMTCT) in resource-limited 
settings, when cART (WHO Option B/B+) is not feasible or available. To cover the prolonged 
 presence of subtherapeutic nevirapine plasma concentrations after single-dose nevira-
pine at labour onset, Option A of the WHO (2012) guidelines recommend adding zidovu-
dine/lamivudine for seven days postpartum.10, 11 This approach reduces resistance deve-
lopment to 4-16%,4 but does not fully eliminate it. 
Nevirapine is extensively metabolized in the liver by cytochrome P450 (CYP) isoen- 
zymes 3A4 and 2B6.12 A pharmacological, rather than antiretroviral, approach of adding 
a CYP3A4 enzyme inducer has been shown to decrease nevirapine elimination half-life 
in healthy women,13 with greatest reductions from carbamazepine and phenytoin. In our 
previous trial (VITA-1), addition of single-dose carbamazepine to single-dose nevirapine 
at labour onset also significantly reduced nevirapine plasma concentrations one week 
after delivery in HIV-infected women, with a trend towards fewer resistance mutations.14
The CYP3A4 enzyme inducer phenytoin is a low cost, widely available anticonvulsant 
and anti-arrhythmic drug, which is not secreted into breast milk in clinically important 
amounts (in contrast to carbamazepine) and can therefore be safely given to breastfee-
ding mothers.15 In this pilot study we investigated the impact of seven days phenytoin 
on nevirapine pharmacokinetics and nevirapine resistance development after single-dose 
nevirapine as a component of antiretroviral (ARV) prophylaxis for pMTCT (VITA-2 trial). 
The hypothesis was that seven days phenytoin would reduce nevirapine elimination half-
life and hence emergence of nevirapine resistance mutations.
Study participants
Participants were recruited from the Pasua and Majengo antenatal clinics (ANCs) in Moshi, 
Tanzania and University Teaching Hospital (UTH) in Lusaka, Zambia. Eligible, HIV-infected, 
pregnant women were aged ≥18 years, ARV-naive, starting ARV prophylaxis for pMTCT, 
not intending to relocate during study participation, and willing to attend follow-up visits. 
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Exclusion criteria were serious illness requiring systemic treatment/hospitalization, use 
of concomitant medication which may interfere with ARVs or phenytoin, or CD4 <350 
cells/mm3 (eligible for cART). All women gave written informed consent; illiterate patients 
gave oral consent documented by their own thumbprint and a witness. The study was 
approved by institutional review boards of Kilimanjaro Christian Medical University 
College (KCMU-Co), Moshi, Tanzania, the National Institute of Medical Research in Dar 
es Salaam, Tanzania, and UTH, Lusaka, Zambia. The study is registered with ClinicalTrials.
gov (NCT01187719).
Eligible women all received pMTCT ARV prophylaxis recommended by national Tanza-
nian/Zambian guidelines. Subjects started zidovudine 300 mg twice daily from 28/14 
weeks of gestation in Tanzania/Zambia, respectively, or as soon as possible thereafter 
pre-delivery. At labour onset, women received 200 mg single-dose nevirapine plus oral 
300 mg zidovudine every three hours and lamivudine 150 mg every 12 hours until delivery 
(Tanzania) or oral zidovudine 600 mg and lamivudine 300 mg every 12 hours until deli-
very (Zambia). Post-delivery zidovudine 300 mg and lamivudine 150 mg was taken twice 
daily for seven days. Newborns were given 2 mg/kg single-dose nevirapine suspension 
within 24-72 hours after birth then zidovudine syrup 4 mg/kg (Tanzania) or nevirapine 
suspension 2 mg/kg (Zambia) twice daily for seven days. All women in the trial breastfed 
their children for six months and then weaned rapidly.
Women were randomized 1:1 in a parallel group design to either the national standard of 
care or the national standard of care plus 184 mg phenytoin (2x 92 mg tablets) once daily 
from labour onset for seven days. The randomization sequence was generated by a trial 
statistician of MRC using simple randomization blocks. Participant codes and allocations 
were held in secure envelopes stored by the project manager at each site. At enrolment 
(pre-delivery), women were randomized by the study doctor at the clinic opening the 
next envelope. When the woman presented in labour at the clinic, a study nurse confir-
med and recorded time of study drug(s) ingestion by direct observation of intake or by 
asking the woman if she had already taken the study drug(s) at home. 
Objectives, outcomes and follow-up
The primary objectives of the pilot study were to determine the effect of seven days 
phenytoin on the elimination half-life of nevirapine and the development of nevirapine 
resistance in HIV-infected pregnant women receiving a single-dose nevirapine as part of 
perinatal HIV prevention. The primary outcomes were nevirapine pharmacokinetic para-
meters (elimination half-life, time to achieve an undetectable plasma concentration) and 
nevirapine resistance (primary nevirapine mutations L100I, K101P, K103N/S, V106A/M, 
V108I, Y181C/I, Y188C/L/H, G190A)16 at weeks 4-6. Secondary outcomes were all ad-
verse events (AEs) possibly/probably related to pMTCT ARV prophylaxis or phenytoin, and 
HIV infection of the infant.
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Haematology and biochemistry tests were performed at enrolment and one week post-
partum. CD4 cell counts and viral load (VL) were assayed at delivery. Infants were tested 
just after birth (<30 minutes) and at week 4-6 by DNA PCR assays. Blood was stored 
from the women at delivery and days 1,3,5,7 and 14 postpartum, and from the children 
at delivery and day 7 post-delivery for retrospective determination of nevirapine (and 
phenytoin) plasma concentrations at the Department of Pharmacy, Radboud University 
Nijmegen Medical Centre, Nijmegen, The Netherlands. Nevirapine assay used high per-
formance liquid chromatography with a lower limit of quantification (LLOQ) of 0.05 mg/L17 
and phenytoin was determined by a validated immunoassay with an LLOQ of 0.4 mg/L. 
Nevirapine resistance was assayed in plasma stored from samples at baseline and week 4/6 
at the Department of Virology of the University Medical Centre Utrecht, The Netherlands. 
Pharmacokinetic and resistance assays were performed blinded to randomized allocation.
The sample size of 50 subjects (25 per arm) delivering in the study clinic provided >80% po-
wer to detect a decrease of at least 27% in nevirapine elimination half-life associated with se-
ven days phenytoin allowing 20% drop-out (without follow-up samples, based on VITA-1).14 
Safety analyses included all women who were observed or reported taking study medica-
tion (safety population). Analyses of pharmacokinetics and resistance included the safety 
population who did not receive a second nevirapine dose, who delivered vaginally (not by 
caesarean section (C/S)) and had pharmacokinetic evidence of nevirapine, and phenytoin 
if allocated (detectable plasma concentration one day post-delivery) (protocol-specified 
primary PK population). Analyses were also done including mothers who delivered by 
C/S, as no difference in pharmacokinetic parameters was observed between C/S and 
vaginal deliveries in VITA-1. Women in the control group with phenytoin detected in any 
sample were excluded from PK/resistance analyses. Pharmacokinetic analysis was per-
formed using Phoenix 64, WinNonlin 6.3 (Pharsight Corporation, CA, USA) and statistical 
analysis using SPSS, version 18.0 (SPSS Inc.). Randomized groups were compared using 
t-tests for continuous pharmacokinetic variables (after transformation to the log scale, ie 
comparing geometric means), ranksum tests for all other continuous variables, and exact 
tests for categorical variables.
RESULTS
Study participants
We screened 335 HIV-infected, pregnant women from July 2010 to June 2011; most of 
the 262 women not randomized were already on cART (n=94), had CD4 <350 cells/mm3 
(n=82) or did not return after screening (n=56) (Figure 1). Seventy-three (22%) women 
were randomized: 35 and 37 were allocated to control and intervention groups, respec-
tively. One woman was randomized twice; the second randomization was excluded and 
the woman followed the first randomization. Demographic characteristics at enrolment 
and delivery were generally reasonably balanced between the two groups (Table 1; Sup-
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Assessed for eligibility 
(n=335) 
  
Excluded (n= 262) 
• On cART (n=94) 
• CD4 <350 cells/mm3 (n=82) 
• Did not return to clinic (n=56) 
• Declined to participate (n=14) 
• Had sdNVP in previous 
pregnancy (n=5) 
• Took part in other trial (n=4) 
• Used medication that interferes 
with study drugs (n=3) 
• <18 years of age (n=2) 
• Not able to understand trial (n=1) 
• Not able to adhere to study 
schedule (n=1) 
 
HIV-infected, ARV-naive, pregnant women ≥18 years  
with CD4 >350 cells/mm3 randomized at 26-40 weeks  
of gestation (n=73) 
Allocated to Control group  (n= 35) Allocated to Intervention group (n=37) 
• LTFU before delivery (n=9)  
• Did not report to take study 
medication, because they  
were not noticed as VITA-
mothers when they  
delivered in clinic (n=2) 
• Double randomization (n=1) 
 
• No PK evidence for nevirapine 
(n=2)  
• No PK evidence phenytoin 
(n=1)       
   
 
PK data analyzed (n=23)  
All women who delivered 
 
Resistance data analyzed (n=21)  
(missed week 6 visit (n=1)) 
(sample failed to amplify (n=1)) 
 
  
 
• LTFU before delivery (n=4)  
• Did not report to take study 
medication, because they  
were not noticed as VITA- 
mothers when they  
delivered in clinic (n=3) 
 
• No PK evidence for  
nevirapine (n=3)  
• LTFU: no PK samples  
(n=2) 
 
Delivered by  
caesarean section (n=7)  
 
Delivered in the study clinic (n=28)  
Safety population 
Delivered in the study clinic (n=26) Safety 
population 
PK data analyzed (n=23)  
All women who delivered 
 
Resistance data analyzed (n=20) 
(missed week 4/6 visit (n=3)) 
 
PK data analyzed (n=16) 
Women who delivered vaginally  
(not by caesarean section) 
 
 
 
PK data analyzed (n=23) 
Women who delivered vaginally  
(not by caesarean section) 
 
 
FIGURE 1  Profile of the VITA-2 trial (CONSORT diagram) 
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plementary Table 1); the main difference was significantly shorter time from nevirapine 
ingestion to delivery in the intervention group, which must have occurred by chance. The 
difference is not expected to have impact on our pharmacokinetic data, as the elimination 
half-life of nevirapine is long. Also, no differences were observed between laboratory 
values at enrolment and delivery within either group (Supplementary Table 1). The study 
finished once the recruitment target had been met.
Pharmacokinetics
At delivery, restricting to women who delivered vaginally (not by C/S), there was no signi-
ficant difference in nevirapine plasma concentrations in the two groups (geometric mean 
(GM) (95% CI) was 1.08 (0.63-1.84) mg/L in control patients versus 1.14 (0.70-1.86) mg/L 
in intervention patients, GM ratio (GMR) (90% CI) 1.05 (0.58-1.92), t-test p=0.82). Subse-
quently nevirapine plasma concentrations decreased significantly faster (Figure 2) and un-
detectable levels were reached significantly earlier (Table 2) in the intervention group com-
pared to the control group. All results were similar including women who delivered by C/S, 
and so those from the (larger) group including women who delivered by C/S are presented 
subsequently (see Supplementary Table 2 for pharmacokinetic results of the (smaller) group 
excluding women who delivered by C/S).
One week post-delivery, nevirapine plasma concentrations were reduced in both groups, 
but to a significantly lesser extent in the control group (GMR (1-week:delivery) (90% CI) 
0.22 (0.18-0.28), 20 matched pairs) than the intervention group (GMR (1-week:delivery) 
(90% CI) 0.031 (0.026-0.038), 22 matched pairs). Overall, levels were 85% lower in 
intervention than control groups (GMR (intervention:control) (90% CI) 0.15 (0.11-0.20), 
t-test p<0.001). The GM (95% CI) nevirapine elimination half-life was 63.2 (52.8-75.7) 
TABLE 1  Demographic characteristics of the women and infants in the VITA-2 trial
Control (n=28)
Intervention 
(7 days phenytoin; n=26)
p-value
At enrolment
Age (years) 27 (23-31) 27 (23-33) 0.74
Weight (kg) 62 (55-73) 66 (56-81) 0.11
BMI (kg/m2) 24.1 (21.7-27.9) 26.2 (23.3-30.9) 0.10
At delivery
Gestational age at delivery 
(weeks)
39 (38-42) 39 (38-41) 0.78
CD4 cell count (cells/µl) 366 (318-522) 412 (317-518) 0.76
HIV-1 RNA (copies/ml) 2832 (1000-26518) 2420 (1542-11261) 0.99
Birth weight (kg) 3.0 (2.7-3.2) 3.0 (2.7-3.4) 0.87
Time from nevirapine 
ingestion to delivery 
(hours)
9.1 (2.5-12.6) 2.1 (1.0-4.9) 0.003
Data are presented as median (IQR) and were tested with Rank-sum. 
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versus 25.5 (21.6-30.1) hours in the control versus intervention groups respectively 
(p<0.001; t-test), a 60% reduction (GMR (90% CI) 0.40 (0.33-0.49)). The GM (95% CI) 
time to achieving an undetectable nevirapine plasma concentration was 16.3 (13.8-19.3) 
versus 6.7 (5.7-7.8) days in the control versus intervention groups respectively (p<0.001; 
t-test). Consequently a significantly greater proportion of control women had detectable 
nevirapine plasma levels at one and two weeks post-delivery (Table 2). All 23 (100%) 
women in the control group versus 7/22 (32%) women in the intervention group had a 
detectable nevirapine plasma concentration at one week post-delivery (p<0.001; exact); 
and 11/21 (52%) women in the control group versus 1/19 (5%) women in the intervention 
group at two weeks post-delivery (p=0.002; exact).
The median (range) phenytoin plasma concentration in all samples taken from delivery to 
one week post-delivery in the intervention group was 1.5 (<0.4-24.7) mg/L. Twenty-one 
of 22 (95%) mothers had only subtherapeutic phenytoin levels (therapeutic range defined 
as 10-20 mg/L).18 One (5%) mother had an undetectable plasma concentration at delivery, 
but her plasma level was detectable on day 1 and increased to 24.7 mg/L one week post-
delivery. The median phenytoin plasma level in the infants was <0.4 (range <0.4-1.9 mg/L).
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FIGURE 2  Geometric mean nevirapine plasma concentrations over time post-delivery 
  (all women who delivered including those who delivered by C/S)
qf_offerte154258_binnenwerk_zw_1-1_01.indd   76 7-7-2013   19:05:19
 Clinical Pharmacology Studies in HIV-Infected Pregnant Women - PART I 77
TABLE 2  Maternal nevirapine plasma concentrations at delivery, week 1 and week 2 of women 
                in the VITA-2 trial, including women who delivered by C/S.
Women who delivered, including women who delivered by C/S 
 Control Intervention p-value
GMR 
(90% CI)
At delivery    
Samples taken (n) 20 22   
nevirapine plasma conc. 
(mg/L; GM (95% CI))
1.02
(0.58-1.78)
1.14 
(0.70-1.86)
0.76†
1.12 
(0.61-2.03)
<0.05 mg/L nevirapine (n (%)) 1 (5%) 1 (5%)   
1 week after delivery    
Samples taken (n) 23 22  
nevirapine plasma conc
(mg/L; GM (95% CI))
0.23 
(0.18 - 0.31)
0.035 
(0.027-0.046)
<0.001†  
0.15 
(0.11-0.20)
<0.05 mg/L nevirapine (n(%)) 0 (0) 15 (68%) <0.001*  
Women with 1 week and delivery 
samples (n) 
20 22  
nevirapine plasma concentration 
1 week : delivery  (GMR (90% CI))
0.22 
(0.18-0.28)
0.031 
(0.026-0.038)
 
2 weeks after delivery     
Samples taken (n) 21 19   
nevirapine plasma conc.
(mg/L; GM (95% CI))
0.044 
(0.031-0.062)
0.026 
(0.024-0.029)
0.006†  
0.59
(0.44-0.80)
<0.05 mg/L nevirapine (n(%)) 10 (48%) 18 (95%) 0.002*  
Women with week 2 and 
delivery samples  (n)
18 18   
nevirapine plasma conc 
2 weeks : delivery  
(GMR (90% CI))
0.030 
(0.026 - 0.034)
0.022 
(0.015 - 0.031)
  
† T-test, * Exact test. Median nevirapine plasma concentrations are similar to GM and are therefore not shown 
in Table 2. 
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Resistance 
Samples 4-6 weeks post-delivery were available from 21 control women (1 missed week 
6 visit; for 1 sample amplification failed due to low VL) and 20 intervention women 
(3 missed week 4/6 visit). One (5%) of the 21 women in the control group had one nevira-
pine-associated resistance mutation (elimination half-life 123.5 hours), which was not 
present at baseline, versus 1/20 (5%) with one nevirapine-associated resistance mutation 
in the intervention group. However, the mutation in the patient from the intervention 
group was already present in a sample stored at delivery. Both mutations were detected 
as mixtures with wild-type nucleotide sequence (V106MV control; K103KN intervention). 
Safety
The 28 control and 26 intervention mothers gave birth to 30 (two pairs of twins) and 28 
babies (two pairs of twins), respectively. Twenty-one (one pair of twins) and 19 (one pair 
of twins) infants respectively were tested just after birth and at weeks 4-6 post-delivery. 
The overall transmission rate was 0/21 (0%) in the control group and 1/19 (5%) in the 
intervention group. However, the infected child tested positive at birth and must there-
fore have been infected during the intrauterine period. In the infants, ten clinical AEs 
were reported: four in the control group (n=1 grade 1, n=1 grade 2, n=2 grade 4) and 
six in the intervention group (n=1 grade 1, n=1 grade 2, n=1 grade 3, n=3 grade 4). The 
grade 4 AEs were a hospitalization for overweight after birth and a death just after birth 
due to congenital malformation in the control group and three still births (two fresh, one 
macerated) in the intervention group.
Both platelets (p<0.001) and alanine transaminase (ALT) (p<0.001) increased significantly 
between enrolment and one week post-delivery in each randomized group, but there 
was no difference between randomized groups in any laboratory safety parameter one 
week post-delivery (p>0.05). In total, 29 laboratory AEs were reported: n=14 in the 
control group versus n=15 in the intervention group (p=1.0; exact). Most were grade 1 
(n=11 in each group), four (n=2 in each group) grade 2, one grade 3 (intervention) and 
two were grade 4 (haemoglobin <6.5 g/dL; one in each group). Eight clinical AEs were 
reported: three in the control group (n=1 grade 2, n=1 grade 3, n=1 grade 4 (an emer-
gency C/S)) and five in the intervention group (n=1 grade 1, n=3 grade 2, n=1 grade 3). 
None of the laboratory and clinical AEs in the mothers or infants were judged possibly/
probably related to study medication.
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Here we demonstrate that adding a seven-day course of phenytoin, as enzyme inducer, 
from labour onset produces a large and significant reduction in the elimination half-life 
of nevirapine in HIV-infected, pregnant women using single-dose nevirapine as part of 
pMTCT ARV prophylaxis. Seven days phenytoin was safe and effective with no new nevira- 
pine resistance mutations observed. 
Importantly, nevirapine plasma concentrations at delivery were similar in those receiving 
and not receiving phenytoin, and also compared with previous studies,5, 13 similarly to our 
previous study evaluating a single-dose of carbamazepine as enzyme inducer.14 The time 
lag in enzyme inducer effect reflects the time required for transcription of CYP enzymes 
and protein synthesis. The delay in enzyme induction and the knowledge that phenytoin 
minimally penetrates into breast milk therefore ensures the protective perinatal effect of 
single-dose nevirapine is maintained. The absence of HIV-transmission during the post-
partum period, similar or even lower than rates in previous studies,10 confirms also the 
efficacy of the pMTCT regime.
Post-delivery, nevirapine pharmacokinetic parameters were substantially affected by 
enzyme induction. Adding phenytoin to single-dose nevirapine reduced nevirapine plasma 
levels by 85% and produced a significantly larger proportion of women with undetectable 
nevirapine levels one and two weeks post-delivery. Both effects are a consequence of 
the 60% reduction in the nevirapine elimination half-life, an absolute difference of -35.8 
hours. This is the largest decline in nevirapine elimination half-life ever reported, especially 
in the target population of HIV-infected, pregnant women. For example, the pilot study 
of L’homme et al found a median elimination half-life reduction of 38% (-19.4 hours) in 
four healthy, Dutch women receiving single-dose nevirapine with seven days phenytoin,13 
and a single-dose of carbamazepine reduced nevirapine levels by 36% in HIV-infected, 
pregnant women receiving single-dose nevirapine.14 Not surprisingly, a seven-day course 
of an enzyme inducer has a greater effect than a single-dose alone on the elimination 
half-life of nevirapine in HIV-infected, pregnant women.
The mechanisms by which the CYP enzymes are induced involves the transcription factors 
pregnane X receptor and the constitutive androstane receptor. The enzyme inducer binds 
to these receptors, thereby stimulating the activation of the CYP enzyme.19 Studies have 
shown that CYP enzyme induction is correlated with dose and drug level20 with higher 
doses and a higher plasma level of the enzyme inducer resulting in lower serum levels of the 
test drug. This likely explains why induction of the CYP enzyme has a greater effect with 
a long-course of an enzyme inducer than only the single-dose used in our previous study.
Although current guidelines, including zidovudine monotherapy pre-delivery and seven 
days zidovudine/lamivudine post-delivery are complex, they have reduced emergence of 
nevirapine resistance substantially by protecting the subtherapeutic nevirapine ‘tail’, since 
the lengthy duration of low and subtherapeutic levels of nevirapine in blood are plausibly 
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associated with increases in nevirapine resistance. A meta-analysis estimated that 4.5% 
of women using single-dose nevirapine and additional ARVs postpartum had nevirapine 
resistance 4-8 weeks post-partum.4 In our study, overall new nevirapine resistance pre-
valence was 2.4% (1 out of 41 samples); although we observed no nevirapine resistance 
mutations after single-dose nevirapine in combination with seven days phenytoin, clearly 
numbers are too few to make any conclusions about nevirapine resistance on the basis 
of this study alone. However, it raises the prospect that full elimination of nevirapine 
resistance could be possible. In the VITA-1 trial we found that women with undetect-
able nevirapine plasma concentrations one week post-delivery were less likely to develop 
nevirapine resistance mutations, and that the elimination half-life in women with new 
nevirapine mutation(s) was almost two and five times longer than the median half-lives 
in the control and intervention groups, respectively. Thus it is plausible that adding a 
seven-day course of phenytoin at labour onset might have significant additional benefits 
in reducing selection of nevirapine resistance mutations, even on top of the current ARV 
prophylaxis “tail”.
The main limitation of the study was its relatively small size. The trial was designed as 
a pilot powered to detect a difference between intervention and control groups in the 
nevirapine elimination half-life. A much larger sample size (~200; 100 per arm) would 
be needed to detect significant differences in the development of nevirapine resistance 
between the two groups. However, this group of women is extremely challenging to 
recruit and retain (Figure 1): only 23% of those assessed for eligibility pre-delivery were 
randomized, a further 26% of those randomized dropped out before delivery, and a 
further 23% of those who delivered in the study clinic did not provide samples 4-6 weeks 
post-delivery. We would therefore have needed to screen ~1,600 women to achieve 200 
women with weeks 4-6 samples. Whilst ideally a larger phase III trial should confirm the 
efficacy of 7-days phenytoin on resistance as a primary outcome, the substantial signi-
ficant reductions in nevirapine half-life, coupled with previous clinical and sophisticated 
modelling studies6, 7 demonstrating a causal association between nevirapine half-life and 
emergence of resistance, suggests it is highly likely to be effective. Another limitation was 
the standard HIV genotyping assay used which only detects mutations present in >20% 
of the viral population, and not subpopulations of mutants. Deep sequencing of these 
samples is planned. 
It is estimated that 18-64% of the women living in Sub-Saharan Africa with HIV are 
receiving cART for pMTCT, as now recommended by WHO (Option B+). However, this 
means that thousands of women are still receiving single-dose nevirapine,21 and demon-
strates the challenge of widespread implementation of the current guidelines. Phenytoin 
can be used safely during pregnancy and breastfeeding 22 and side-effects are expected 
to be infrequent using such a low dose for only a short period. Where it is not possible 
to provide cART, phenytoin is cheap and available in almost every clinic. Phenytoin may 
also be a useful intervention when women stop nevirapine at the end of breastfeeding 
within Option B+. We have demonstrated that implementation of this intervention would 
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substantially and significantly reduce nevirapine half-life; previous data demonstrating 
a causal relationship between nevirapine half-life and resistance emergence6, 7, 14 sug-
gest that implementation would not only facilitate the reduction of nevirapine resistance, 
but also enable further increases in coverage for pregnant women in need of perinatal 
HIV prophylaxis, whilst likely retaining the benefits of single-dose nevirapine in reducing 
transmission. This strategy might therefore support the overarching goal of the technical 
consultation of the WHO to reduce the overall HIV transmission rate from pMTCT to <5% 
at the population level by the end of 2015.
In summary, addition of an enzyme inducer for seven days to single-dose nevirapine for 
pMTCT greatly reduced the presence of subtherapeutic nevirapine levels by significantly 
shortening the nevirapine elimination half-life, with no new nevirapine resistance muta-
tions observed. Since prolonged subtherapeutic nevirapine exposure is known to lead 
to nevirapine resistance emergence,6, 7, 14 and since phenytoin is safely and widely used 
in women,15 to minimise HIV transmission from mother-to-child, single-dose nevirapine 
could be used with phenytoin as an alternative if other ARV drugs are unavailable.
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SUPPL. TABLE 1  Laboratory values of the women in the VITA-2 trial
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Data are presented as median (IQR) and were tested with Rank-sum. 
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SUPPL. TABLE 2  Maternal nevirapine plasma concentrations at delivery, week 1 and week 2 of
                      women in the VITA-2 study, who delivered vaginally (not by C/S)
 Women who delivered vaginally (not by C/S)
 Control Intervention p
GMR 
(90% CI)
At delivery    
Samples taken (n) 13 22   
nevirapine plasma conc. 
(mg/L; GM (95% CI))
1.08 
(0.63-1.84)
1.14
(0.70-1.86)
0.82†
1.05 
(0.58-1.92)
<0.05 mg/L nevirapine 
(n (%))
0 (0) 1 (5)   
1 week after delivery     
Samples taken (n) 16 22   
nevirapine plasma conc. 
(mg/L; GM (95% CI))
0.25 
(0.18-0.34)
0.035 
(0.027-0.046)
<0.001†
(0.14
(0.10-0.20)
<0.05 mg/L nevirapine (n(%))
0 
(0)
15
(68)
<0.001*  
nevirapine plasma conc 1 
week : delivery  (n of pairs)
13 22   
nevirapine plasma conc 1 
week : delivery  
(GMR (90% CI))
0.23 
(0.20-0.26)
0.031 
(0.026-0.038)
  
2 weeks after delivery     
Samples taken (n) 15 19   
nevirapine plasma conc. 
(mg/L; GM (95% CI))
0.045 
(0.029-0.074)
0.026 
(0.024-0.029)
0.005†
0.58
(0.42-0.80)
<0.05 mg/L nevirapine (n(%))
7 
(47)
18 
(95)
0.004*  
nevirapine plasma conc 2 
weeks : delivery  (n of pairs)
12 18   
nevirapine plasma conc 2 
weeks : delivery  
(GMR (90% CI))
0.036 
(0.029 - 0.044)
0.022 
(0.015 - 0.031)
  
† T-test, * Exact test. Median nevirapine plasma concentrations are similar to GM and are therefore not shown 
in Table 1. 
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Objectives
To evaluate pharmacokinetics of nevirapine, lamivudine and stavudine in HIV-
infected Zambian infants receiving fixed dose combination (FDC) antiretroviral 
tablets (Triomune Baby).
Design
Phase I/II study.
Methods
16 HIV-infected children ≥1 month, weighing 3-<6kg were enrolled. Blood was 
sampled at t=0, 2, 6 and 12 hours after observed intake of one FDC tablet (50 mg 
nevirapine, 6 mg stavudine, 30 mg lamivudine) 4 weeks after starting treatment. 
Safety and viral load response over 48 weeks were determined. 
Results
The median (interquartile range, IQR) age, body weight and daily nevirapine dose 
in 15 included children (8 girls) were 4.8 (4.2,8.4) months, 5.3 (4.3,5.5) kg and 
348 (326,385) mg/m2, respectively. The median (IQR) nevirapine area under the 
concentration-time curve (AUC0-12h), Cmax and C12h were 70 (56,104) h.mg/L, 7.5 
(6.2,10) mg/L, and 4.3 (2.9,6.9) mg/L, respectively. Values were on average higher 
than reported in adults, but ~20% lower than previously reported in children 
>6kg. Four of 15 (27%) children had a subtherapeutic nevirapine C12h (defined 
as <3.0 mg/L) compared to only 3/63 (5%) children >6kg (p=0.02), whilst child-
ren aged <5 months (3/6 (50%)) may have the highest risk for subtherapeutic 
nevirapine C12h (p=0.24). No association was found between viral load values and 
nevirapine plasma pharmacokinetic parameters (p>0.3). Stavudine/lamivudine 
pharmacokinetic parameters were broadly comparable to heavier children.
Conclusion
Exposure to nevirapine in African, HIV-infected infants with low body weight 
taking FDC tablets appears on average to be adequate, but due to large inter-
subject variability a relatively high proportion had subtherapeutic nevirapine C12 
levels, particularly those aged <5 months.
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Given high morbidity/mortality risks, WHO 2010 guidelines1 recommend HIV-infected 
infants initiate antiretroviral therapy (ART) immediately at diagnosis, regardless of CD4 
or WHO clinical stage. Small, scored, dispersible fixed-dose-combination tablets (FDCs) 
have been developed for HIV-infected infants/children: Triomune Baby (50 mg nevirapine, 
6 mg stavudine, 30 mg lamivudine) and Triomune Junior (double Baby dose). They have 
higher nevirapine to nucleoside reverse transcriptase inhibitor (NRTI) dose ratios compared 
to adult FDCs, consistent with paediatric dose recommendations1, 2. Using the same ratios 
as adult FDCs would underdose nevirapine3-7, because children metabolize nevirapine 
more rapidly than adults. They have somewhat lower stavudine and higher lamivudine 
doses than licensed paediatric mg/kg doses, considering toxicity profiles.
A previous 12-hour pharmacokinetic (PK) study in Zambian, HIV-infected children taking 
Triomune Baby/Junior4 found higher but more variable nevirapine levels than in adults8. 
However, only two children weighing 3-<6kg were included. We therefore undertook a new 
phase I/II study of PK, safety and viral load (VL) responses with Triomune Baby in infants 
weighing 3-<6kg. 
CHAPAS-1 (Children with HIV in Africa-Pharmacokinetics and Adherence of Simple anti-
retroviral regimens) was an open, randomised trial to assess appropriate dosing of FDC 
tablets of nevirapine/lamivudine/stavudine9. This PK substudy included 16 HIV-infected 
infants aged ≥1 month, weighing 3-<6 kg and fulfilling WHO criteria for initiating ART, 
enrolled in CHAPAS-1 June 2006-June 20089 and followed until trial closure (October 
2008).. Exclusion criteria for the main trial9 were previous ART exposure (including ART to 
prevent mother-to-child transmission); and for the PK substudy were abnormal laboratory 
values (week 2), reported non-adherence, active opportunistic infections and treatment 
with medication known to interact with any ART. All caretakers gave written informed 
consent. Since children were identified prospectively after birth due to acute illness, and 
mothers were referred to adult facilities for treatment/care, no mother was receiving ART 
at enrolment/PK day. The study was approved by the Biomedical Research Ethical Com-
mittee in Lusaka, Zambia and Ethics Committee of UCL London, United Kingdom. 
Daily nevirapine, stavudine and lamivudine doses targeted 300-400 mg/m2, 2 mg/kg and 
8 mg/kg respectively, in an FDC (Triomune Baby: 50 mg nevirapine, 6 mg stavudine, 30 mg 
lamivudine) taken as one tablet twice-daily for the 3-<6 kg weight-band, following WHO 
recommendations10. 
At least four weeks after initiating Triomune Baby at enrolment, when steady state nevi-
rapine plasma concentrations were achieved, a 12-hour PK limited sampling session was 
performed11, with 2.0mL samples at t=0, 2, 6 and 12 hours after observed intake of one 
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tablet. AUC0-12h was calculated by WinNonlin (version 5.2; Pharsight, CA) . Two children 
had full PK curves (at t=0,1,2,4,6,8 and 12 hours after observed intake) in the original 
PK study4. HIV-1 RNA viral load (VL) was assayed on available plasma stored at base-
line, weeks 4, 12, and then 12-weekly until trial closure in October 2008. Small sample 
volumes necessitated dilution, so lowest cut-offs ranged from <80 to <1600 copies/mL. 
(See4, 12, 13 for details on plasma drug concentration measurement and pharmacokinetic 
analysis). PK parameters for nevirapine, lamivudine and stavudine were compared with 
those from children ≥ 6kg using ranksum tests. Subsequent analysis focussed on nevira-
pine given previous data relating plasma concentrations, and VL response2 assessed here 
using Spearman correlations and virologic failure defined as VL>5000 copies/mL after 24 
weeks on ART, following WHO10, 14.
Sixteen children were enrolled; one was excluded due to evidence of non-adherence 
(C0 <C12h/3). In the 15 included children (eight girls) median (interquartile range, IQR) 
age and body weight were 4.8 (4.2,8.4) months and 5.3 (4.3,5.5) kg, respectively. All 
15 children were breastfed. Fourteen were moderately-to-severely stunted (height-for-
age z-score<-2: median (IQR) -3.30 (-5.18,-2.81)) and wasted (weight-for-age z-score <-2 
median (IQR): -3.23 (-4.52,-2.64)). The median (IQR) daily prescribed nevirapine dose 
at enrolment and time from ART initiation to PK day was 348 (324,386) mg/m2 and 29 
(28,29) days, respectively. 
The median (IQR) AUC0-12h, Cmax and C12h of nevirapine were 70 (56,103) h.mg/L, 7.5 
(6.2,10) mg/L, and 4.3 (2.9,6.9) mg/L, respectively (Table 1), ~20% lower than in children 
weighing ≥ 6kg, although differences were not statistically significant (ranksum p>0.08). 
Moreover, mean values in infants 3-<6kg were higher than reported in adults8. Stavudine 
and lamivudine PK parameters were broadly comparable with those reported in children 
weighing ≥ 6kg and adults15, 16. Lamivudine C12h was somewhat higher and stavudine Cmax 
somewhat lower than heavier children.
 
Inter-infant variability in nevirapine PK parameters was moderate-to-large. Coefficients 
of variation were 31%, 40% and 55% for Cmax, AUC0-12h, and C12h, respectively, similar to 
those reported previously in children ≥6kg (38% Cmax, 41% AUC0-12h, 50% C12h). Nevira- 
pine C12h were subtherapeutic (defined as <3.0 mg/L)2 in 27% (4/15) 3-<6kg children 
versus only 5% (3/63) children ≥ 6kg (exact p=0.02). The 3-<6kg children with C12h <3.0 mg/L 
were aged 3.6, 3.6, 4.8 and 8.4 months. Visual inspection (Figure 1 (a)) suggested risks 
might be higher in those aged <5 versus ≥5 months (3/6 versus 1/9, respectively), but 
numbers were too small to reach statistical significance (exact p=0.24). Children aged <5 
months received adequate  nevirapine doses (range 324-406 mg/m2/day).
VL at ART initiation was high (median (IQR) 347610 (70404,1689820) copies/mL) 
(Figure 1 (b)). The median (IQR) VL at week 4 (PK-day) was 1820 (804,2920) in eight 
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infants with (supra)therapeutic C12h versus 1793 (158, 5027) copies/mL in four infants with 
subtherapeutic C12h (ranksum p=0.87, Figure 1 (c)). There was no evidence of any associa-
tion between VL and nevirapine PK parameters at PK day (Spearman p>0.3). All VLs after 
week 4 were <5000 copies/mL (WHO failure threshold) except one of 16021 copies/mL at 
week 36 in a child with week 12 and 24 VLs <80 and 1670 copies/mL, respectively. This 
child had C12h<3.0 mg/L at week 4. 
None of the 15 children discontinued Triomune Baby due to adverse events (AEs), and no 
serious adverse events or clinical AEs were reported. Thirty-eight asymptomatic labora-
tory events occurred in the first 8 weeks on ART in 14/15 children; all resolved without 
ART modification. The most common were single elevated AST or ALT (n=3 grade 3; n=2 
grade 2; n=10 grade 1), with other AEs being hyperbilirubinaemia (n=1 grade 4; n=4 
grade 2; n=4 grade 1), anaemia (n=2 grade 3; n= 1 grade 2; n=7 grade 1), neutropenia 
(n=1 grade 3; n=2 grade 1) and thrombocytopenia (n=1 grade 3). There was no evidence 
of association between raised AST/ALT and supratherapeutic (>8.0 mg/L) nevirapine C12h 
plasma levels (exact p=0.20), nor between the number of AEs per child (median 3 (range 
0-5)) and nevirapine PK parameters (Spearman p>0.8).
In this study, 16 Zambian, HIV-infected 3-<6kg infants  receiving paediatric FDC Triomune 
Baby tablets twice-daily had plasma nevirapine concentrations that were slightly lower, 
but generally comparable with ≥ 6kg children, and were higher than historical adult data. 
However, large interinfant variability (55%) led to a relatively high proportion of children, 
particularly those <5 months, with low nevirapine trough concentrations. Stavudine and 
lamivudine PK parameters of were broadly comparable to heavier children/adults. 
Our results agree with previous studies4-7 showing younger children have higher risks 
of subtherapeutic nevirapine levels compared with older children. For example, using 
divided adult Triomune30 tablets (200 mg nevirapine, 30 mg stavudine, 150 mg lamivu-
dine), subtherapeutic nevirapine levels were more common in children <3 years7, and in 
the three lowest weight-bands (40% versus 8% subtherapeutic in <12kg versus >12kg 
respectively). However, nevirapine doses in adult FDCs are known to be too low for child-
ren3. More recently, in children receiving paediatric FDCs with a higher nevirapine NRTI 
ratio, age remained the major predictor for low nevirapine levels6; a substantial propor-
tion (35%) had subtherapeutic nevirapine trough levels, more pronounced in children 
≤3years6. This is consistent with our study using a comparable paediatric FDC where 27% 
of children weighing 3-<6kg (most <10 months) had a subtherapeutic nevirapine C12h 
concentration versus only 5% children ≥6kg4. 
Low nevirapine plasma levels may occur from noncompliance, malabsorption, drug 
interactions, low dose, increased metabolism or pharmacogenetics. Clinical signs of 
malabsorption and concomitant medications that could interfere with ART were substudy 
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exclusion criteria; furthermore we found no evidence that levels were related to weight- 
or height-for-age (Spearman p>0.7). We used WHO paediatric dose recommendations 
to prevent nevirapine underdosing17; nevirapine dose ranged from 320-438 mg/m2/day 
meaning overt underdosing cannot explain our findings. Drug metabolism varies with 
age, so the low plasma levels in our youngest children could be explained by increased 
metabolism at younger ages. Children have an increased ability relative to adults to 
eliminate drugs metabolized by some cytochrome P450 (CYP) isoenzymes, including 
CYP3A4 and CYP2B6 which metabolise nevirapine. However, the relationship is not 
linear6,18,19, and after birth newborns initially have a decreased ability to eliminate drugs.
It is unknown at precisely which age the switch from reduced to increased metabolic 
capacity occurs but our data suggest this is before month 6 for nevirapine. Lastly, relatively 
little is known about the influence of CYP2B6 and 3A4 gene polymorphisms on nevirapine 
PK parameters in African children20-22. Whilst pharmacogenetics can explain the high inter-
subject variability, polymorphisms should be similar in children weighing 3-<6kg and ≥6kg, 
although chance imbalances due to small numbers could partly explain our results. 
VL responses in these young children were generally good with 42% having VL <1000 
copies/mL at week 4, with no associations between VL and nevirapine plasma PK pa-
rameters.. Low nevirapine plasma concentrations (<3.0 mg) are usually associated with 
an increased risk of subsequent virological failure and nevirapine resistance2, 23, 24. One 
reason why we could not confirm this association  may be that children remain in the 3-<6kg 
weight band for only a short time (median (IQR) 113 (59-156) days in our study) before 
doses are increased. One child with subtherapeutic week 4 nevirapine C12h subsequently 
failed virologically, although as always non-adherence cannot be excluded. Numbers are 
too small and follow-up too short to generalise further. Cutaneous hypersensitivity and 
hepatic toxicity are the most important nevirapine-associated side-effects8, 25-27. However, 
adult studies have not consistently identified a relationship between toxicity and nevira-
pine PK parameters, and such a relationship has never been observed in children. Here 
no infant developed a rash (despite 8/15 initiating nevirapine at full dose within the 
CHAPAS-1 randomisation)9 and we found no association between AEs and nevirapine PK 
parameters, consistent with our findings in heavier children4. These results suggest that 
virological failure due to underexposure and potentially lower-than-optimal dosing is of 
greater concern than toxicity due to overdosing in these young infants.
Apart from small numbers, one major study limitation was lack of sufficient plasma for VL 
assays. Power to detect associations between nevirapine levels and treatment responses 
was therefore low, and nevirapine resistance could not be assayed to confirm treatment 
failure over poor adherence. A study strength was demonstration that PK data can be 
obtained on very young infants using a limited sampling model11. This used fewer blood 
sampling timepoints to predict a precise AUC0-12h for nevirapine, lamivudine and stavu-
dine in HIV-infected children.
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In conclusion, based on this study exposure to nevirapine in 15 African, HIV-infected 
infants with body weight 3-<6kg taking Triomune Baby following WHO guidelines was 
on average adequate but, with large inter-infant variability a rhigher proportion had sub-
therapeutic nevirapine plasma concentrations (than heavier children. However, given fast 
growth rates after starting ART such that most infants spend only a short time in the 
lowest weight band, and encouraging VL responses four weeks after ART initiation, WHO 
weight band tables for nevirapine-containing FDCs appear reasonable for 3-6kg infants. 
Larger population PK studies in young children taking FDCs in the CHAPAS-3 trial are 
ongoing, and will be linked to longer-term VL outcomes.
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FIGURE 1   Nevirapine C12h concentrations, age and viral load  (by week after antiretroviral 
          therapy initiation)
\
Note for Figure 1 (b): VL was available for 11 (73%), 12 (80%), 9 (60%), 10 (67%), 8 (53%), 7 (47%), 5 (33%) and 
1 (7%) infants at baseline, week 4, 12, 24, 36, 48, 60 and 96, respectively. 
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Table 1  Pharmacokinetic parameters of nevirapine, lamivudine and stavudine in children 
     weighing 3 kg to less than 6 kg, compared with heavier children and adults.
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Objectives
Young children metabolize nevirapine faster than older children/adults. We evalu-
ated nevirapine pharmacokinetics with/without dose-escalation in Zambian, HIV-
infected infants/children and its relationship with safety/efficacy.
Design
A retrospective pharmacokinetic substudy of the CHAPAS-1 trial.
Methods
HIV-infected, Zambian children were randomized to initiate ART with full-dose 
twice-daily nevirapine versus 2-week nevirapine dose-escalation. Samples taken 
3-4 hours postmorning-dose two weeks after nevirapine initiation were assayed 
for nevirapine levels. Viral load was measured on available samples at weeks 4 and 
48; adverse events were prospectively reported.
Results
Of 162 (77%) children with week-2 samples, 79 (49%) were randomized to nevi-
rapine dose-escalation. At ART initiation, median (IQR) age, weight and CD4% 
were 5.2 (1.5-8.7) years, 13.0 (8.1-19.0) kg and 13 (8-18)% respectively; 81 (50%) 
were male. With full-dose, few children <2 years (3/23, 13%) or >2 years (4/60, 
7%) had subtherapeutic nevirapine levels (defined as <3.0 mg/L), but with dose- 
escalation, 7/22 (32%) <2 years versus 7/57 (12%) >2 yrs had subtherapeutic 
nevirapine levels (p=0.05). There was no difference between week-2 nevirapine 
levels in those with VL >250 c/ml versus <250 c/mL at week 4 (p=0.97) or week 
48 (p=0.40). 11/162 children had grade 1/2 rash; all were >2 years (p=0.04), and 
10 were randomized to full-dose.
Conclusions
Subtherapeutic nevirapine levels 3-4h post-dose were more frequent in young 
children on dose-escalation. Younger children were at lower risk for rash. To simplify 
ART initiation and reduce the risk of sub-optimal dosing, full-dose nevirapine at ART 
initiation should be considered for African HIV-infected children <2 years of age.
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In resource-limited settings, nevirapine is generally the most frequently used non- 
nucleosidereverse transcriptase inhibitor (NNRTI) and is frequently the only option 
available for first-line combination antiretroviral treatment (cART) of HIV-infected infants/
children (if not perinatally exposed to nevirapine)1. The drug has many advantages as it 
is relatively inexpensive, has been used extensively with good virological efficacy and an 
acceptable safety profile, and is available in pediatric fixed-dose combination (FDC) tablets.
At nevirapine initiation, a dose-escalation strategy (half nevirapine dose for the first 
14 days) is recommended1 to minimize the risk of early adverse reactions2. Nevirapine 
induces its own metabolism and without dose-escalation high plasma concentrations 
occur during the first weeks of therapy. Elevated nevirapine levels have been associated 
with higher risks of rash and hepatotoxicity3, 4. 
However, young children metabolize nevirapine more rapidly than older children or 
adults5-7 and hence the impact of auto-induction on nevirapine pharmacokinetics may 
be less relevant. Indeed, early nevirapine-induced adverse events have been reported to 
be less frequent among children, particularly the youngest, compared to adults5. On the 
contrary, dose-escalation in young children may result in lower and suboptimal nevirapine 
levels during the dose-escalation period which might increase the potential for slower 
viral load suppression or virological failure8. Here we evaluate the pharmacokinetics of 
nevirapine with and without dose-escalation strategy in Zambian HIV-infected infants 
and children, and investigate its relationship with safety and efficacy.
CHAPAS-1 (ISRCTN31084535) was an open, randomized trial, performed at the Univer-
sity Teaching Hospital, Lusaka, Zambia, to investigate appropriate pediatric dosing of 
pediatric FDC tablets of nevirapine/lamivudine/stavudine: Triomune Baby (50 mg nevira-
pine, 6 mg stavudine and 30 mg lamivudine) and Junior (double Baby dose)7. Eligible 
HIV-infected, Zambian children, aged 3 months to 14 years, weighing <30 kg, and ful- 
filling WHO criteria for ART initiation, were enrolled June 2006-June 2008 and followed 
to October 2008 (trial closure).  Exclusion criteria were previous exposure to ART (in-
cluding to prevent mother-to-child transmission), severe laboratory abnormalities, active 
opportunistic infections/other illnesses and use of concomitant medication which may 
interfere with ART. Children were randomized 1:1 to initiate cART following WHO 2006 
weight-band dosing1 with either nevirapine full-dose using Triomune Baby/Junior taken as 
one tablet twice daily from ART initiation or nevirapine dose-escalation using 50% of the 
normal daily dose for Triomune Baby/Junior in the morning together with FDC Lamivir-S 
Baby (30 mg lamivudine and 6 mg stavudine) or Junior (double Baby dose) in the evening 
during the first two weeks of treatment. After two weeks, dose-escalation children 
stopped Lamivir-S Baby/Junior and continued with full dose Triomune Baby/Junior twice 
qf_offerte154258_binnenwerk_zw_1-1_01.indd   105 7-7-2013   19:05:22
CHAPTER 06 - NVP Dose Escalation in Young Children 106
daily. All carers (and children where appropriate) gave written informed consent. The 
study was approved by Ethics Committees in Lusaka, Zambia and London, UK.
In this retrospective pharmacokinetic substudy, a single plasma sample taken 3-4 hours 
post morning-dose of Triomune Baby/Junior two weeks after initiating ART was assayed. 
Nevirapine plasma levels were measured using ultra-performance liquid chromatography 
with a lower limit of quantification of 0.05 mg/L9. Subtherapeutic plasma concentra-
tions were defined as <3.0 mg/L3. HIV-RNA viral load was measured on available stored 
samples at weeks 4 and 48, as previously described7. Nevirapine plasma concentrations 
were compared between full-dose and dose-escalation groups, under and over 2-year-
olds, those with/without viral load <250 copies/mL, and those with/without adverse 
events using rank-sum tests. Exact tests were used similarly to compare proportions with 
subtherapeutic concentrations.
211 HIV-infected children were randomized to full-dose versus dose-escalation. 162 
(77%) children had week-2 samples available for determining nevirapine plasma concen-
trations; 79 (49%) of them randomized to the dose-escalation group. At ART initiation, 
median (interquartile range; IQR) age, weight and CD4% in the 162 included children 
were 5.2 (1.5-8.7) years, 13.0 (8.1-19.0) kg and 13 (8-18)% respectively (very similar to 
the whole trial7). 81 (50%) children were male. They were moderately-to-severely stunted 
and wasted (median (IQR) height-for-age z-score -3.23 (-4.09,-2.26); weight-for-age 
z-score -3.09 (-4.15,-2.17)). The median (IQR) prescribed daily nevirapine doses at enrol-
ment were 362 (344-400) mg/m2 and 175 (152-193) mg/m2 in the full-dose and dose-
escalation groups, respectively.
Two weeks after ART initiation at enrolment, median (IQR) nevirapine plasma concen-
trations were 9.2 (6.4-12) versus 4.9 (3.6-6.4) mg/L in the in the full-dose versus dose-
escalation groups respectively (p<0.001; ranksum). Smaller differences between full-dose 
and dose-escalation groups were observed in those below 2 years of age (5.3 (4.2-9.0) in 
the full-dose versus 4.8 (2.9-6.4) mg/L in the dose-escalation groups). In children over 2 
years, the median (IQR) nevirapine plasma concentrations were 10.0 (7.9-12.2) versus 5.0 
(3.9-6.6) mg/L in the full-dose versus dose-escalation groups, respectively (interaction 
p<0.001; Table 1, Figure 1 (a)). In the full-dose group, 3 of 23 (13%) children <2 years 
and 4 of 60 (7%) children >2 years had subtherapeutic nevirapine plasma concentrations 
(p=0.39; Exact). However, with dose-escalation, 7 of 22 (32%) children <2 years of age 
versus 7 of 57 (12%) children >2 years of age had subtherapeutic nevirapine plasma con-
centrations (p=0.05; Exact). 
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There was no difference between week 2 nevirapine plasma concentrations in those children 
with viral load >250 copies/mL versus <250 copies/mL at week 4 (p=0.97; ranksum) or 
week 48 (p=0.40; ranksum). Four weeks after ART initiation 12 of 28 (43%) children in the 
full-dose group versus 11 of 34 (32%) children in the dose-escalation group had a viral load 
<250 copies/mL (p=0.44; exact), compared to 44 of 61 (72%) children in the full-dose group 
versus 45 of 60 (75%) children in the dose-escalation group at 48 weeks (p=0.84; exact). 
Eleven of 162 (7%) children developed a rash, which were all graded as 1 or 2. All (100%) 
children with rash were older than 2 years of age (11/117 (9%); p=0.04, exact, versus 
0/45 under 2 years), and 10/11 were in the full-dose group (p=0.009; exact versus dose- 
escalation). Only one child was between 2-3 years of age (2.4 years) on full-dose. In 
children over 2 years, median (IQR) nevirapine plasma concentration was 15.1 (10.4-19.6) 
mg/L in those with rash (n=11) versus 6.8 (4.5-9.7) mg/L in those without rash (n=106) 
(p<0.001; ranksum; Figure 1 (b)).
TABLE 1  Nevirapine plasma concentrations of children in the study
Children 
<2 years 
(n=45)
Children 
>2 years
(n=117)
P-value
Nevirapine plasma concentration, mg/L
Full-dose group (n=83) 5.3 (4.2-9.0) 10.0 (7.9-12.2) 0.001
Dose-escalation group (n=79) 4.8 (2.9-6.4) 5.0 (3.9-6.6) 0.41
P-value comparing full-dose versus 
dose-escalation
0.14 <0.001 *
Subtherapeutic nevirapine concentrations, n (%)
Full-dose group (n=83) 3 of 23 (13%) 4 of 60 (7%) 0.39
Dose-escalation group (n=79) 7 of 22 (32%) 7 of 57 (12%) 0.05
P-value comparing full-dose versus 
dose-escalation
0.16 0.35 **
* Interaction (heterogeneity) p<0.001 
** Interaction (heterogeneity) p=0.65. Nevirapine concentrations compared using ranksum tests and median 
regression: subtherapeutic concentrations compared using exact tests and logistic regression.
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FIGURE 1  Nevirapine plasma concentrations of children in the study
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This randomized trial is the first, and currently only, to evaluate plasma nevirapine con-
centrations under full-dose or dose-escalation strategies during the initial two weeks 
of treatment in children. Despite the relatively small sample size, with nevirapine dose-
escalation at cART initiation more subtherapeutic nevirapine plasma concentrations 3-4 
hours post-dose were observed in children <2 years of age compared to older children. 
This finding is compatible with earlier studies describing more rapid nevirapine systemic 
clearance in younger than in older children5, 6. 
Of note, the P1060 trial8 found less favorable outcomes with nevirapine compared with 
ritonavir-boosted lopinavir among young children (median 1.7 years of age), regardless of 
whether they were previously exposed to nevirapine or not; virological failure (including 
deaths) by 24 weeks was significantly (15.6 percentage points) higher with nevirapine 
versus ritonavir-boosted lopinavir. Although no pharmacokinetic data were available, dose- 
escalation in infants was hypothesized to be a potential contributing factor for inferior 
response to nevirapine therapy8. We did not find evidence for an association between 
week-2 nevirapine plasma concentrations with short (week 4) or longer term (week 48) 
viral load suppression (which might be due, at least in part, to small numbers of samples 
assayed), but the high observed proportion of subtherapeutic nevirapine plasma concen-
trations two weeks after cART initiation in young children supports the hypothesis from the 
P1060 trial that the nevirapine dose-escalation strategy might be suboptimal in children 
<2 years of age. Unfortunately we did not assay VL in 24 week samples, so we are 
unable to directly compare our results with P1060. Interestingly however, we observed 
11% higher viral load suppression <250 copies/ml in the full-dose group at week 4; whilst 
the small number of samples that could be assayed (n=62) precluded us from excluding 
chance as an explanation, this does suggest that it is plausible that full-dose initiation 
could have some virological benefits.
Another argument supporting the use of full-dose nevirapine from ART initiation in 
young children is that none of those in the present study developed rash, which has pre-
viously been described to be less frequent in younger children5, 7. All rashes occurred in 
those over 2 years (only one child between 2-3 years old), and all but one in those starting 
full-dose nevirapine; further our results demonstrate the first pharmacokinetic-pharma-
codynamic association between high nevirapine plasma concentrations and rash, since 
all those with rash had high week 2 levels (most >10 mg/L) in the potentially toxic range3.
A third argument for full-dose nevirapine from ART initiation in young children is con-
venience. The use of three separate liquid formulations of these drugs is impractical, 
confusing for caregivers, and expensive; in studies in children aged 2-3 years carers 
strongly preferred tablet to syrup medications10. A half-dose of Triomune Baby/Junior 
from ART initiation should not be used, since the resulting substantial initial lamivudine 
underdosing at a time when very young children have very high viral loads could lead to 
early resistance development given its low genetic barrier. Another way to escalate the 
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nevirapine dose is to use one morning dose of Triomune Baby/Junior plus one evening 
dose of Lamivir-S Baby/Junior during the first two weeks of cART (as in CHAPAS-1). These 
low-cost pediatric FDCs enable safe and simple dose-escalation in contrast to cutting parts 
of adults NRTI FDCs. However, initiating nevirapine using full-dose is a less complicated 
approach; based on our findings this could certainly be considered in young African 
children <2 years of age.
One limitation of our study was that it was unknown if trial drugs were taken the days 
prior study visit; however the proportions with very low concentrations suggesting non-
adherence were similar across randomised and age groups (Figure 1 (a)). The exact time 
between nevirapine ingestion and blood sampling was also not recorded, but its relati-
vely long elimination half-life (25-30 hours) coupled with the fact that its subtherapeutic 
concentration (defined as <3.0 mg/L) applies for the entire 12-hour dosing interval3 makes 
nevirapine tolerant to minor variability in time from ingestion to sampling, here estimated 
as 3-4 hours. The other main limitation was the relatively small sample size, a consequence 
of failure to locate specimens taken at weeks 2 and 4 three years after study closure. 
In conclusion, using a dose-escalation strategy, subtherapeutic nevirapine levels 3-4 hours 
post-dose were more frequent in younger than older children. Younger children had a 
low risk for rash with a full-dose initiation strategy. To simplify ART initiation in young 
children and reduce the risk of suboptimal dosing, full-dose nevirapine at ART initiation 
should be considered for African HIV-infected children <2 years of age. Children >2 years 
of age could continue to receive dose-escalation to avoid the development of rash, or 
should have easy access to clinics to enable timely review if rashes recur with temporary 
discontinuation and nevirapine re-initiation at half-dose7.
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Objectives
To evaluate international pediatric efavirenz dosing recommendations using full 
pharmacokinetic information.
Design
Open-label, multi-centre, pharmacokinetic study
Methods
41 HIV-infected Ugandan children (3-12 years) on efavirenz+ lamivudine+ abacavir 
were enrolled in a study of twice- to once-daily lamivudine+abacavir 36 weeks 
after ART initiation in the ARROW trial. Once-daily efavirenz doses were 200, 
250, 300*, 350* mg for children weighing 10-<15, 15-<20, 20-<25, 25-<30kg 
respectively,using 200/50 mg capsules or *halved 600 mg tablets. Intensive plas-
ma PK sampling (t=0,1,2,4,6,8,12h post observed ingestion) was performed at 
steady state (PK1) and repeated 4 weeks later (PK2, including a further 24h sample). 
Results
41 and 39 children had evaluable efavirenz profiles at PK1 and PK2, respectively. 
Seventeen (41%) were boys. Five, 16, 17, 3 were in the 10-<15, 15-<20, 20-<25, 
25-<30kg weight-bands. The geometric mean (%CV) AUC0-24 was 50.8 (90.8%) 
and 55.5 (82.7%) h.mg/L at PK1 and PK2 respectively. Six children at PK1 and 
seven at PK2 had subtherapeutic C8h and/or C12h (<1.0 mg/L), 7/41 (17%) at either 
visit. At PK2, 15/39 (38%) children had C24h<1.0 mg/L (median (IQR) [range] 1.1 
(0.7-2.9) [0.3-18.4] mg/L). Ten children at PK1 and 11 at PK2 had C8h and/or C12h 
>4.0 mg/L; 12/41 (29%) at either visit. 
Conclusions
African children aged 3-12 years, on efavirenz dosed according to 2006 WHO/
manufacturer's recommendations, had lower and highly variable efavirenz PK 
parameters compared to adult data from manufacturer’s leaflet. There were no 
differences across weight-bands, suggesting no major effect of using half-tablets. 
Higher pediatric efavirenz doses, as per WHO 2010 recommendations, should be 
used and investigated further, but may risk increasing the proportion of children 
with potentially toxic levels.
CHAPTER 07 - Pediatric Underdosing of Efavirenz
qf_offerte154258_binnenwerk_zw_1-1_01.indd   116 7-7-2013   19:05:23
 Clinical Pharmacology Studies in HIV-Infected Children - PART II 117
The revised WHO guidelines of 2010 for the treatment of HIV-1 infected children older 
than three years of age recommend two nucleoside reverse transcriptase inhibitors (NRTI) 
plus a non-nucleoside reverse transcriptase inhibitor (NNRTI) for first-line antiretroviral 
therapy (ART)1. Efavirenz, an NNRTI, has potent antiviral activity and a long elimination 
half-life (40-55 hours), which makes it suitable for once daily dosing2. It is also suitable 
for co-administration with anti-tuberculosis medications. For these reasons, the drug is 
therefore one of the most preferred first-line antiretroviral agents and is currently used 
widely in HIV-infected children. The licensed and recommended pediatric dosages for 
efavirenz are based upon weight-bands (Table 1), with allometric doses targeting at least 
300 mg/m2 in each. However doses have not been established for children younger than 
three years and/or weighing below 10 kg, due to problems in achieving appropriate drug 
levels despite giving high doses1,3. 
Until now, there is limited knowledge about steady state pharmacokinetics of efavirenz 
in children, particularly in African populations. Studies have reported high proportions 
of children with subtherapeutic plasma concentrations of efavirenz4-7 receiving doses in 
accordance with current licensed doses2 and previous 2006 WHO guidelines, which were 
mainly based on data assessed in adult patients8,9. 
However, most pediatric studies to date have analyzed sparse pharmacokinetic (PK) 
samples rather than full pharmacokinetic curves, including the only two studies that have 
been reported in African children4,6. Ren et al found a high prevalence (40%) of sub-the-
rapeutic plasma concentrations of efavirenz in a small cohort of 15 children, based on 3 
samples taken 12-24 hours after observed dose. Hirt et al conducted a population pharma- 
cokinetic study based on 3 samples taken before, 1 and 3 hours after efavirenz admin-
istration in 48 children in Burkina Faso (9 of whom had full pharmacokinetic samples 
taken) and found an association between estimated AUC0-24 >51 h.mg/L and virological 
efficacy. They concluded that younger children should receive higher efavirenz doses than 
currently recommended. In both studies4,6 doses were derived from the licensed dose 
(Table 1)2. Together with earlier studies, these findings suggest that a large proportion of 
children taking efavirenz following the pediatric licensed or WHO 2006 dosing guidelines 
might need a higher dose. 
Since there are few studies validating international weight-band dosing recommenda-
tions for efavirenz to date, in particular in African HIV-infected children, we conducted 
a pharmacokinetic substudy to determine whether the 2006 WHO weight-band dosing, 
similar to the manufacturer's recommendations, resulted in optimal exposure in 41 Ugan-
dan children over 3 years old in the AntiRetroviral Research fOr Watoto (ARROW) trial.
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Population and study design
ARROW is an open-label randomised trial comparing routine laboratory (toxicity, CD4) 
versus clinically driven monitoring strategies, and also comparing three different NRTI-
based ART strategies in 1,206 symptomatic HIV-infected infants and children in Uganda and 
Zimbabwe (www.arrowtrial.org). Forty-one children aged 3-12 years from two Ugandan 
ARROW centers (the Joint Clinical Research Centre (JCRC), Kampala and the Paediatric 
Infectious Disease Centre (PIDC), Mulago Hospital) who had been taking lamivudine + aba-
cavir twice daily with once-daily efavirenz for at least 36 weeks in ARROW and were not 
expected to change weight-bands in the next 4 weeks participated in a two-period, 
crossover, open-label PK study comparing twice versus once daily lamivudine+abacavir10. 
Efavirenz was dosed once daily according to WHO 2006 pediatric recommendations as 
50 mg or 200 mg capsules or halved 600 mg tablets (Table 1), except that children 
weighing 14-<15 kg received 200 mg (the licensed dose) rather than 250 mg efavirenz to 
harmonize with NRTI weight-bands. The 200 mg, 250 mg, 300 mg and 350 mg efavirenz 
dose consisted of one 200 mg capsule, one 200 mg plus one 50 mg capsule, one halved 
600 mg tablet and one halved 600 mg tablet plus one 50 mg capsule, respectively.  Efa-
virenz 600 mg tablets were unscored, but were cut in the pharmacy before dispensing 
at four weekly visits. Children on any concomitant medication with known interactions 
to any drug in the ARV regimen or with anemia or illnesses that could influence the 
pharmacokinetics of efavirenz, such as diarrhea, vomiting, renal or liver disease were not 
eligible. Children who missed any dose of any antiretroviral drug in the 3 days prior to the 
pharmacokinetic evaluation (confirmed by pill count and questionnaire) were excluded. 
All carers gave fully informed written consent for both the main trial and the PK study, and 
children provided additional assent as appropriate according to age and knowledge of 
HIV-status. The pharmacokinetic study was approved by the Ethics Committee from each 
participating centre as well as by the Uganda National Council of Science and Technology.
Efavirenz blood sampling and analyses
Four weeks before the pharmacokinetic evaluation was undertaken (32 weeks after 
starting ART), children were changed to efavirenz administration in the morning if they 
were taking efavirenz in the evening. At week 36 after starting ART (once-daily efavirenz 
plus twice daily NRTIs) a 12-hour pharmacokinetic sampling session was done. Samples 
were taken immediately before directly observed medication intake (t=0) and at 1, 2, 4, 6, 
8 and 12 hours later. Breakfast (non-standardized, but mostly milk/milky tea with samosas/ 
bread/chapati) was provided two hours after the morning dose. One and a half ml of 
blood was collected per time point. Plasma was separated and stored at -80°C until trans-
portation on dry-ice for analysis of efavirenz (and NRTI) plasma concentrations. After the 
pharmacokinetic evaluation at week 36 the children were switched to a completely once 
daily regimen (morning administration). At week 40 the intensive plasma pharmacokinetic 
sampling was repeated, including an extra pharmacokinetic sample at 24 hours after 
observed intake. Serum biochemistry and hematology were performed at week 36.
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Plasma concentrations of efavirenz were assayed by a validated high-performance liquid 
chromatography method at the Department of Clinical Pharmacy of Radboud University 
Nijmegen Medical Centre, Nijmegen, the Netherlands, using a validated high-perfor-
mance liquid chromatography assay with UV detection11. The lower limit of quantification 
was 0.05 mg/L. Three samples had concentrations below the detection limit. They were 
treated as zero for the determination of PK parameters in WinNonlin, and as 0.05 mg/l 
for estimation of geometric mean concentration.
Statistical methods
Since WHO growth charts only go up to ten years of age, weight-for-age and height-
for-age z-scores were calculated using the 1990 British Growth Charts12 in STATA statis-
tical software, version 11.1 (STATA Corp., College Station, Texas, USA). Pharmacokinetic 
parameters (C24h, Cmax, the area under the concentration-time curve 0-24 hours post-dose 
(AUC0-24h) and CL/F) of efavirenz were calculated by noncompartmental analysis of the 
plasma concentration data using WinNonlin software version 5.2 (Pharsight Corporation, 
Mountain View, CA). AUC was calculated using a trapezoidal rule. C24h at week 36 was 
estimated by extrapolation of the 12-hour PK curve using the exponential equation for 
first-order pharmacokinetics: ln(C24h)=ln(C12h)-(∆t0-12h*k) with k=ln2/t1/2. Elimination half-
life was calculated on ≥3 time points after Cmax. Four children had R2<0.85 for the log- 
linear regression to calculate the elimination rate constant or elimination half-life. C24h was 
therefore not extrapolated. Efavirenz pharmacokinetic parameters were compared across 
weight-bands and predictors of log10 AUC0-24 and CL/F/kg including sex, age, weight- and 
height-for-age and dose, were assessed using mixed models, fitting random effects for 
each child. As CYP2B6 516G>T genotype is known to strongly increase plasma EFV expo-
sure13-15, but was not measured in this study. We used finite normal mixture modeling to 
estimate the geometric mean EFV exposure in and the size (percentage of the population) 
of three population subgroups to correspond to GG, GT and TT genotypes.
Forty-one children (24 girls, 17 boys) were included in this ARROW pharmacokinetic sub-
study. Four children increased weight-bands between weeks 36 and 40 (2 from 10-<15 
to 15-<20 kg; 2 from 20-<25 to 25-<30 kg) and are included in all analyses as the primary 
goal was to evaluate the weight-band based dosing. Two children had implausible time 
concentration curves (possible labeling errors) at week 40 which were excluded from 
analysis. The median (interquartile range, IQR) age and bodyweight were 7.6 (5.6-9.1) 
years and 20.0 (16.6-23.0) kg, respectively at 36 weeks after starting ART. Eighteen and 
23 children were aged 3-6 years and 7-12 years, respectively. The majority were moder-
ately stunted (median (IQR) height-for-age -1.85 (-2.78 to -1.11)) and wasted (median (IQR) 
weight-for-age -1.56 (-2.15 to -0.82)). Five (12%), 16 (39%), 17 (41%) and 3 (7%) were in 
weight-bands 10-<15/15-<20/20-<25/25-<30 kg, receiving 200, 250, 300 and 350 mg 
efavirenz, respectively at the first PK day (Table 1, 300 and 350 mg doses including halved 
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TABLE  1  Efavirenz pediatric dosing guidelines
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adult 600 mg tablets). Median (IQR) [range] doses per bodyweight were 13.6 mg/kg 
(12.8-14.6) [11.6-16.7] and 13.9 mg/kg (12.8-14.7) [11.9-16.7] at first and second PK days 
respectively; and 345 mg/m2 (323-360) [291-400] and 352 mg/m2 (329-367) [296-395] 
respectively per unit surface area. Doses in mg/kg received were highest in the 15-<20 
kg weight-band (median 14.7) and lowest in the 20-<25 kg weight-band (median 13.0) 
(Kruskal-Wallis p=0.001). Doses in mg/m2 were lowest in the 10-<15 kg weight-band 
(median 315) and were higher in other weight-bands (medians between 342 and 363; 
Kruskal-Wallis p=0.0002).
The geometric mean efavirenz plasma concentration versus time curves obtained at the 
pharmacokinetic evaluation days 36 and 40 weeks after starting ART were very similar 
(Figure 1). Seven of the 41 (17%) children in total had subtherapeutic (<1.0 mg/L) plasma 
concentrations at 8 hours (C8h) and/or at 12 hours (C12h) after observed intake at one or 
both PK days (Figure 2). Six of the 41 (15%) children had subtherapeutic C8h and/or C12h 
plasma concentrations at week 36 and 7/39 (18%) children at week 40. Twenty-two 
(59%) of the 37 children in whom C24h could be extrapolated at week 36 had values <1.0 
mg/L, and 15/39 (38%) observed C24h plasma levels at week 40 were <1.0 mg/L. Supra-
therapeutic and potentially toxic C8h and/or C12h plasma levels (>4.0 mg/L) were found 
in 12 (29%) children: 10 (24%) children at week 36 and 11 (28%) children at week 40. 
FIGURE 1  Mean efavirenz levels at week 36 (PK1) and week 40 (PK2)
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The geometric mean pharmacokinetic parameters of efavirenz are presented in Table 2. In 
the 35 children who stayed on the same efavirenz dose and had both PK evaluations, there
was no evidence of variation in Cmax, AUC0-24h, and clearance between the two pharma-
cokinetic evaluation days (geometric mean ratio (90% CI) 0.99 (0.88-1.10) p=0.83, 0.92 
(0.82-1.02) p=0.18, 1.09 (0.98-1.21) p=0.18 respectively). Efavirenz concentrations were 
mainly lower than those previously reported in adult patients2. In particular 26/41 (63%) 
and 20/39 (51%) children had AUC0-24 <50 h.mg/L at week 36 and 40 respectively, 27 
(66%) at either PK visit. A large intersubject but moderate intrasubject variability was 
found in efavirenz pharmacokinetic parameters: being 57% and 28% for Cmax, 81% and 
28% for AUC0-24, 84% and 27% for clearance, and 113% and 39% for Cmin (estimated 
not observed in 37 patients at week 36). There was no evidence of significant difference 
in efavirenz across the four weight-bands for Cmax (p=0.58), AUC0-24 (p=0.12), clearance 
(p=0.22) or Cmin (p=0.52). However, with only 41 children power was relatively low. Com-
pared to the 15-<20 kg weight-band (which had the most children), AUC0-24 was 29% 
lower (95% CI 55% lower to 10% higher) in those weighing 10-<15 kg, and 25% lower 
(95% CI 53% lower to 20% higher) in those weighing 20-<25 kg. AUC0-24 was more 
similar in the small number of children weighing 25-<30 kg (11% higher, 95% CI 38% 
lower to 99% higher).
FIGURE 2  Efavirenz concentrations 8, 12 and 24 hours after observed intake
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Although pharmacogenetic testing was not performed in this study, we used finite normal 
mixture modeling to identify the three most likely sub-populations for AUC0-24. 40% of 
the children had a geometric mean AUC0-24 of 27.2 h.mg/L, 32% 49.9 h.mg/L, and 28% 
137.7 h.mg/L (Figure 3). However, there was no evidence of association between sex, age, 
weight, receipt of halved tablets, weight- or height-for age with AUC0-24 (p>0.2). There 
was a marginal trend towards higher AUC0-24 with greater doses, (+8.8 per mg/kg higher
(95% CI-1.2,+18.9); +20.3 per 50 mg/m2 higher (-3.2,+43.8); both p=0.09). No child sub-
stituted efavirenz for toxicity, and there were no grade 3/4 clinical events considered defi-
nitely/ probably related to efavirenz in these children, with the exception of 3 rashes during 
the first week on ART (children had week 36 AUC0-24 42, 56 and 258 h.mg/L). 
A group of 41 HIV-infected Ugandan children aged between 3 and 12 years, receiving
efavirenz once daily and using the 2006 WHO weight-band dosing recommendations had 
lower and highly variable pharmacokinetic parameters of efavirenz compared to historical 
data from adults. The efavirenz Cmax, Cmin and AUC0-24 in our patients were 15%, 36% and 
10% lower, respectively than those observed in adult patients receiving once daily efavirenz 
600 mg (Table 2)2. If we compare our week 36/40 data to previously reported efavirenz data 
in African children, Cmax, Cmin and AUC0-24 were similar or even somewhat lower than those 
FIGURE 3  Subpopulations of AUC0-24 efavirenz within the ARROW PK substudy
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of previous studies: 4.10/4.10 mg/L, 0.84/1.40 mg/L and 50.79/55.41 h.mg//L, respectively 
in our study compared to 3.71 mg/L4, 1.18 to 1.64 mg/L4,6 and 65.2 h.mg/L4, respectively. 
Based on the study of Marzolini relating efavirenz t o efficacy and toxicity in adults, a 
minimum target of 1.0 mg/L 8-20 hours post-dose and a maximum target of 4.0 mg/L is 
advocated16. Of note, this study did not measure the true trough concentration at 24 hours, 
but was based on samples taken 8-20 hours post-dose. Fifteen percent (week 36) and 18% 
(week 40) of the children in the current study had subtherapeutic plasma concentrations 
(<1.0 mg/L) 8-12 hours post-dose, which is consistent with other pharmacokinetic studies 
of efavirenz in African children. The study by Ren et. al, where the 15 children received 
lower efavirenz doses2 than in our study1,17, found 40% of the patients had estimated Cmin 
extrapolated from samples taken 12-24 hours post-dose <1.0 mg/L6, compared to 59% 
extrapolated and 38% observed C24 in our study. Ren et. al also found a higher chance of 
detectable viral load in children with subtherapeutic plasma concentrations. Another study 
evaluating efavirenz exposure in African children demonstrated that 19% had estimated Cmin 
<1.0 mg/L4, and again, subtherapeutic exposure was linked to suboptimal antiviral efficacy.
In addition to adult and pediatric data showing an association between a Cmin target of 
1.0 mg/L and virological efficacy, two recently published studies have found an exposure-
efficacy link for efavirenz AUC in children4,18. Both found an efavirenz AUC0-24 above ~50 
h.mg/L significantly improved virological efficacy. In our study the geometric mean AUC0-24 
of efavirenz is only just above this 50 h.mg/L threshold (Table 2). Twenty-six of 41 (63%) 
children at week 36 and 20 of the 39 (51%) evaluable pharmacokinetic profiles at week 40 
had an efavirenz exposure lower than 50 h.mg/L.
Taken together, our data, added to the previously reported information, strongly suggests 
that children should receive efavirenz doses higher than the WHO 2006 recommendations 
TABLE 2  Pharmacokinetic parameters of efavirenz
Efavirenz
Week 36 (PK1) 
geometric mean 
[95% CI] (range)
Week 40 (PK2) 
geometric mean 
[95% CI] (range)
Lit. data adults2
arithmetic mean [SD]
Cmax (mg/L)
4.10 [3.37-4.98]
(1.45-14.87)
4.10 [3.41-4.93]
(1.18-21.97)
4.072 [1.16]
AUC0-24 (h.mg/L)
50.79 [39.77-64.88]
(16.04-258.84)
55.49 [43.91-70.11]
(18.18-479.91)
58.08 [23.04]
CL/F (l/h)
5.29 [4.12-6.80]
(0.77-15.99)
4.94 [3.90-6.25]
(0.52-17.92)
NA
C24h (mg/L)
0.84 [0.60-1.18]*
(0.17-9.28)
1.40 [1.03-1.90]
(0.27-18.39)
1.77 [1.01]
* Extrapolated (n=37)  Note: ranges provided with geometric means to describe the variation across children. 
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to increase the percentage of children with Cmin and/or AUC in the target ranges, leading 
to maximal antiviral efficacy. The fact that these WHO 2006 recommendations17 are very 
similar to the manufacturers leaflet2 daily dose (50 mg higher only for those children weighing 
14-<15 kg and 30-32.5 kg) highlights the importance of our results for children in resource-
rich as well as resource-limited settings. On the other hand, due to the large interpatient 
variability (81% in our patients), we found a considerable proportion of children (29%) with 
an efavirenz Cmax in the supratherapeutic and potentially toxic range (>4.0 mg/L). Because 
of the relatively large proportions of children with efavirenz exposure outside the therapeu-
tic range, it is not difficult to understand that only a small majority of children (22 of the 
41 (54%)) was dosed adequately (1.0-4.0 mg/L) 8-12 hours post-intake, which is consistent 
with data from the previous two studies in African children: 47% and 66%4,6. The latest 
2010 WHO dosing guidelines have higher efavirenz doses than evaluated in our study 
(and than licenced) for children weighing 14-<20, 25-<30 and 35-<40 kg: of note, these 
higher doses were chosen not only to reflect concerns about underdosing raised by the two 
previous African studies4,6, but also to remove the 50 mg capsules from dosing tables, as 
these were becoming no longer available. Our data suggest that, whilst these doses should 
lead to greater exposure and thus greater virological efficacy, the necessary trade-off is 
that more than one third of children will be exposed to potentially toxic efavirenz levels. 
Whilst overt grade 3/4 toxicity was not reported and CNS side-effects is transient in most 
adults, CNS side-effects associated with efavirenz in children (colorful dreams, impaired 
concentration) can be problematic, particularly at school, without ever reaching high toxic-
ity grades or without recognition that their source may be an adverse event and their 
importance should not be ignored. However, WHO 2010 guidelines retain the same 300 
mg dose for children weighing 20-<25 kg as we evaluated in ARROW: 21/31 (68%) AUC0-24 
in this weight-band were below the 50 h.mg/L target with this 300 mg dose, suggesting 
this should be increased. All children in ARROW weighed 14-30 kg, so our data cannot 
inform whether the WHO 2010 doses for the 10-14 kg (200 mg) or 30-<35 kg (400 mg) 
weight-bands are sufficient. However, efavirenz CNS side-effects can be more problematic 
in adolescents where problems with concentration can have major impacts on schooling, 
so avoidance of very high levels may be more important in those >30 kg.
Lower plasma concentrations found for efavirenz in these African children showed one 
important distinction compared to adults, namely that the apparent clearance for efa- 
virenz in our patients is faster than that observed in adult patients18. These data support 
the hypothesis that efavirenz metabolism is affected by age and that children are pharma- 
cokinetically different from adults. Another factor that could influence efavirenz 
metabolism is genetic polymorphisms in CYP2B6, the enzyme responsible for metabolism 
of efavirenz. African patients have been found to have higher frequencies of 516G>T poly-
morphism for the CYP2B6 enzyme19-22, which is associated with much higher and poten-
tially toxic efavirenz concentrations7. Additionally, Leger et al showed that distinct CYP2B6 
polymorphisms decreased plasma efavirenz exposure in patients of African descent23. 
Although we do not have pharmacogenetic data available for our patient population, the 
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trimodal distribution of efavirenz AUC as shown in Figure 3 suggests a division of patients 
being either normal metabolizers (homozygote wild-type CYP2B6), intermediate meta-
bolizers (heterozygote CYP2B6 mutants) and slow metabolizers (homozygote CYP2B6 
mutants). Our small patient set is roughly divided in three equal-sized subpopulations 
with a gene frequency of 0.44 for the T allele.
One limitation of our study is that it included only Ugandan (East African) children: howe-
ver, results are broadly compatible with earlier studies in South Africa4,6 and Burkina Faso 
(West Africa)4,6, and we were able to include a larger number of children than Ren et al. 
As far as we know, our study is the first using full pharmacokinetic information to evaluate 
the 2006 WHO weight-band dosing table which harmonized the licensed dosing recom-
mendations for efavirenz with weight-bands for other antiretrovirals. This dosing table used 
split adult 600 mg tablets to provide 300 mg as all or part of another dose in those 20-
<30 kg. Whilst exposure appeared slightly lower in children receiving these split tablets in 
the 20-<25 kg weight-band in our study, given the low exposures in all weight-bands it is 
difficult to attribute all or even much of this to a possible effect of splitting tablets. Using 
split adult tablets enables a far larger number of children to receiving life-saving ART, and is 
also recommended in WHO 2010 dosing guidelines: our findings highlight the importance 
of testing all pediatric dosing recommendations regardless of dosing modality. In terms of 
methodology, both previous studies used population pharmacokinetic models to determine 
of pharmacokinetic parameters, with the disadvantage that full efavirenz exposure can only 
be estimated by complex models. Here we used a full pharmacokinetic curve for every 
individual child after observed intake, which is more reliable for the estimation of pharma-
cokinetic parameters. Whilst grade 3/4 and ART-modifying toxicity was collected as part of 
the ARROW trial, lower grade adverse events which may be important for children, such 
as poor concentration, were not collected. Thus, while we observed no severe or serious 
toxicity associated with high efavirenz levels, we cannot rule out other toxic effects. 
The final limitation of the study is the lack of virological data to evaluate the association of 
pharmacokinetic parameters of efavirenz with virologic response. However, previous studies 
have demonstrated a strong concentration-effect relationship, not only in adults (subthera-
peutic C8-24h<1 mg/L)16, but also in children (AUC0-24 <~50 h.mg/L)4,18. The lack of  virological 
data in this study is thus less important than for drugs where such associations have not 
been previously described. Hence, we are confident that our efavirenz exposure data are truly 
suboptimal, and that those treating children with efavirenz in resource-limited and resource-
rich settings should move urgently to the adjusted WHO 2010 dosing recommendations. 
However, even with these new recommendations, dosing in some weight-bands (particularly 
from 20-<25 kg but also possibly 10-<14 kg and  30-<35 kg) remains relatively low. A new 
PK substudy within the CHAPAS-3 trial has just started to evaluate increased efavirenz dosing 
in African children. Extensive monitoring of efavirenz-associated toxicity, particularly active 
solicitation for lower grade side-effects, and retrospective evaluation of virological efficacy 
will be performed for this important, but difficult to handle, antiretroviral agent.
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Ugandan children aged between 3-12 years, on efavirenz once daily and using the 2006 WHO 
weight-band dosing recommendations, had lower and highly intersubject variable pharma-
cokinetic parameters of efavirenz compared to data from adults. There were no statistically 
significant differences across weight-bands, suggesting no major effect of some using half-
tablets. Our findings suggest that children receiving efavirenz dosed according to 2006 WHO 
guidelines (or licensed recommendations on which these were based) could be at a higher 
risk of virological failure, and all pediatricians in resource-limited and resource-rich countries 
should move to WHO 2010 guideline dosing as a matter of urgency. Nevertheless, doses in 
some weight-bands may need to be increased still further, and this should be investigated 
promptly. Yet, the higher proportion of children expected to have high and potentially toxic 
levels remains a concern. 
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This study evaluated middosing interval efavirenz plasma concentrations and the 
influence of CYP2B6 polymorphisms in relation to efficacy, tolerability and 
adherence in 97 Rwandan HIV infected children (3-16 years). Plasma drug 
concentrations and CYP2B6 polymorphisms were determined. Ten children were 
excluded for non-adherence. Large intersubject variability in efavirenz plasma 
concentrations was found. Of the 87 remaining, efavirenz concentrations were 
therapeutic, supratherapeutic and subtherapeutic in 67%, 20% and 14%, respec-
tively. No associations were found between efavirenz concentrations and CNS 
disturbances or virological failure. Minor allele frequencies were 0.32 (516G>T), 
0.33 (785A>G) and 0.09 (983T>C). Polymorphisms in CYP2B6 were strongly 
associated with high efavirenz levels.
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Current Rwandan national guidelines recommend two nucleoside reverse transcriptase 
inhibitors (NRTIs) plus a non-NRTI for first-line antiretroviral therapy (ART) of HIV-infected 
children >3 years of age1;2. Efavirenz is given as an alternative to nevirapine, when the 
child develops nevirapine associated side-effects or receives anti-tuberculosis treatment1;2. 
The drug is clinically and virologically effective, safe and well tolerated in children3,4. 
Its prolonged half-life enables once daily dosing which facilitates adherence to ART3.
An efavirenz plasma concentration of 1.0-4.0 mg/L 8-20 hours after ingestion is recom-
mended as appropriate for achieving viral suppression and for limiting side-effects6. 
Studies evaluating efavirenz pharmacokinetics in African children are sparse but indicated 
a high prevalence of virologic failure after exposure to efavirenz plasma concentrations 
<1.0 mg/L4 and a disadvantage of efavirenz is the large inter- and intrapatient pharma-
cokinetic variability, both in adults and children7-13.  High variability in efavirenz plasma 
levels is associated with various factors, like ethnicity, body weight, dosing, non- 
adherence and concomitant medication14,15. Notably, since efavirenz is mainly meta-
bolized by cytochrome-P450 CYP3A4, both elevated and decreased efavirenz plasma 
concentrations have been associated with CYP2B6-polymorphisms12, 16-19. Studies have 
shown a high prevalence of some genotypic variants in CYP2B6 enzyme in African adults 
that would lead to higher efavirenz plasma levels, and potentially more toxicity20,21. 
This study aimed to evaluate the middosing interval efavirenz plasma concentrations and 
the influence of CYP2B6-polymorphisms in relation to treatment efficacy, tolerability, and 
adherence in Rwandan HIV-infected children. 
 
Study population
Ninety-seven children (3-16 years) on efavirenz based regimens from the Department 
of Paediatrics, Kigali University Teaching Hospital and the Treatment and Research AIDS 
Centre; Kigali, Rwanda participated in the study. Efavirenz was prescribed once-daily as a 
(halved) 600 mg tablet, and/or capsules containing 200 mg and/or 50 mg in weight-band 
doses according to Rwandan 2009 National Guidelines and WHO 2006 paediatric recom-
mendations1;5. No children were on anti-tuberculosis treatment or other co-medication 
interfering with the efavirenz based regimen. All legal guardians gave informed written 
consent. Children ≥12 years provided additional consent. The study was approved by the 
Rwandan National Ethical Committee.
Study procedures
Demographic data were collected using patient’s medical record and a case report form 
with standardised questionnaires. All caregivers and children if ≥12 years were inter- 
viewed and all children underwent physical examination. 
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Adherence was assessed using questionnaires, self-reports and monthly pharmacy refill 
forms. For children with undetectable efavirenz plasma concentrations, adherence was 
also assessed by determination of lamivudine plasma levels. For evaluation of safety and 
acceptability, a complaint checklist was developed indicating whether the child had ex-
perienced adverse events (AEs) in the past month. AEs were stated as unlikely, possibly, 
probably or definitely related to the drugs.
Blood sampling and laboratory investigations
The study visit was planned 8-20 hours after the last efavirenz intake to collect one 
blood sample for determination of mid-dosing interval efavirenz plasma concentrations, 
CYP2B6-genotype testing, haematology, biochemistry, CD4 count and HIV1-RNA con-
centration (viral load, VL). The bioanalyses of efavirenz  and (if applicable) lamivudine 
were done at the Department of Pharmacy, Radboud University Medical Centre, Nij-
megen, The Netherlands using two validated HPLC assays with ultraviolet detection23, 
24. Genotype testing for CYP2B6 was performed at the Pharmacogenetics Core Labora-
tory, Department of Clinical Chemistry, Erasmus Medical Centre, Rotterdam, The Nether-
lands, using validated PCR-RFLP assays with primers 5’-CTGTTGCAGTGGACATTTG-3’ 
and 5’-ATCTCACTCCTGCACTCAC-3’ for 1459C>T, with digestion of the 460 bp pro-
duct with BglII (New England Biolabs), yielding 460 bp for wild type, and 258 and 202 
bp for variant alleles. For 785A>G primers 5’-GACAGAAGGATGAGGGAGGAA-3’ and 
5’-CTCCCTCTGTCTTTCATTCTGT-3’ were used: the 640 bp product was digested with 
BstN1 (New England Biolabs) for 2 h at 60 oC. The fragments for wild-type alleles were 
312, 136, 109 and 83 bp, and for variant alleles 295, 136, 109, 83 and 17 bp. For 516G>T, 
primers 5’-GGTCTGCCCATCTATAAAC-3’ and 5’-CTGATTCTTCACATGTCTGCG-3’ were 
used: the product of 526 bp was digested with Bsr1 (New England Biolabs) yielding frag-
ments for wild-type of 268, 241 and 17 bp, and for variant alleles 509 and 17 bp. All 
three PCR-RFLP assays were validated by direct sequencing. Assays for haematology, bio-
chemistry, CD4 counts and VL (lower limit of detection 40 copies/mL) were done at the 
National Reference Laboratory at Kigali, Rwanda. Virologic failure was defined as VL ≥ 
400 copies/mL. 
Statistical methods 
Logistic regression models were used for associations between efavirenz plasma concentra-
tions and VL suppression (<40 copies/mL), CD4 count (≥350 cells/mm3). Separate univariate 
logistic regression analyses were done to determine correlations between efavirenz plasma 
concentrations and reported side-effects. Analyses were conducted with STATA version 10. 
qf_offerte154258_binnenwerk_zw_1-1_01.indd   134 7-7-2013   19:05:25
 Clinical Pharmacology Studies in HIV-Infected Children - PART II 135
  
General characteristics
The median (IQR) age of the 97 children (55% female) was 12.0 (10.0-13.7) years. Efavirenz 
was combined with lamivudine and either zidovudine (70%), stavudine (28%), or tenofovir 
(1%). The average efavirenz dose was 11.4 (10.0-12.9) mg/kg and median efavirenz dura-
tion was 3.7 (1.5-4.9) years. 5/97 children (5%) were on efavirenz for ≥2 but <6 months. 
Median (IQR) CD4 cell count was 643 (444-925) cells/mm3.  All children were in good 
clinical condition although the majority was moderately wasted and stunted with median 
(IQR) WAZ -1.3 (-2.4;-0.3) and HAZ -1.2 (-2.2;-0.6). One (1%), 6 (6%), 17 (18%), 17 (18%), 
36 (37%) and 20 (21%) children were in weight-bands 10-14.9, 15-19.9, 20-24.9, 25-29.9, 
30-39.9 and ≥40 kg, receiving 200, 250, 300, 350, 400 and 600 mg efavirenz, respectively. 
Pharmacokinetics
Median (IQR) time of plasma sampling was 15.9 (14.8-16.8) hours after the last efa-
virenz intake. Twenty-two (22.7%) children had subtherapeutic efavirenz plasma con-
centrations (<1.0 mg/L). Ten children with undetectable plasma concentrations of 
both efavirenz and lamivudine were considered non-adherent and excluded from 
further analysis. Eighty percent of them had reported to be adherent by self-report. 
From the remaining 87 children, the median (IQR) efavirenz plasma concentrations were 
2.05 (1.41-3.17) mg/L. Twelve (13.8%) children had subtherapeutic efavirenz plasma con-
centrations (<1 mg/L), while 58 (66.7%) had therapeutic (≥1.0-4.0 mg/L) and 17 (19.5%) 
supratherapeutic efavirenz plasma levels (>4.0 mg/L). Four children had a concentration 
of >12.0 mg/L. A large intersubject variability in efavirenz middosing interval plasma con-
centrations was found (coefficient of variation of 107%). 
Efficacy, adherence and safety  
Sixty-one out of 87 (70%) remaining children were fully virologically suppressed (< 40 
copies/mL), 26 (30%) were not. Seventeen (20%) had a VL ≥400 copies/mL. No association 
was found between virological response and efavirenz plasma concentration groups 
(OR:1.7, 95CI% 0.7-4.3) (Table 1). However, the proportion of children with virologic 
failure was higher in the sub- and therapeutic group (>20%) compared to the group 
with supratherapeutic levels (6%). The majority of children (87%) self-reported to be well 
adherent (intake >95% of prescribed doses in previous month) including children with 
treatment failure. Adherence was not found to be associated with middosing interval 
efavirenz plasma concentrations: OR (95% CI): 1.1 (0.3-4.1).
Of 41 AEs reported, all were grade 1 or 2. Fourteen percent reported ≥1 CNS side-effect, 
including insomnia, nightmares, concentration disturbances, and dizziness (all grade 1). 
We did not find a significant relationship between efavirenz plasma concentrations and 
CNS side-effects (OR: 0.8, 95CI%:0.3-4.1). Skin problems reported by another 14% were 
atypical and not compatible with allergic reactions to antiretroviral drugs. Seventeen 
children (20%) had elevated AST and ALT concentrations. No serious AEs were reported.
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TABLE 1  Associations between efavirenz plasma concentrations and efficacy and safety.  
efavirenz and 
lamivudine 
undetectable
(n=10)
efavirenz plasma 
level <1.0 mg/L
(n=12)
efavirenz 
plasma 
level 1.0-
4.0 mg/L
(n=58)
efavirenz 
plasma level
>4.0 mg/L
(n=17)
Odds 
ratio 
(95% 
CI)*
HIV-RNA (c/mL)
median (IQR)
97200 
(13270 - 703500)
66050  
(17354 - 548350)
1240  
(178-4590)
88  
(51-14000)
0.9  
(0.9-1.0)
Proportion 
< 40 c/mL, 
n (%)
0 
(0)
8 
(67)
39 
(67)
14 
(82)
Proportion 
>40 c/mL, n 
(%)
10 
(100)
4 
(33)
19 
(33)
3 
(18)
1.7  
(0.7-4.3)
Proportion 
≥400 c/mL, 
n (%)
8 
(80)
3
(25)
13
(22)
1 
(6)
0.5  
(0.2-1.4)
CD4 count
cells/mm3  
(median 
(IQR))
684 
(445 - 916)
672  
(441-815)
684  
(445-922)
580  
(507-864)
0.9  
(0.9-1.0)
Adherence
Adherent by 
self report
8 
(80)
2 
(17)
7
(12)
3 
(18)
0.8
Side-effects
CNS distur-
bances,  
n (%)
2 
(20)
2
(17)
7 
(12)
3 
(18)
0.8  
(0.3-4.1)
* Multivariate analysis, including possible confounders adherence (even if no association still added to model), 
age, weight-for-age z-score, height-for-age z-score and sex; factors not included were NRTI backbone, duration 
of efavirenz use, time between drug ingestion and blood sampling, co-medication and biochemistry as no cor-
relation was observed with these and the middosing interval efavirenz plasma concentration.
qf_offerte154258_binnenwerk_zw_1-1_01.indd   136 7-7-2013   19:05:25
 Clinical Pharmacology Studies in HIV-Infected Children - PART II 137
Efavirenz plasma concentrations and pharmacogenetics 
Genotyping results are shown in Table 2. The CYP2B6 516GT-genotype was present in 46% 
(37/80), 516GG in 45% (36/80) and 516TT-genotype in 9% (7/80) children. CYP2B6 785AA, 
785AG and 785GG genotypes were present in 45% (37/83), 46% (38/83) and 9% (8/83) 
children, respectively. The CYP2B6 785A>G and the CYP2B6 516G>T gene polymorphisms 
were mostly found together in our population (CYP2B6*6, *19, *20 or *26 (www.cypal-
leles.ki.se)). The minor allele frequency for 516G>T, 785A>G and 983T>C was 0.32, 0.33 
and 0.09, respectively. All polymorphisms were in Hardy-Weinberg equilibrium (p>0.05). 
Median efavirenz concentrations were strongly associated with CYP2B6 516G>T, 785A>G 
and 983T>C polymorphisms (Table 2). Six out of seven (86%) children with the CYP2B6 
516TT homozygous genotype had supratherapeutic (>4.0 mg/L) mid-dosing interval efa-
virenz plasma concentrations whereas no individual in this group had an efavirenz plasma 
concentration <1.0 mg/L. Four out of 36 (11%) 516GG children had subtherapeutic efavi-
renz plasma concentrations and none of the children had a plasma level >4.0 mg/L. Similar 
data were observed for the CYP2B6 785A>G and 983T>C polymorphisms. 
TABLE 2  Gene polymorphisms in the G516T, T983C and A785G genotypes of the CYP2B6 enzyme
Variables Number of 
children  
n (%)
efavirenz middosing 
interval plasma 
concentration, median 
(IQR)
p-value*
CYP2B6 516G>T 80
GG 36 (45) 1.7 (1.3-2.2)
<0.001GT 37 (46) 2.4 (1.8-3.1)
TT 7 (9) 8.4 (5.0-13.0)
CYP2B6 983T>C 87
TT 71 (82) 1.8 (1.4-2.2)
<0.001TC 16 (18) 3.1 (1.4-8.3)
CC 0 -
CYP2B6 785A>G 83
AA 37 (45) 1.7 (1.4-2.2)
0.01AG 38 (46) 2.2 (1.7-3.1)
GG 8 (9) 7.3 (5.2-12.0)
*p-values were calculated using Wilcoxon rank-sum test
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In this study, a high level of intersubject variability in middosing interval efavirenz plasma 
 concentrations was observed. Only two-third of children had efavirenz concentrations 
within the therapeutic range. High variability (i.e. 107%) resulted in 14% children with 
subtherapeutic levels and 20% with potentially toxic plasma levels. Virologic failure 
was found in nearly a fifth of children with detectable efavirenz levels. Although the 
difference was not significant in this small study, a higher proportion of virologic failure was 
observed in children with (sub)therapeutic efavirenz levels. 
In pediatric studies from South Africa and Burkina-Faso, a large intersubject variability 
was also found (137% and 143%) and two-thirds of the children with persistent sub- 
therapeutic efavirenz levels experienced virological failure7, 10, 15. In these studies, results 
were not corrected for adherence. In two other pediatric studies, sub-therapeutic efavirenz 
exposure was also linked to suboptimal antiviral efficacy7, 25.
Variability in efavirenz plasma concentrations can occur due to different factors. Low con-
centrations of antiretrovirals can result from poor adherence, and subsequently lead to viro-
logical failure26, 27. The majority of children reported to be fully adherent by self-report. The 
fact that nearly half of children with subtherapeutic efavirenz levels also had undetectable 
lamivudine concentrations confirms that self- or proxy-reporting of adherence is unreliable 
and therapeutic drug monitoring provides more accurate information on adherence.
We also explored the influence of CYP2B6-polymorphisms on efavirenz plasma con-
centrations. The 516G>T polymorphism frequency of 0.32 was comparable to other 
reports17 and a significant correlation between this polymorphisms and middosing interval 
}efavirenz plasma concentrations was found. This is consistent with other studies, like the 
ACTG-trial (one-third African patients), a Zimbabwean study in adults and with the study 
by ter Heine et al12, 21, 28 in a Dutch pediatric population including 89% black children, 
which showed that clearance was 30% lower for 516GT compared to 516GG patients. 
The Zimbabwean study recommended a dose reduction of 35% for 516TT patients.
We found that CYP2B6 785AA patients had significantly lower efavirenz levels com-
pared to 785GG or 785AG patients. The 785A>G allele frequency was 0.33 in our study 
population, which was not earlier explored in paediatric populations, but are comparable 
to findings by Mukonzo et al in Ugandan adults20. The increase in CYP2B6 activity by 
the additional 785A>G polymorphism appears not to overcome the decrease in CYP2B6 
expression or activity produced by the 516G>T variant(29;30). Therefore, these findings 
indicate that the 516G>T effect is more relevant. In addition, the 983T>C polymorphism 
was also associated with efavirenz plasma concentrations. The prevalence is comparable 
to African adult populations16, 21, 31.
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CNS side effects, were not significantly associated with middosing interval efavirenz 
plasma concentrations comparing groups with efavirenz concentrations of <1.0, 1.0-4.0, 
>4.0 mg/L, which is in agreement with paediatric studies from different continents15, 17, 25. 
Reported skin problems were mild and not typical for efavirenz associated drug reactions, 
which usually occur in the first weeks after initiation2. 
One of the limitations of this study was the small number of children. It was also not 
possible to observe the ingestion of efavirenz the evening before study visit to reduce 
the number of non-adherent participants, nor were we able to collect full pharma-
cokinetic curves for every individual as this is a more reliable estimation of pharmaco- 
kinetic parameters. However, many paediatric studies have this shortcoming. Sparse blood 
sampling in children is recommended and hence middosing concentration levels are fre-
quently  used9. Currently only one pharmacokinetic study of efavirenz in African children 
is published with full pharmacokinetic curves7, 10, 15.
Conclusions
This study presented a large variability of efavirenz middosing interval concentrations in 
Rwandan HIV-1 infected children, when they were dosed according to the national guide-
lines. The World Health Organisation recently moved to higher paediatric weight-band-
based doses, these recommendations should continue to be reviewed for risks of high 
efavirenz concentrations and potential toxicity problems. Both adherence and CYP2B6-
genetic polymorphisms are major factors influencing variability in mid-dosing interval 
plasma concentrations. Significantly higher efavirenz levels are correlated to CYP2B6 
516TT, 785GG and 983CC individuals. Therefore, children with these CYP2B6 variants 
may have an increased chance of toxicity. 
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Data on zidovudine pharmacokinetics in children dosed using WHO weight-bands 
are limited. 45 HIV-infected, Ugandan children, 3.4 (2.6-6.2) years, had intensive 
pharmacokinetic sampling. Geometric mean zidovudine AUC0-12h was 3.0 h.mg/L, 
which is higher than previously observed in adults, and was independently higher in 
those receiving higher doses, younger and underweight children. Higher exposure 
was also marginally associated with lower hemoglobin.
qf_offerte154258_binnenwerk_zw_1-1_01.indd   144 7-7-2013   19:05:26
 Clinical Pharmacology Studies in HIV-Infected Children - PART II 145
Current WHO 2010 guidelines for the treatment of HIV-infected children recommend 
two nucleoside reverse transcriptase inhibitors (NRTIs) as part of first-line combination 
antiretroviral therapy (ART)1. For infants/children, the preferred NRTI backbone is twice-
daily lamivudine+zidovudine, which is effective, inexpensive, and available as fixed-dose-
combination (FDC) scored adult tablets (Combivir)2 which can be split for pediatric do-
sing, or generic dual or triple (with nevirapine) pediatric FDCs. However, whereas studies 
have investigated the pharmacokinetics of the current lamivudine doses3, surprisingly most 
zidovudine pharmacokinetic data is based on old 6-8 hourly and/or higher dosing4, 5. Data 
on zidovudine pharmacokinetics and pharmacodynamics at currently recommended lower/
less frequent doses in children remain sparse, particularly in African children6. Pharmacoki-
netic-pharmacodynamic studies are particularly important as anemia is a common, plausi-
bly dose-related, toxicity7, 8. As ~90% HIV-infected children needing ART are in Africa, 
we investigated zidovudine exposure in Ugandan, HIV-infected children receiving WHO- 
recommended twice-daily weight-band based dosing (not studied to date). 
ARROW was an open randomized trial comparing monitoring and first-line ART strategies 
in HIV-infected Ugandan/Zimbabwean children eligible for and initiating ART9. Allocation 
to zidovudine-containing regimens or not was part of the first-line ART strategy random- 
ization9. Once stable on ART (>24 weeks after initiation) children from two Ugandan 
ARROW centers (Joint Clinical Research Centre, Kampala; Paediatric Infectious Disease 
Centre, Mulago, Kampala) were approached for additional consent to participate in two 
intensive crossover pharmacokinetic substudies. The first compared twice- versus once- 
daily lamivudine and abacavir in children aged 3-12 years, before and four weeks after 
move to once-daily dosing, 36 weeks after ART initiation3. All children were taking 
efavirenz; some were also taking zidovudine as a fourth drug at the first (36-week) pharma-
cokinetic sampling day. The second substudy compared twice-daily zidovudine, lamivudine 
and abacavir as syrups versus tablets in children aged 1-4 years, at and four weeks after 
moving from syrups to tablets6 (median (IQR) 56 (40,70) weeks on ART).  
This analysis included all available zidovudine pharmacokinetic data from both substudies. 
Children on concomitant medication which could interfere with ART, or who had illnesses 
that could influence ART pharmacokinetics were excluded, as were children who reported 
missing any ART dose in the previous three days. All caretakers provided fully informed 
written consent. The pharmacokinetic substudies were approved by the Ethics Committee 
from each centre.
Zidovudine was dosed twice-daily as syrups or halved or whole 300 mg solid formulation, 
scored FDC tablets (provided by GlaxoSmithKline; Table 1). Doses followed WHO 2006 
recommendations, except that children weighing 12-15kg received 240 mg zidovudine 
syrup daily instead of 220 mg, children weighing 20-21kg on lamivudine/zidovudine 
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FDCs received 300 mg zidovudine rather than 450 mg and children 21-<25kg received 
450 mg zidovudine to harmonize with the lamivudine weight-band. Blood samples of 1.5 
mL were taken at t=0, 1, 2, 4, 6, 8 and 12 hours after observed ART intake. Breakfast 
(mostly milk/milky tea with samosas/bread/chapati) was provided two hours post morning 
dose. Plasma concentrations were assayed by a validated high-performance liquid chro-
matography-tandem mass spectrometry method10, with lower limit of quantification 
0.0025 mg/L, by Worldwide Bioanalysis, GlaxoSmithKline, Research Triangle Park, North 
Carolina. Zidovudine pharmacokinetic parameters (C12h, Cmax, AUC0-12h) were calculated 
using WinNonlin version 5.2 (Pharsight Corporation, Mountain View, CA). In exploratory 
analyses, associations between zidovudine AUC0-12h and sex, age, dose (mg/m2), weight- and 
height-for-age, and formulation were investigated using multivariable mixed models including 
a child-level random-effect (STATA version 11.1, STATA Corp, College Station, USA).
RESULTS
Zidovudine pharmacokinetic data were included from 45 children (17 (38%) male). Twenty-
eight (62%) children aged 1-4 years had two pharmacokinetic profiles (one each on syrup 
and tablets) and 17 (38%) aged 3-12 years had one profile on tablets. One child had 
C0h>3·C12h and was excluded, leaving 72 pharmacokinetic profiles available for analyses. Me-
dian (interquartile range, IQR) age and weight at the first pharmacokinetic day were 3.4 (2.6-
6.2) years and 12.6 (12.3-18.0) kg, respectively. Median (IQR) weight-for-age and height-for-
age z-scores were -1.09 (-1.62,-0.56) and -1.85 (-2.68,-1.20), indicating moderate wasting 
and stunting. Of the 72 evaluable profiles, median (IQR) zidovudine morning and total 
daily doses were 242 (218-278) and 466 (432-546) mg/m2 respectively (10 (9.4-12.2) and 
20 (18.5-23.9) mg/kg respectively). Eight (11%), 20 (27%), and 36 (50%) profiles were from 
children on 100 mg syrup, 120 mg syrup, and 150 mg lamivudine/zidovudine FDC tablets 
twice-daily, respectively; and 8 (11%) were on 150 mg morning and 300 mg evening tablets.
The geometric mean (95% confidence interval (CI)) AUC0-12h, Cmax and C12h was 3.0 (2.7-
3.3) h.mg/L, 1.8 (1.6-1.9) mg/L and 0.009 (0.007-0.010) mg/L, respectively (Figure 1 (a)) 
with CV% of 40%, 42% and 70%, respectively. Zidovudine AUC0-12h was 27-150% higher 
than previously reported in adults2, 11. GM Cmax were 1.84 mg/L and 1.58 mg/L in children 
<4 years and >4 years (p=0.12, ranksum), respectively.  
In multivariable models, higher zidovudine exposure (AUC0-12h) was independently as-
sociated with higher dose, younger age and lower weight-for-age. AUC0-12h was 0.43 
h.mg/L higher for every 50 mg/m2 higher zidovudine dose [95% CI 0.15,0.71] (p=0.003). 
Associations between age and zidovudine exposure varied across the age range (test for 
non-linearity p=0.001). Independently of the dose effect, zidovudine exposure was 1.06 
h.mg/L lower for every year older up to 4 years of age [0.48,1.63] (p<0.001), but there 
was no association >4 years (p=0.72) (Figure 1 (b). Thus, for the same dose in mg/m2, 
youngest children had higher plasma zidovudine exposure. Exposure was 0.72 h.mg/L 
lower for every unit higher weight-for-age [0.30,1.13] (p=0.001). Adjusted for these fac-
tors, there was no independent effect of sex (p=0.56), height-for-age (p=0.57) or for-
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mulation (syrups/tablets) (p=0.75). There was a trend towards higher Cmax in children <4 
years (GM=1.9 mg/L (95% CI 1.7-2.1)) versus >4 years (GM=1.5 mg/L (1.3-1.9) p=0.096).
Thirty-seven children had viral load (VL) measured within 4 weeks of PK day. Thirty-two 
(86%) had VL <80c/mL; only one (3%) had VL >400c/mL (17174c/mL). This child had an 
AUC0-12h of 3.7 h.mg/L.
Thirty-four children had hemoglobin assayed within one day of the pharmacokinetic 
sampling. There was marginal evidence for 0.31 g/dL lower hemoglobin per 1 h.mg/L 
higher zidovudine AUC0-12h [-0.65,+0.03] (p=0.07) (Figure 1 (c)).
TABLE 1  Zidovudine pediatric dosing 
Weight 
band
(kg)
Approx. 
Surface 
Area 
(m2)
WHO 
guidelines 
2006
WHO 
guidelines 
2010
ARROW protocol Choke-
phai-
bulkit 
et al12
Zidovudine Zidovudine Zidovudine Combi-vir GPOVIR 
syrup tablet syrup tablet syrup tablet tablet2 tablet
daily dose (mg)
10-<12 0.49 to 0.56 200 - 240 - 200 - - 180
12-<14 0.56 to 0.62 220 - 240 - 240 - - 240
14-<15 0.62 to 0.65  300 - 300 240 300 300 240
15-<17 0.65 to 0.71 - 300 - 300 - 300 300 240
17-<20 0.71 to 0.79 - 300 - 300 - 300 300 300
20-<21 0.79 to 0.82 - 300 - 450 - 450 300 360
21-<25 0.82 to 0.92 - 300 - 450 - 450 450 360
25-<30 0.92 to 1.1 - 450 - 600 - 450 450 420
≥30 ≥1.1 - 600 - 600 - 600 600 -
Note: shaded cells show agreement between ARROW protocol doses and WHO 2006 guidelines, and bold cells 
between ARROW protocol doses and WHO 2010 guidelines. Underlining shows where zidovudine doses were in-
creased between 2006 and 2010 WHO guidelines. The ARROW protocol was submitted for ethical approval before 
WHO 2006 guidelines were published, and also harmonised doses with weight-bands for lamivudine and other drugs.
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FIGURE 1  Mean zidovudine concentrations, exposure, age & hemoglobin at pharmacokinetic 
         sampling
(A) MEAN ZIDOVUDINE PLASMA CONCENTRATIONS
(B) RELATIONSHIP BETWEEN ZIDOVUDINE EXPOSURE (AUC0-12H ) AND AGE (YEARS) AT PHARMACOKINETIC SAMPLING
(C) RELATIONSHIP BETWEEN HEMOGLOBIN AND ZIDOVUDINE EXPOSURE (AUC0-12H) AT PHARMACOKINETIC SAMPLING
Note: in panel (b) fi tted effect of age is shown for a child with median weight-for-age (-1.09) and median dose 
(242 mg/m2). Points demonstrate the relationship between age and dose which is adjusted for within the multi-
variable model. 
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Here, we have found higher zidovudine exposure in Ugandan children aged 1-12 years 
dosed twice-daily according to WHO 2006 weight-bands compared to exposure pre- 
viously reported in adults receiving the standard dose of 300 mg zidovudine twice- 
daily2,11. Exposure was also higher (GMs were 2.36h.mg/L and 1.58h.mg/L) than in the only 
two previous pediatric zidovudine pharmacokinetic studies5, 12, which used lower doses 
than our study (Table 1 and 360 vs 360 -480 mg/m2/day, respectively). Subsequent 2010 
WHO guidelines1 have further increased the recommended zidovudine dose for all children 
except those weighing 15-20 or >30kg (Table 1), without new evidence, but reflecting con-
cerns that children had often been under-dosed with antiretrovirals. Thus exposure in chil-
dren currently receiving zidovudine in Africa is likely to be even higher than observed here. 
As well as the expected association between higher zidovudine exposure and higher 
zidovudine mg/m2 dose in this study, we also found strong independent evidence that 
higher exposure was associated with lower age in children <4 years and with lower 
weight-for-age. Whilst one study suggested that zidovudine clearance increased most 
rapidly during the first weeks of life, reaching adult levels at 2 years of age8, a small 
study in six Dutch children5 showed elimination rate increased with age between 2 and 
14 years, implying further maturation of metabolism during childhood. This agrees with 
our study, where we found that exposure from the same mg/m2 dose decreased in chil-
dren from 1 through to 4 years. An alternative explanation might be greater absorption 
in younger children; although we did not find any evidence that this might be due to 
liquid vs solid formulations, there was a trend to higher Cmax in younger children. We did 
not find any association between exposure and age among 19 children >4 years, but 
moderate-to-large variability may have obscured this. 
Available information about the relationship between zidovudine exposure and toxicity 
is limited7, 8. Although only 34 children had paired hemoglobin and pharmacokinetic 
measurements, we found marginal evidence for an association between higher zidovudine 
exposure and lower hemoglobin values. This is similar to a previous population pharma- 
cokinetic study8, which found mild anemia occurred in 23% of those with average 
zidovudine concentration >350 ng/mL (versus 8% without). However these children were 
receiving zidovudine as part of only mono or dual therapy; as chronic HIV-related anemia 
is common in HIV disease, the contribution of replicating HIV to these findings is unclear. 
Further, all but two hemoglobin values in our study were in the normal range (one grade 
1, one grade 2 toxicity). Whether higher exposure increases the risk for more severe 
toxicity over the longer-term is unknown. 
A limitation of our study is that we included only Ugandan (East African) children, thus 
limiting generalisability to other populations where host genetics may result in different 
pharmacokinetics. A population pharmacokinetic study including data from 100 children 
from six pediatric trials, including this study, is ongoing and is expected to provide further 
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insight in the pharmacokinetics and potential co-factors which may impact the pediatric 
pharmacokinetics of zidovudine. Another limitation is that the true Cmax (Tmax is 0.5 hours2) 
could have been missed and consequently AUC0-12h might be underestimated. Lastly, because 
of challenges in sampling relatively young children over 24h, we were unable to directly 
estimate the impact of unequal am/pm dosing in those weighing 20-30kg.
In summary, zidovudine is a common component of first-line pediatric ART, especially 
in resource-limited countries and only limited data are available on the widely applied 
twice-daily dosing regimen. Children dosed following WHO 2010 guidelines, younger 
children, and those with low weight-for-age are likely to have even higher zidovudine 
exposure than that observed here and substantially higher than previously reported in 
adults. Our findings suggest that this higher exposure could be associated with greater 
suppression of hemoglobin levels within the normal range and probably with no change 
in efficacy, since viral load suppression was already very good using WHO 2006 dosing. 
The impact on severe anemia warrants further investigation, particularly with regards to 
current WHO 2010 dosing.
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Objective
To evaluate the pharmacokinetics/acceptability of lopinavir/ritonavir (LPV/r) in a novel 
minitab sprinkle formulation (40/ 10 mg, Cipla Pharmaceuticals) versus innovator 
syrup or Cipla tablets (100/ 25 mg) in HIV-infected Ugandan infants/children.
Design 
Open-label, comparative bioavailability (randomized cross-over) studies in three 
age groups.
Methods 
Twice-daily minitabs were compared versus syrup in infants 3-<12 months 
(cohort-2) and children 1-4 years (cohort-3) and versus tablets in children 4-<13 
years (cohort-1). 12-hour intensive pharmacokinetic sampling after observed intake 
of LPV/r plus two NRTIs following WHO 2010 dosing with food was performed 
4 weeks post-enrolment. Children then switched formulation and sampling was 
repeated at week-8. Acceptability data were also collected.
Findings 
77 infants/children were included in cohort-2 (n=19)/ 3 (n=26)/ 1 (n=32). Among 132 
evaluable PK profiles, 13/ 21/ 25 pairs in cohort-2/ 3/ 1 were available for within-child 
comparison. For minitabs versus syrup, geometric mean (GM) (95% CI) AUC0-12h was 
88.6 (66.7-117.6) versus 77.6 (49.5-121.5) h.mg/L in cohort-2 (GM ratio (GMR) (90% 
CI) = 1.14 (0.71-1.85)) and 138.7 (118.2-162.6) versus 109.1 (93.7-127.1) h.mg/L in 
cohort-3 (GMR (90% CI)=1.27 (1.10-1.46)). For minitabs versus tablets, GM (95% CI) 
AUC0-12h was 83.1 (66.7-103.5) versus 115.6 (103.0-129.7) h.mg/L; GM ratio (GMR) 
(90% CI) 0.72 (0.60-0.86). Subtherapeutic levels (<1.0 mg/L) occurred in 0 (0%)/ 2 
(15%) minitabs/syrup in infants (p=0.48), no children 1-4 years and 4 (16%)/ 1 (4%) 
minitabs/tablets (p=0.35). 13/17 (76%) and 19/26 (73%) carers of infants and children 
1-4 years respectively chose to continue minitabs after week 8, mainly for reasons of 
convenience; only 7/29 (24%) older children (five <6 years) remained on minitabs. 
Conclusions
LPV/r exposure from minitabs was comparable with syrup, but lower than from ta-
blets, with no significant differences in subtherapeutic concentrations. Minitabs were 
more acceptable than syrups for younger children, but older children preferred tablets. 
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The new 2013 WHO guidelines recommend a ritonavir-boosted protease inhibitor (bPI) 
plus two nucleoside reverse transcriptase inhibitors (NRTIs) for first-line antiretroviral 
 therapy (ART) in HIV-infected children <3 years, particularly if perinatally exposed to 
NNRTI, and for second-line ART in HIV-infected children receiving 2 NRTIs plus a non-
nucleoside reverse transcriptase inhibitor (NNRTI) first-line1. In 2011, only 28% of children 
urgently needing to initiate treatment were receiving first-line ART, compared to 58% 
of adults2, and only 3% of children on ART were on ritonavir-boosted PI second-line 
therapy. As children face a life-time requirement for ART, the number of children in need 
of second-line treatment is expected to rise substantially in the future.
Simplifying NNRTI plus 2 NRTI pediatric first-line ART regimens by making fixed dose 
combination (FDC) solid formulations, dosed according to simplified WHO weight band 
tables, has significantly aided the programmatic scale up of first-line pediatric treatment, 
albeit that coverage remains low compared with adults (28% vs 58% in 20112). An 
additional factor constraining wider use of second-line ART, and bPI-based first-line ART 
in children <3 years exposed to perinatally to NNRTI, is the lack of affordable and appro-
priate pediatric bPI-based formulations for resource-limited settings. The only currently 
available combination bPI is ritonavir-boosted lopinavir (LPV/r) in liquid formulation for 
young children and as pediatric tablets for older children. The syrup is unpleasant tasting, 
has a high alcohol concentration (42%), and contains propylene glycol, which is especially 
undesirable in children <2 years of age3. Moreover, LPV/r syrup requires refrigeration, 
which makes it challenging for storage, transport and use in resource-limited settings. 
The tablet formulation is relatively large and must not be crushed; a recent study found 
a 40% decrease in bioavailability with crushed compared to whole tablets4. As well as 
being the only combined bPI formulation, LPV/r is the only bPI licensed for young children. 
Further, ritonavir as a booster for other PIs is only available for children as an even more 
unpleasant tasting liquid or a large tablet (minimum 100 mg dose). Therefore, alternative 
formulations of LPV/r with better taste and which do not require cold-chain transport and 
storage are urgently needed, particularly in resource-limited settings.
 LPV/r has recently been developed by a generic pharmaceutical company (Cipla Pharma-
ceuticals) as a heat-stable tablet containing half the dose (100/25 mg LPV/r; Lopimune) of 
the currently FDA approved and available adult tablets, and the same dose as pediatric 
tablets from the innovator company, and also as a novel minitab sprinkle formulation which 
is stored in capsules (40/ 10 mg LPV/r; Lopimune). The capsules can be opened and given 
even to the smallest children, as the sprinkles within them can be mixed with food or milk. 
In the CHAPAS-2 (Children with HIV in Africa - Pharmacokinetics and Adherence of Simple 
Antiretroviral Regimens) study, we evaluated the pharmacokinetics and acceptability of the 
minitab formulation versus the innovator syrup (80/20 mg LPV/r per mL; Kaletra, Abbott) 
and versus the generic pediatric tablets in HIV-infected Ugandan infants and children.
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CHAPAS-2 was an open, randomized, phase I, two-period cross-over comparative bio-
availability trial in HIV-infected infants/children from 3 months to <13 years of age taking or 
about to start first-line (infants exposed to perinatal nevirapine for pMTCT) or second-line 
ART with LPV/r plus 2 NRTIs (older children) from two pediatric clinics in Kampala, Uganda 
(Joint Clinical Research Centre, Baylor-Uganda; ISRCTN01946535). Infants/children were 
not eligible if they were expected to change weight bands resulting in a dose increase 
after enrolment and before the second pharmacokinetic sampling day at week 8, or if they 
were on concomitant medication known to interact with their ART, or if they had liver 
enzymes grade 2 or higher, anemia (hemoglobin <8.5 g/dL) or other illnesses (e.g. severe 
diarrhea, vomiting, renal or liver disease) that could influence LPV/r pharmacokinetics. En-
rolled chil-dren who missed any dose of any antiretroviral drug in the three days before the 
pharma-cokinetic sampling session (assessed by adherence questionnaire) were excluded 
from pharmacokinetic analyses, as were children with pharmacokinetic evidence of poor 
compliance (C0h below the lower limit of quantification (LLOQ) and C12h >3.0 mg/L). All 
carers, and children where appropriate, gave written informed consent and assent respec-
tively. The study was approved by the Ethics Committee from each participating site, the 
Uganda National Council of Science and Technology and by University College London, UK. 
At enrolment, all infants 3-<12 months were included in a non-randomized two-period 
crossover design (cohort-2) and all children 1-4 years of age in a 1:1 randomized two-
arm, two-period crossover design (cohort-3). All children 4-<13 years of age, weighing 
<25 kg were randomized 1:1 in a two-arm, two-period crossover study comparing the 
novel LPV/r minitab sprinkle formulation with the new generic pediatric tablets (cohort-1) 
(Supplementary Figure 1). The two first designs compared the novel LPV/r minitabs with 
innovator syrup. Children were only included in cohort-1 if they were able to swallow 
pediatric tablets. Children in cohort-1 and cohort-3 were randomized using computer-
generated randomization lists produced by the trial statistician at the MRC Clinical Trials 
Unit (CTU) in London, UK. Randomization was done by phoning the CTU. LPV/r was 
dosed twice-daily according to WHO 2010 pediatric weight-band based dosing recom-
mendations (Supplementary Table 1) as syrup, minitab-contained capsules (which have to 
be opened) and whole pediatric tablets. 
Four weeks after enrolment, when steady state was achieved on allocated treatment 
(syrup cohort-2; minitabs/syrup cohort-3 and minitabs/tablets cohort-1), an intensive 12-
hour pharmacokinetic session was performed. Samples were taken immediately before 
directly observed intake of the morning LPV/r dose (t=0 hours) and 1, 2, 4, 6, 8, and 
12 hours later. Children, if not breastfed, fasted >3 hours before the pharmacokinetic 
session and breakfast (mainly porridge) was given with the morning dose. Following the 
week 4 sampling session, all infants and children switched LPV/r formulation. Cohort-2 
switched from syrup to minitabs (arm 3), and cohort-3 switched from minitabs to syrup 
(arm 4) or vice versa (arm 5) and cohort-1 switched from tablets to minitabs (arm 1) or vice 
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versa (arm 2) (Supplementary Figure 1). At week 8, four weeks after switching LPV/r for-
mulation, a second intensive pharmacokinetic sampling session was performed. Data on 
acceptability of each LPV/r formulation were collected from standardized questionnaires 
at baseline (if already on LPV/r at enrolment), and weeks 4, 8 and 12 after enrolment. At 
week 8, children and carers chose which formulation they wished to continue.
Concentrations of LPV and ritonavir in plasma samples were determined using ultra per-
formance liquid chromatography with UV detection5. The analytical assay LPV and ri-
tonavir ranges were 0.109-31.2 mg/L and 0.044-29.4 mg/L, respectively. Intraday and 
interday precision ranged from 0.6 to 4.2% (coefficient of variation (CV)), and 0.3 to 
1.8%, respectively. The assay accuracy range was 98.2-105.6%.
For cohort-1 and cohort-3, the sample size of 24 children provided at least 80% power for 
the width of the 90% confidence interval (90% CI) for the geometric mean ratio (GMR) 
between formulations to lie within 0.80 to 1.25 (bioequivalence6) if no difference was ob-
served (GMR=1), based on an estimated standard deviation of change in log10 area under 
the concentration-time curve 0-12 hours post dose (AUC0-12h) between sprinkle and ta-
blet/syrup of approximately 0.26. For primary analysis, steady state LPV pharmacokinetic 
parameters (AUC0-12h, maximum concentration (Cmax) and concentration at 12 hours post 
dose (C12h)) were determined using Phoenix version 6.3 (Pharsight Corporation, CA, USA) 
and compared between formulations within-child using GMRs and their corresponding 
90% CIs. The proportion of children with subtherapeutic LPV concentrations (defined 
as <1.0 mg/L7) were compared between formulations using the exact-test. LPV AUC0-12h 
were compared across weight bands using analysis of variance on log-transformed data 
(equivalent to the geometric mean (GM)).
In total 79 children were recruited in CHAPAS-2 from August 2011 until September 2012. 
One was ineligible (not receiving LPV/r, on efavirenz-based first-line) and one withdrew con-
sent shortly after enrolment (because the carer was not able to attend the sample session 
days), leaving 77 children for analyses (19 infants in cohort-2, 26 children in cohort-3 and 
32 children in cohort-1). Median (interquartile range, IQR) age and CD4% were 0.5 (0.4-
0.7), 2.0 (1.8-2.8), and 6.2 (5.8-7.8) years and 24% (19-30), 32% (28-37) and 32% (27-37) 
in cohort-2, -3 and -1, respectively (Table 1). Infants/children were moderately wasted and 
stunted; median weight-for-age z-scores were -1.11, -1.19 and -0.82 and median height- 
for-age z-scores were -1.99, -2.05 and -1.24 in cohort-2, -3, and -1, respectively. 
Primary pharmacokinetic analyses were based on 13 infants in cohort-2 (6 excluded), 21 
children in cohort-3 (5 excluded) and 25 children in cohort-1 (7 excluded), each with two 
pharmacokinetic profiles. Children excluded from primary pharmacokinetic analyses had 
been wrongly dosed (3 cohort-1), unable to swallow pediatric tablets (1 cohort-1), non-
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compliant at one of the two sampling sessions (C0h<LLOQ and C12h>3.0 mg/L; 1 cohort-1, 
4 cohort-2, 4 cohort-3), changed weight-bands between week 4 and 8 (2 cohort-1, 1 
cohort-3), developed tuberculosis (1 cohort-2), or had transferred to another clinic so only 
one PK curve was undertaken (1 cohort-2).
Pharmacokinetic analyses
In cohort-2 (infants 3-<12 months), LPV concentrations and pharmacokinetic parameters 
were slightly higher with minitabs compared to innovator syrup (Figure 1 (b), Table 2). 
The GMR(minitabs:syrup) for AUC0-12h, Cmax and C12h all lay within the range of 0.80-1.25, 
but the lower and the upper 90% CI limits fell outside this range (Table 2). This was a 
consequence of high but similar inter-individual variability with both minitabs (CV% 46%, 
38% and 68%, AUC0-12h, Cmax and C12h respectively) and innovator syrup (51%, 40% and 
73%, respectively). Two (15%) and zero (0%) of 13 (15%) children had a subtherapeutic 
concentration on syrup and minitabs respectively (Figure 2; p=0.48; Exact).   
Similar to our data in infants (cohort-2), in cohort-3 (children 1-<4 years), LPV concentra- 
tions and pharmacokinetic parameters were slightly higher with minitabs compared to 
innovator syrup (Figure 1 (c), Table 2). The GMR(minitab:syrup) for AUC0-12h, Cmax lay within 
the range of 0.80-1.25, with C12h GMR just above this, with the upper 90% CI limits all 
above 1.25 (Table 2). There was no impact of randomization order on any estimated GMR 
(p>0.4). The AUC0-12h, Cmax and C12h CV% were 33%, 27% and 50%, respectively in mini-
tabs, compared to 33%, 27% and 55% with syrup. None (0%) of the children had sub-
therapeutic concentrations 12 hours after intake of either formulation (Figure 2).
In cohort-1 (children 4-<13 years), LPV concentrations of the new generic pediatric tablets 
were higher compared to the novel minitabs (Figure 1 (a)). Compared to historical data, 
LPV pharmacokinetic parameters were higher with tablets, but similar with minitabs 
(Table 2). The GMR(minitabs:tablets) (90% CI) for AUC0-12h, Cmax, and C12h were 0.72 (0.60-
0.86), 0.74 (0.64-0.85) and 0.59 (0.43-0.81), respectively, all lying outside the bioequiva-
lence range of 0.80-1.25. There was no impact of randomization order on any estimated 
GMR (p>0.15). The inter-individual variability (CV%) of the pharmacokinetic parameters 
was moderately high for minitabs (49%, 42% and 76%, for AUC0-12h, Cmax, and C12h res-
pectively), compared with tablets (28%, 19% and 66%, respectively). One (4%) and four 
(16%) of the 25 included children had subtherapeutic LPV trough concentrations after 
receiving tablets and minitabs, respectively (Figure 2; p=0.35; Exact). 
Ritonavir pharmacokinetic data and comparisons were consistent with the LPV data in 
all three cohorts. There were no differences across weight-bands in LPV or RTV pharma-
cokinetic parameters in the different cohorts, or in cohorts 2 and 3 combined (p>0.23; 
ANOVA).
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FIGURE 1  Geometric mean LPV plasma concentrations in infants/children after intake of LPV/r. 
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Acceptability
Administration of the minitabs required that they should be taken with food. In cohort-2, 
83% of infants were breastfed; in older children the most common food caregivers gave 
minitabs with was porridge (34% cohort-1, 62% cohort-3). 
Among younger children in cohorts 2 and 3, more problems were reported with taking 
the syrups than the sprinkles (Figure 3). In contrast, the older children, all but one of 
whom were already established on tablets for >6 months, reported more problems with 
taking minitabs. The problem reported most often with all formulations was taste; taste 
was worse with minitabs than tablets (50% versus 0%), but similar with minitabs and 
syrup (53% minitabs versus 67% syrups, cohort-2, and 38% minitabs versus 38% syrup, 
cohort-3) (Figure 3). At week 8, 71% cohort-1 children who had switched from tablets 
to minitabs reported problems with taste, whereas this was 47% and 36% in those that 
switched from syrups to the minitabs, cohort-2 and cohort-3 respectively. Difficulty swal-
lowing was reported as a problem in 13% minitabs versus 0% tablets (cohort-1), 20% 
minitabs versus 60% syrups (cohort-2) and 27% minitabs versus 19% syrup (cohort-3). 
Storage, transport and conspicuousness were less problematic for minitabs compared 
FIGURE 2  LPV plasma concentrations 12 hours after intake of LPV/r versus age in cohorts 2, 3 and 1.
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with syrups. However, several caregivers were concerned about the number of capsules 
needing to be opened to give minitabs to the older children.
On ease of switching from the original formulation to minitabs, 76%, 94% and 79% of the 
carers in cohort-1, cohort-2 and cohort-3 respectively reported that it was easy or very easy. 
At enrolment 37%, 12% and 41% of caregivers in cohort-2, cohort-3 and cohort-1 thought 
they would prefer minitab sprinkles. This compares with 72%, 64% and 19% reporting pre-
ference for minitabs at week 12. At week 8, 14/18 (78%) caregivers in cohort-2 and 19/26 
(73%) in cohort-3 chose to continue minitabs rather than syrups; however, in cohort-1 only 
7/32 (22%) caregivers/children chose minitabs, five of the seven children being under 6 years. 
Caregivers provided multiple comments about the formulations at each visit. It was clear that 
minitabs were preferred to syrup in cohorts 2 and 3 largely because they were considered to 
be easier to administer, store (including not requiring refrigeration) and transport. For those 
preferring syrup, key issues were: first that minitabs were also bitter; second that carers felt 
more confident that they could administer the whole dose with syrup than with minitabs 
even if the child struggled; third, the requirement to give sprinkles with food was of concern 
to some carers, because some felt they needed to sweeten food with sugar or give with 
honey (which is expensive) to mask the taste. One carer in cohort-2 reported that the child 
subsequently refused the food which had been previously administered with minitabs. 
Only one grade 4 adverse event (AE) was reported (malaria with severe anemia, Hb <6.5 
g/dL) in a child on innovator syrup. This AE was also reported as a serious AE (SAE) and 
was considered unrelated/unlikely related to the study medication. Apart from this SAE, 
no other grade 3 or 4 AEs were reported among children taking any of the formulations.
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TABLE 1  Baseline characteristics of children in CHAPAS-2 
Cohort-1 sprinkles 
vs tablets in 
children 4-<13 years 
(n=32)
Cohort-2 sprinkles vs 
innovator syrup in 
infants 3-<12 months 
(n=19)
Cohort-3 sprinkles 
vs innovator syrup 
in children 1-<4 
years (n=26)
Age, years 6.2 (5.8-7.8) 0.5 (0.4-0.7) 1.9 (1.8-2.7)
Male, n (%) 14 (44%) 11 (58%) 14 (54%)
Height, cm 112 (107-117) 63 (60-65) 80 (77-86)
Weight, kg 19.3 (18.0-20.9) 6.3 (5.9-6.7) 10.7 (9.4-12.6)
Weightbands, n (%)
5-<7 kg 0 15 (79%) 0 
7-<10 kg 0 4 (21%) 8 (31%)
10-<12 kg 0 0 11 (42%)
12-<14 kg 1 (3%) 0 3 (12%)
14-<20 kg 16 (50%) 0 4 (15%)
20-<25 kg 13 (41%) 0 0 
>25 kg 2 (6%) 0 0 
BMI, kg/m2 15.2 (14.3-15.8) 16.1 (15.1-17.5) 16.5 (15.5-17.6)
CD4% 32 (27-37) 24 (19-30) 32 (28-37)
Height-for-age 
z-score
 -1.24 
(-0.30 to -2.05)
 -1.99 
(-1.02 to -2.66)
 -2.05 
(-1.37 to -3.43) 
Weight-for-age 
z-score
 -0.82 
(-0.18 to-1.70)
 -1.11 
(-0.76 to -2.42)
 -1.19 
(-0.18 to -2.11) 
First-line
Second-line
0 
33 (100%)
20 (100%)
0
26 (100%)
0
Already on LPV/r for 
>1m at enrolment
If yes, years on LPV/r
31 (97%)
2.3 (1.2-3.3)
10 (53%)
0.3 (0.2-0.4)
25 (96%)
1.1 (0.9-1.5)
Daily LPV dose, mg/kg 22.3 (21.1-24.7) 38.1 (36.1-40.7) 28.3 (25.9-30.0)
Daily LPV dose, mg/m2 553 (530-591) 723 (696-769) 627 (565-663)
Values are n (%) for categorical variables and median (interquartile range, IQR) for continuous variables. 
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TABLE 2  Pharmacokinetic parameters of LPV in cohorts-1-3
Cohort-2 Sprinkles Syrup Sprinkles: Syrup
Historical 
data in 
children 3*
IMPAACT 
1083 
study 9†
PK 
parameter
GM 
(95% CI) 
[range]
GM 
(95% CI) 
[range]
GMR 
(90% CI)
AUC0-12h 
(h.mg/L)
88.6
 (66.7-117.6) 
[41.1-174.7]
77.6 
(49.5-121.5) 
[12.2-175.5]
1.14 
(0.71-1.85)
72.6
(31.1)
119.8 
(29.3-
261.0)
Cmax (mg/L)
10.7 
(8.6-13.4) 
[6.3-20.6]
10.6 
(7.8-14.3) 
[3.7-17.7]
1.01 
(0.72-1.42)
8.2 
(2.9)
13.4 (3.8-
29.2)
C12h (mg/L)
3.9 
(2.6-6.0) 
[1.6-10.0]
3.1 
(1.7-6.0) 
[0.4-10.5]
1.25 
(0.61-2.54)
3.4
(2.1) 
5.5 (0.03-
13.8)
Cohort-3 Sprinkles Syrup Sprinkles: Syrup
Historical 
data in 
children 3*
IMPAACT 
1083 
study 9†
PK 
parameter
GM 
(95% CI)
[range]
GM 
(95% CI) 
[range]
GMR 
(90% CI)
AUC0-12h 
(h.mg/L)
138.7
(118.2-162.6)
[72.5-228.5]
109.1 
(93.7-127.1)
 [57.3-191.3]
1.27 
(1.10-1.46)
72.6
(31.1)
119.8 
(29.3-
261.0)
Cmax (mg/L)
15.3
 (13.4-17.4) 
[9.6-24.8]
12.6 
(11.1-14.3)
 [7.3-18.9]
1.21 
(1.09-1.36)
8.2 
(2.9) 13.4 (3.8-29.2)
C12h (mg/L)
6.4 
(4.8-8.6) 
[1.3-13.8]
4.3 
(3.3-5.7) 
[1.3-10.5]
1.49 
(1.12-1.97)
3.4
(2.1) 
5.5 (0.03-
13.8)
Cohort-1 Sprinkles tablets Sprinkles:tablets
Historical 
data in 
children 3*
IMPAACT 
1083 
study 9†
PK 
parameter
GM 
(95% CI) 
[range]
GM 
(95% CI) 
[range]
GMR
 (90% CI)
AUC0-12h 
(h.mg/L)
83.1 
(66.7-103.6) 
[22.6-222.7]
115.6 
(103.0-129.7) 
[68.4-204.6]
0.72 
(0.60-0.86)
72.6
(31.1)
119.8 
(29.3-
261.0)
Cmax (mg/L)
10.3 
(8.6-12.2) 
[4.0-25.1]
13.9 
(12.8-15.1) 
[8.7-18.8]
0.74 
(0.64-0.85)
8.2 
(2.9)
13.4 (3.8-
29.2)
C12h (mg/L)
2.6
(1.7-4.1) 
[0.2-13.4]
4.4 
(3.3-5.9) 
[0.5-18.1]
0.59 
(0.43-0.81)
3.4
(2.1) 
5.5 (0.03-
13.8)
*mean (SD) steady state LPV PK parameters of 53 children 6 months to 12 years of age receiving 230/57.5 mg/m2 
twice daily LPV/r innovator syrup. † GM (range) LPV PK parameters of 48 children 4.2 (0.4-12.9) years of age receiving 
316 (258, 451) mg/m2 twice daily LPV/r of the innovators heat-stable pediatric LPV/r tablets or liquid formulation. 
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(A): COHORT-2 (SPRINKLE VS SYRUP IN INFANTS 3-<12 MONTHS)
(B): COHORT-3 (SPRINKLE VS SYRUP IN CHILDREN 1-<4 YEARS)
(C): COHORT-1 (SPRINKLE VS TABLET IN CHILDREN 4-<13 YEARS)
FIGURE 3  Percentage reporting each problem for the different formulations.
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This phase I bio-equivalence study has shown slightly higher, but still broadly equivalent, 
LPV/r exposure from the newly developed minitab sprinkle formulation together with 
food in infants/children from 3 months to 4 years of age compared with LPV/r exposure 
from the currently used innovator syrup and historical data3. Exposure from minitab 
sprinkles in older children (4-<13 years of age) was also generally consistent with our 
younger cohort. However, exposure to LPV/r from the generic tablets was significantly 
higher than from minitabs. Variability in LPV/r pharmacokinetic parameters was mode-
rate to high in all formulations, but no LPV/r exposure differences were found between 
weight-bands for twice daily dosing recommendations (Supplementary Table 1) between 
the three formulations. Carers found minitabs more acceptable than syrups for their in-
fants/children, particularly for transport and storage reasons. However, for older children 
already able to swallow tablets, these were more acceptable than minitabs, where taste 
remained a concern. 
LPV/r exposure in children in this study was slightly higher than adults and historical data 
from children on the same formulation3, 8, probably because the children in our study 
received higher doses (median range 553-723 mg/m2/day) following the WHO 2010 
weight-band based dosing recommendations (Supplementary Table 1) rather than being 
dosed at 230/57.5 mg/m2 twice daily following the manufacturers leaflet3. Exposure from 
the two novel formulations was higher than from the syrup, despite equivalent mg dosing, 
thus bioequivalence could not be confirmed. Despite the higher LPV/r exposure found in 
these children, LPV/r treatment was well tolerated. Only one (serious) adverse event was 
reported, which was not related to study medication. Our findings are compatible with 
the interim results of the IMPAACT 1083 study9, which also described drug exposure and 
safety profiles in infants and children dosed according to the WHO weight-band dosing 
guidelines. AUC0-12h, Cmax, and C12h were estimated as 119.8 h.mg/L, 13.4 mg/L and 5.5 
mg/L, respectively, in children 0-13 years of age on the innovator heat-stable pediatric 
LPV/r tablets or liquid formulation. Similarly to our findings, in the 1083 study there were 
no grade 3 or higher adverse events definitely related to study treatment.
Apart from relatively small numbers (59 children with two full pharmacokinetic pro-
files), one limitation is that our study included only Ugandan children. However, 
genetic polymorphisms in children on LPV/r have been shown to have minimal clinically 
relevant influence on LPV exposure and clinical outcomes10, so this is unlikely to have 
materially affected results. Another study limitation was the lack of concurrent viro-
logical data, although the fact that exposure from the new formulations was higher 
than previously reported suggests that this is likely to have remained adequate. Varia-
bility in the pharmacokinetic parameters within and between our study arms was high, 
but the proportion of subtherapeutic trough concentrations (<1.0 mg/L) was absent 
or low in most groups. In only 2 groups (children 4-<13 years on minitabs and infants 
3-<12 months on syrups) were trough concentrations sub-therapeutic in 15–16%. This 
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proportion is similar to the 13% observed in the IMPAACT 1083 study; this study also 
reported favorable 24 week HIV-1 RNA responses and increases in CD4 percentage9. 
Overall, the pharmacokinetics of the novel minitab sprinkle and generic pediatric tablet 
formulation of LPV/r with the newly developed dosing schedule, based on WHO dosing 
recommendations for children in resource-limited settings, are acceptable. The accepta-
bility data for the minitab sprinkle formulation investigated in our study also suggest that 
carers found it to have important advantages over the syrup formulations. Most young 
children (1-<4 years) in cohort-3 and around half the infants (3-<12 months) enrolled in 
cohort-2 had already been taking LPV/r syrup for >1 month (median 1.1 years in these 
young children from both cohorts). Despite being stable on syrup for some time, most 
chose to continue minitabs at the end of the study, mainly because of improved ease of 
transportation and/or storage than syrup. However, for older children (all able to swal-
low tablets) minitabs were less acceptable and taste in particular was a concern. A few 
carers in the younger cohorts (1 and 2) also preferred syrup to minitabs, citing poor taste 
of the minitabs, requirement to take with food (particularly if food refusal occurred by 
association or if additional expensive food items such as honey were deemed necessary). 
Finally, as a consequence of mixing the minitab sprinkle with a small amount of food, 
some carers were unsure that the whole dose was taken when administering minitabs. 
The unmet need for child-friendly formulations to facilitate the scale-up of second-line 
ART access for older children, and bPI-based first-line access for infants in resource-
limited settings is clear. We have shown that the novel, heat-stable, solid drug minitab 
sprinkle formulation of LPV/r evaluated in the CHAPAS-2 trial had an acceptable pharma-
cokinetic profile when dosed according to weight-band dosing recommendations and 
was generally more acceptable and preferred to syrup in the short term. 
For countries choosing to follow new WHO 2013 recommendations and move to LPV/r 
as first-line ART for children <3 years, the minitab sprinkle formulation (being submit-
ted for regulatory approval) offers an alternative to syrup which has well known limi- 
tations in terms of acceptability, administration and logistics of transportation and 
storage. Further follow-up of the CHAPAS-2 cohorts is planned to describe longer term 
acceptability and efficacy through to one year. In addition, further pharmacokinetic 
and|acceptability studies for an improved finer ‘granule’ sprinkle formulation with better 
taste masking are planned.
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*Based on standard from paediatric oncology11. † Target daily LPV dosage of WHO 2010 is 230-350 mg/m2 twice-
daily (=460-700 mg/m2 LPV daily dose) Note: bold indicates where CHAPAS-2 protocol dosing differed from 
WHO 2010. 
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SUPPLEMENTARY FIGURE 1  CHAPAS-2 trial design. 
* who were able to swallow LPV/r paediatric tablets.
Note: all infants/children were either initiating LPV/r based ART or were already on LPV/r-based ART and interes-
ted/willing to try the new generic sprinkle formulation. Children on LPV/r were already taking tablets in cohort-1 
and most already taking syrup in cohort-2 and cohort-3.
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Since the turn of the millennium, remarkable successes have been achieved in the fight 
against HIV/AIDS worldwide. In Sub-Saharan Africa, the region most severely affected by 
the life-threatening disease, a massive scale-up of access to combination antiretroviral 
treatment (cART) have been realized during the past ten years and this has saved millions 
of lives1, 2. Despite the increasing number of HIV-infected individuals receiving ART, the 
drugs are still not universally accessible. To date, the global coverage, in particular for the 
most vulnerable populations in need for cART, is modest3. It is, however, rapidly expan-
ding in order to reach the goal of UNAIDS’ commitment that by 2015 15 million people, 
including pregnant women and children, should be using the life-saving medicines3. To 
allow cART scale-up in resource-limited settings, the World Health Organization (WHO) 
recommends a population-based strategy, which is mainly focused on standardized cART 
protocols, such as simplified drug regimens and appropriate fixed-dose combination 
(FDC) drug formulations for HIV infected individuals. 
In line with WHO’s public health approach for resource-limited settings, this thesis has 
two objectives: The first section investigated simple, accessible and affordable strategies 
for the prevention of mother-to-child transmission (pMTCT) of HIV using enzyme indu-
cers for the elimination of nevirapine resistance after single-dose exposure as part of the 
antiretroviral prophylaxis for pMTCT. The second section aimed to optimize antiretroviral 
regimens for children to facilitate the scale-up of HIV treatment in resource-limited set-
tings by evaluating new appropriate antiretroviral paediatric drug formulations and vali-
dating newly developed WHO weight-band based dosing recommendations for the use 
in resource-constrained settings. The current chapter (general discussion) addresses the 
challenges in translating our research findings into practice in resource-limited settings 
focusing on antiretroviral prophylaxis for pMTCT of HIV, HIV-treatment for children in 
resource-limited settings, research capacity development and our international collabo-
ration for clinical research.
Antiretroviral prophylaxis for pMTCT of HIV
The World Health Organization (WHO) issued the first recommendations on pMTCT in 
resource-limited settings in the year 2000. It recommended a single-dose nevirapine at 
labor onset, which has been shown to reduce MTCT by ~50%4, 5. These recommendati-
ons were revised in 2004 and later in 20066, 7, since nevirapine resistance development 
became a major concern. Single-dose nevirapine alone was no longer endorsed as a 
preferred option, and was recommended only as part of a longer prophylactic regimen. 
The field is dynamic, as in 2010 and soon thereafter in 2012 the WHO presented its 
new guidelines on pMTCT8, recommending two options: Option A and Option B/B+. 
Option A recommends antenatal prophylaxis with zidovudine followed by intrapartum 
and postpartum prophylaxis with single-dose nevirapine and zidovudine plus lamivudine. 
Option B recommends cART until after finishing breastfeeding and Option B+ recom-
mends lifelong cART, regardless of CD4 cell count8. The programmatic update of WHO 
indicates that Options B and specifically B+ is likely to be preferable to Option A. The shift 
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in pMTCT policy is driven by the lack of operational feasibility of the complex regimen in 
Option A, the clear benefits to pMTCT models of Option B that emphasizes the expansion 
and access of HIV treatment and the contribution of option B’s cost-effectiveness9.
However, because of the fragility of health systems, new guidelines, such as Option B/
B+, are difficult to implement. By the end of 2011, 57% of HIV-infected women world-
wide were estimated to have received an antiretroviral regimen during pregnancy; only 
30% of those who were eligible for treatment had initiated cART3. The current Tanzanian 
National guidelines on pMTCT recommending Option A were developed in July 201210, 
but implementation of these recommendations nationwide, especially in rural regions, 
is still behind. Lack of infrastructure and constraints on human and financial resources 
contribute to poor uptake of new recommendations in resource-limited settings, as in 
Tanzania11, 12. Single-dose nevirapine alone has turned into a fading concept, but in practice, 
this simple intervention is still widely used by thousands of women in resource-limited set-
tings, particularly in more rural areas where access to cART is not feasible or unavailable3.
For as long as pMTCT programs are still including single-dose nevirapine, the risk for 
nevirapine resistance development remains a major concern. In our systematic review 
(Chapter 2) it was demonstrated that single-dose nevirapine alone results in a prevalence 
of 31% nevirapine resistance. Addition of antepartum zidovudine reduced the proportion 
of nevirapine resistance by 30% to 21%. Combining antepartum zidovudine with a post-
partum course of two other antiretroviral drugs for 4-7 days reduces the risk of nevirapine 
resistance mutations to 0.011%. Longer duration of the postpartum course (20-30 days) 
appeared to be most effective, as it nearly eliminated nevirapine resistance. This sounds 
promising, but may require even more self-discipline of the mothers’ drug compliance in 
these yet complex regimens.
We therefore set up a trial investigating adding simple strategies of enzyme inducers 
(a single-dose carbamazepine or seven days of phenytoin at labor onset) to single- 
dose nevirapine for pMTCT in HIV-infected pregnant women. A pharmacological, rather 
than antiretroviral, approach of adding a CYP3A4 enzyme inducer has been shown to 
decrease nevirapine elimination half-life in healthy women13, with greatest reductions 
from carbamazepine and phenytoin. In our first trial (VITA-1; Chapter 3), a simple inter-
vention of adding a single-dose carbamazepine to single-dose nevirapine at labour onset 
significantly reduced nevirapine plasma concentrations one week after delivery in HIV-
infected Tanzanian women, with a trend towards fewer resistance mutations14. Intensi-
fying the current Option A with a 7-days postpartum regime of phenytoin once daily from 
labour onset (VITA-2; Chapter 4) demonstrated a larger enzyme induction effect with a 
significant reduction in the elimination half-life of nevirapine in HIV-infected, pregnant 
women compared to a single-dose carbamazepine. Seven days phenytoin was further-
more safe and effective with no new nevirapine resistance mutations observed. 
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Where it is not possible to provide cART, phenytoin and carbamazepine are cheap and 
available in almost every clinic. These interventions may also be useful when women stop 
nevirapine at the end of breastfeeding within Option B. Implementation of this inter-
vention would not only facilitate the reduction of nevirapine resistance, but also enable 
further increases in coverage for pregnant women in need of perinatal HIV prophylaxis. 
It would likely retain the benefits of single-dose nevirapine in reducing transmission, with 
plausibly lower rates of emergence of major resistance mutations. Therefore, adding an 
enzyme inducer to single-dose nevirapine shows new possibilities for pMTCT programs 
to reduce the selection of nevirapine resistance mutations in settings where other options 
are limited and might therefore support the overarching goal of the technical consulta-
tion of the WHO to reduce the overall HIV transmission rate from pMTCT to <5% at the 
population level by the end of 2015.
It is important to note that conducting these VITA trials has been challenging. Due to lack 
of research capacity and experience within the team at the start of the VITA-1 trial, many 
women were lost to follow-up after delivery and data management procedures were 
insufficiently developed for optimal operation. It was therefore possible that the guidelines 
of Good Clinical Practice (GCP) provided by the International Conference on Harmo-
nization (ICH) were not fully followed. Support from other African (University Teaching 
Hospital, Lusaka, Zambia) and European (Medical Research Council, Clinical Trials Unit, 
London, UK) clinical research groups became extremely valuable in a successful comple-
tion of the trial. Hence, the execution of the subsequent multi-centre VITA-2 trial was 
tremendously improved, with considerably greater GCP-compliance.
Partially due to financial support derived from funding of the VITA studies a new research 
building has been constructed at the Kilimanjaro Christian Medical Centre that current-
ly enables enhanced collaboration between different clinical research disciplines (PhD 
candidates, research nurses, data management team, meeting rooms, computer rooms 
with wireless internet). The VITA studies have shown that conducting clinical research 
in low-experienced resource-limited settings is not only about asking relevant scientific 
questions, here as simplified and better strategies in the reduction of nevirapine resistance 
after-single-dose exposure for pMTCT in regions where this intervention is still being 
used, but also about research capacity development at the clinical research site in favor 
of future clinical trials (see section research capacity development).
HIV-treatment for children in resource-limited settings
To date only 28% of the children who need cART are reported to be receiving the medi-
cines3, 15. The scale-up of pediatric treatment programs has always lagged behind that of 
adults. Treatment options for children remain insufficient and have restricted roll-out in 
resource-limited settings, where most (90%) children with HIV infection live3. Therefore, 
one of the specific challenges in the scale-up of treating HIV-infected children is the unmet 
need for more appropriate pediatric drug formulations that are inexpensive and easily usable.
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When pediatric drug formulations are unavailable, adult tablets are used in an attempt 
to create child-size doses. Carers of pediatric patients may break or crush the (mostly 
unscored) tablets meant for an adult patient. This may lead to administration of in- 
appropriate doses, as they are unequally divided. Furthermore, the dosage after breaking 
might not allow administration of a dosage small enough for an infant or young child16.
Even when appropriate formulations of antiretroviral agents are available for children, 
pharmacokinetic data are often insufficient to appropriately guide drug dosing, especially 
in the youngest children, who metabolize these drugs differently17, 18. Due to growth 
and development of these children pharmacokinetic parameters change. It causes large 
interpatient and intrapatient variability in the pharmacokinetics of antiretroviral drugs 
complicating optimal dosing. Adequate drug exposure is essential in HIV treatment of 
children, who generally start treatment earlier and will need to take it for far longer than 
adults; it is therefore a major goal in the development of appropriate pediatric fixed-dose 
combination tablets (FDCs). 
In the CHAPAS-1 (Children with HIV in Africa-Pharmacokinetics and Adherence of Simple 
antiretroviral regimens) trial, appropriate dosing of FDC tablets, approved based on early 
pharmacokinetic data generated within the trial, was assessed. It is known that children, 
particularly the youngest, metabolize nevirapine more rapidly than adults19-21. The tablets 
therefore have higher nevirapine to lamivudine/stavudine dose ratio compared to adults 
FDCs. Our findings in Chapter 5 have confirmed that younger children (weighing 3-6 kg) 
have higher risks of subtherapeutic nevirapine levels compared to older children. Also, 
evaluating plasma nevirapine concentrations under full-dose or dose-escalation strategies 
during the initial two weeks of treatment in children, more subtherapeutic nevirapine 
plasma concentrations 3-4 hours post-dose were observed in children <2 years of age 
compared to older children with nevirapine dose-escalation at cART initiation (Chapter 6). 
Drug metabolism varies with age, and so the low nevirapine plasma levels in the youngest 
children in our studies could be explained by increased metabolism at younger age. 
Studies, such as the abovementioned trials, are key to safety and rational dosing recom- 
mendations of new FDCs established for children. Regulatory approval needs to be 
gained through the US Food and Drug Administration or European Medicines Agency to 
ensure that those formulations become more widely available to children living with this 
life-threatening disease. The WHO pediatric antiretroviral working group (PAWG) advised 
a higher nevirapine to lamivudine/stavudine dose ratio compared to adults FDCs, based 
on the findings of CHAPAS-1 and it is hoped that in the future children <2 years will be 
recommended by the WHO’s PAWG to start full-dose nevirapine at ART initiation in order 
to avoid subtherapeutic nevirapine levels. 
Only few studies have validated international weight-band dosing recommendations 
for efavirenz. In Chapters 7 and 8, the pharmacokinetics of efavirenz were evaluated 
in African HIV-infected children, dosed according to weight-band based 2006 WHO or 
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manufacturer's recommendations. Low and highly variable efavirenz PK parameters and 
middosing interval concentrations were reported with subtherapeutic efavirenz trough 
levels (<1.0 mg/L) in 14-59% of the Rwandan and Ugandan children. It was obvious that 
efavirenz underdosing was of a major concern using the previous WHO 2006 guidelines. 
These and earlier studies22, 23 have therefore been warning WHO and national authorities 
to urgently move to higher paediatric weight-band based dosing for efavirenz, although 
to date, the current higher WHO 2010 dosing guidelines have not been validated. This is, 
however, especially necessary as doses in some weight-bands may need to be increased 
still further. A new pharmacokinetic substudy within the CHAPAS-3 trial has been done in 
African children dosed with a new generic pediatric efavirenz tablet following the current 
dosing recommendations. First study results have shown similar values as our previous 
studies, but collection and analysis of pharmacokinetics, toxicity and efficacy data is still 
ongoing. Final outcomes of this study should advise WHO’s PAWG for better rational 
efavirenz dosing recommendations.
A number of FDC tablets, such as Triomune Baby and Junior, with dose ratios correct for 
children have and are being developed in order to simplify first-line treatment and increase 
the number of children on cART24. Generic pharmaceutical manufacturing companies are 
leading many of these initiatives and trying to fill the pressing gap in resources for the 
unmet need of cART in the pediatric population in Africa. With more people receiving 
cART in resource-limited settings, treatment failure and the need to switch to second-line 
regimens is likely to increase, but second-line drugs are clearly under prescribed in deve-
loping countries. In 2011, only 3% adults and children receiving cART in resource-limited 
settings were on a ritonavir-boosted protease inhibitor (PI) as second-line cART, even 
though the proportion with virological failure on first-line cART is substantially higher25, 26.
The only currently available second-line drug in resource-limited settings is ritonavir- 
boosted lopinavir in liquid formulation for infants and in paediatric tablets for older 
children. Whereas these formulations have many limitations, ritonavir-boosted lopinavir 
remains the preferred PI for use in infants and children and, therefore, alternative for-
mulations with better taste and which do not require cold-chain transport and storage 
are urgently needed in resource-limited settings. Recently, two new paediatric lopinavir/ 
ritonavir formulations have been developed by a generic pharmaceutical company 
(Cipla Pharmaceuticals), a heat-stable tablet containing half the dose of the currently 
available adult tablets and a novel sprinkle formulation in capsules, which can be opened 
and given even to the smallest children, as it allows the drug to be easily mixed in with 
food. In the CHAPAS-2 study (Chapter 10), where we evaluated the pharmacokinetics 
and acceptability of these novel/generic formulations in HIV-infected Ugandan infants 
and children, it was demonstrated that these formulations had acceptable pharma- 
cokinetic profiles and were preferred by the children and their carers compared to the 
currently available innovator syrup. Also, the current WHO weight-band dosing recom-
mendations appeared to be appropriate for use in children. 
qf_offerte154258_binnenwerk_zw_1-1_01.indd   181 7-7-2013   19:05:29
CHAPTER 11 - General Discussion 182
It is hoped that the novel sprinkle formulation and the new generic paediatric tablet 
will soon become accessible at low cost to international roll-out programmes. To date, 
affordable second-line formulations are rare. Second-line treatment is still 4-5 times more 
expensive than first-line regimens26. Another hurdle for patients to receive second-line 
cART is the inability to measure viral load. Uncertainty in the diagnosis of treatment 
failure together with unavailability of these drugs is a barrier for prescribers to switch 
to second-line27. Infrastructure, personnel, and supply chain constraints all affect the 
ability to monitor, and tests for measuring efficacy are generally unavailable, particularly 
at primary care facilities28. However, the DART trial has demonstrated that on the basis 
of clinical or immuno-clinical criteria, such as simple point-of-care CD4 tests, it can be 
decided to switch to second-line in adults29, 30. In children, monitoring of weight gain 
can be used as an important additional clinical aid for identification of first-line failure, 
as demonstrated in the ARROW trial (www.arrowtrial.org)28 Subsequently, the need for 
third-line therapy for children is expected to grow in future years27. Ritonavir-boosted 
darunavir and raltegravir are options for third-line regimens by WHO guidelines29. 
However, this treatment is even more hindered by the lack of pediatric formulations and 
high costs, with dosing especially problematic for young children31. Importantly, the aim 
of future (CHAPAS) trials should focus on inexpensive, new generation drugs for second-
line and third-line treatment with appropriate formulations for children.
A final challenge in the scale-up of HIV-treatment for children is the need for large 
investments from international government initiatives and private foundations. In the 
last decade a massive increase in substantive funding streams for global health has 
occurred32. At the current pace at which treatment and clinical care is scaled up, reaching 
the targets of 2015 is feasible3. However, the continued global economic crisis has put 
the humanitarian aid for developing countries under pressure. A strategic evaluation 
of how to make each dollar/euro spent on HIV treatment programs more efficient and 
sustainable is crucial32. Donors and governments should not compete with each other, 
but should more effectively collaborate. The international community should learn from 
this situation that it should not only respond with short term solutions that often reflect 
the donor’s priorities, but that it is important to fund durable health systems, including 
the availability of appropriate drug formulations, that can withstand crises.
Joining forces to develop research capacity 
It has been widely recognized that resource-limited settings need more appropriate drug 
formulations, but also stronger health systems in the fight against HIV/AIDS. This must 
involve clinical research. However, total research outputs from Africa are low; the number 
of research publications in peer-reviewed journal from the African continent is smaller than 
the number of research publications produced individually by several countries33, 34. Research 
capacity development is crucial for the success of performing clinical trials and to strengthen 
health systems in resource-limited settings. In this last section, practice-based lessons are 
provided from three clinical trials contributed to this thesis: VITA, CHAPAS and ARROW.
qf_offerte154258_binnenwerk_zw_1-1_01.indd   182 7-7-2013   19:05:29
183 Joining Forces in the Fight against HIV/AIDS in Africa 
The first lesson that can be learned from these clinical trials is that management and com-
munication structures are fundamental for a trial. In ARROW and CHAPAS, coordination, 
planning and completion of the trial plus proper administrative procedures were led by 
a well-trained trial management team from the Medical Research Council Clinical Trials 
Unit (MRC CTU), London, UK. In these studies, the trial manager regularly visited the 
research sites to discuss the progress and difficulties. Also regular and structured 
telephone conferences were important to ensure the progress at every research site. Trial 
managers are essential as trials need to follow guidelines and procedures (ICH-GCP and 
the study protocol itself), the trial paper work is enormous and there is always need to 
motivate others in a team. Since MRC CTU has over 20 years expertise in conducting 
field studies and clinical trials in the developing world, they were asked to share their 
experience with the VITA study team. The VITA-1 trial (Chapter 3) was primarily set up 
at Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania in collaboration with 
Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen, The Netherlands. 
However, both institutes had little experience in conducting clinical trials. The subsequent 
VITA-2 trial (Chapter 4) was established as a multi-country and a more ICH-GCP com-
pliant study at KCMC and at the University Teaching Hospital (UTH), Lusaka, Zambia with 
great contributions from the MRC CTU. 
Secondly, infrastructures are important for the high scientific workload in ICH-GCP com-
pliant clinical trials. For ARROW and CHAPAS, particular research clinics were raised with 
clinical care units for the children enrolled in the study, but also for data management 
and trial meetings. During the VITA studies, the Kilimanjaro Clinical Research Institute 
building was constructed, containing study, meeting and archiving rooms, a data 
management department and clinical care units. Well equipped laboratories with clinical 
research capacity were already in place or further expanded. Given the lack of equip-
ment for the bio-analysis of antiretroviral agents, it was decided to store plasma samples 
and ship them to the laboratories of RUNMC that ensured standardization and quality 
assurance of the laboratory procedures. Recently, a north-south collaboration was started 
between RUNMC and Makarere University Hospital, Kampala, Uganda. It is hoped that 
exchanging experience of laboratory staff from African and European countries enables 
the development of standardized and qualitative bio-analysis programs for laboratories in 
resource-limited settings in the enhancement of research capacity for future trials.
Thirdly, it is important to bring research sites to ICH-GCP standards and sustain quality 
of sites by (refresher) trainings and maintaining staff. Staff from all clinical sites received 
additional training in ICH-GCP and in the specific procedures which they were involved 
in. When ARROW and CHAPAS started, the infrastructure and well-trained staff were 
already in place, since the same study clinics and study team were involved in pre- 
vious trials35. These two trials were fully ICH-GCP compliant. In contrast, the VITA project 
was yet completely lacking in research capacity. Many medical professionals in the VITA 
studies did not have any prior research experience. As was done in CHAPAS and in ARROW, 
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monitoring visits to the participating VITA sites in Zambia and Tanzania were conducted 
and were partly dedicated to teaching and training of basic research skills to site 
clini-cians, nurses and data managers. Also, the so-called sandwich model was introduced; 
two PhD students from Tanzania and the Netherlands were working together at the 
clinical trials to exchange knowledge, such as in data analysis, which remains in many 
studies predominantly under the control of the Northern partner. Annual workshops 
were used to provide skills on ICH-GCP and HIV-disease management (HIV-PENTA 
trainings) and to strengthen the North-South collaboration.
Finally, the abovementioned clinical trials, in particular CHAPAS and ARROW, have 
shown that key to success in conducting clinical trials is attributable to the commitment 
of project staff and goodwill of all northern and southern partners and their professional 
leadership and collaboration. CHAPAS and ARROW have been accomplished very well; 
the research team of the VITA project has learned very much, particularly in clinical phar-
macology studies of HIV, for future research at this site. The next step for these developed 
research collaborations in Sub-Saharan Africa is to partner with less developed sites in the 
regions to facilitate training and to further expand research capacity.
Conclusions and future perspectives
Clinical pharmacology studies are highly relevant for improving and expanding the roll-
out of HIV-treatment and clinical care in pregnant women and children in resource-limited 
settings. Strategies, such as option A (with the addition of an enzyme inducer?), should 
be used in pMTCT when WHO’s Option B/B+ is not available or unfeasible. However, it is 
hoped that the roll-out of Option B/B+ for pMTCT will be expanded soon to be globally 
accessible in meeting one of the ambitious targets of UNAIDS/WHO to reduce the overall 
mother-to-child HIV transmission rate to <5% at the population level by the end of 2015.
More appropriate pediatric drug formulations that are inexpensive and easily usable are 
urgently needed to widen global access of HIV-treatment for children. WHO PAWG’s 
standardized dosing guidelines should be evaluated in the global goal to optimize treat-
mentin resource-limited settings. Future trials should focus on inexpensive, new genera-
tion drugs with correct dosing guidelines and appropriate formulations for second-line 
and third-line treatment in children.
Research capacity development is essential in performing clinical trials and strengthening 
health systems in resource-limited settings. This thesis has shown that north-south 
collaboration plays an important role in exchanging knowledge about clinical pharma-
cology studies. The next step for these developed research collaborations in Sub-Saharan 
Africa is to partner with less developed sites in the regions to facilitate training and to 
further expand research capacity’
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More than twenty years ago, professor Chifumbe Chintu (one of the investigators of 
CHAPAS) from UTH, Lusaka, Zambia developed one of the first African-led, North-South 
collaborations in research for pediatric infectious diseases36. He and his team had a motto 
launched that also comprises the conclusion of this thesis: ‘Holding hands together and 
moving forward in the fight against HIV/AIDS in Africa.’
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To date, more than 30 million people have died from HIV/AIDS and currently 34 million 
people are estimated to be living with HIV. The southern part of Africa is the region most 
severely affected, and it accounts for approximately 68% of the global total persons 
living with HIV. Since the prevalence is high in women of reproductive age, mother-to-
child transmission of HIV (MTCT) is also common in the region. In 2011, 330.000 children 
acquired HIV infection (90% due to MTCT) and more than 90% of those were living in 
Sub-Saharan Africa. 
Since the turn of the millennium, a massive scale-up of access to ART in resource-limited 
countries, especially in Africa, has been realized with political commitments and extensive 
international financial support. After introduction of combination antiretroviral therapy 
(ART) in resource-limited settings the overall growth of the HIV epidemic appears to have 
stabilized, as the number of people newly infected globally each year is continuing to fall and 
fewer people are dying from AIDS-related causes worldwide. Despite these major gains, ART 
is still unfortunately not universally accessible. The global coverage for the most vulnerable 
population in need for ART is still low to moderately low; only 28% of children 0-14 years 
of age in need of ART and 50% of pregnant women and infant pairs in need of antiretro-
viral prophylaxis for the prevention of MTCT (pMTCT) are currently receiving the life-saving 
medicines. Significant progress has been made, but the HIV problem has not yet been solved.
This thesis presents studies that were undertaken to optimize HIV treatment in HIV- 
infected pregnant women and children in Africa by studying the clinical pharmacology of 
antiretroviral drugs in the most vulnerable populations in resource-limited settings.
The first part of this thesis deals with clinical pharmacology studies in HIV-infected 
pregnant women using single-dose nevirapine as part of antiretroviral prophylaxis for 
pMTCT. We investigated simple, accessible and affordable strategies for the prevention 
and the reduction of MTCT of HIV in Sub-Saharan Africa using enzyme inducers for the 
elimination of nevirapine resistance after single-dose nevirapine as part of pMTCT.
The second part of this thesis focuses on the clinical pharmacology of ART in HIV- 
infected African children to optimize paediatric antiretroviral regimens for the scale-up of 
HIV treatment. We evaluated new appropriate antiretroviral drug formulations and we 
validated newly developed WHO weight-band based dosing recommendations for the 
use in children living in resource-limited settings.
Part I: Clinical pharmacology studies in HIV-infected pregnant women
Single-dose nevirapine is still being used globally in pMTCT, with a risk of 1-76% of women 
developing resistance against nevirapine from just this single-dose. Chapter 2 of this thesis 
includes a systematic review together with a meta-analysis of different drug interventions, 
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which have been investigated to date, for reducing the development of nevirapine 
resistance. Pooling data from 18 eligible studies, single-dose nevirapine alone resulted in a 
prevalence of 31% (95% CI 7.6-54) nevirapine resistance in the mother. Addition of ante-
partum zidovudine reduced the proportion of women with detectable nevirapine resistance 
by 30% to 21% (95% CI 8.6-33). Combining antepartum zidovudine with a postpartum 
course of two other antiretroviral drugs for 4-7 days nearly eliminated the risk of nevirapine 
resistance mutations, to a prevalence of 0.011% (95% CI -0.11-0.13). The summary effect 
of longer 20-30 days of postpartum drug regimens combined with antepartum zidovudine 
and single-dose nevirapine was associated with similar incidence of nevirapine resistance, 
namely 0.003% (95% CI -0.054-0.060). The WHO guideline option A (antepartum zido-
vudine, single-dose nevirapine and one week of lamivudine/zidovudine postpartum) should 
be followed wherever feasible to achieve the minimum risk of nevirapine resistance in 
regions where single-dose nevirapine is still being used.
Most interventions to reduce the risk of nevirapine resistance development are antiretro- 
viral-based, but a totally different approach is a pharmacological strategy of adding a 
CYP3A4 enzyme inducer to the single-dose of nevirapine. In Chapter 3 a clinical trial 
(VITA-1) was presented investigating the effect of a single-dose carbamazepine on nevira-
pine pharmacokinetics and the development of nevirapine resistance in 158 HIV-infected 
pregnant women in Tanzania. This trial provides the first data on adding a single-dose 
of an enzyme inducer (carbamazepine) to single-dose nevirapine for pMTCT in HIV- 
infected, pregnant women. Single dose carbamazepine significantly reduced nevirapine 
plasma concentrations one week after delivery by 36%, with a trend towards fewer re- 
sistance mutations. We also found a trend towards lower rates of nevirapine resistance 
in women with undetectable nevirapine concentrations across the whole population. 
Our study demonstrated the validity of this approach, and showed that that enzyme 
inducers, such as carbamazepine, have new possibilities for pMTCT programs to reduce the 
development of nevirapine resistance in settings where other options are limited.
In Chapter 4, we demonstrated the results on nevirapine pharmacokinetics of a pilot study 
investigating the effect of a seven-day course of phenytoin, as enzyme inducer (VITA-2 
trial) in 50 Zambian and Tanzanian HIV-infected pregnant women. Adding a seven- 
day course of phenytoin, as enzyme inducer, from labour onset produced a large and 
significant reduction in the elimination half-life of nevirapine in HIV-infected, pregnant 
women using single-dose nevirapine as part of pMTCT prophylaxis. Seven days phen-
ytoin was safe and effective with no new nevirapine resistance mutations observed. 
Since prolonged subtherapeutic nevirapine exposure is known to lead to nevirapine 
resistance emergence and since phenytoin is safely and widely used in women, to mini-
mise pMTCT, single-dose nevirapine can be used with a seven-day course of phenytoin 
as an alternative if other antiretroviral drugs are unavailable.
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Part II: Clinical pharmacology studies in HIV-infected children
Adequate drug exposure is essential in HIV treatment of children, who generally start 
treatment earlier and will need to take it for far longer than adults. However, obtaining 
optimal drug exposure in children is challenging, as they cannot simply be regarded as 
small adults. Pharmacokinetics of antiretroviral drugs are highly variable in the paediatric 
population as children mature and grow rapidly. 
In an open randomized trial, called CHAPAS-1 (Children with HIV in Africa-Pharmacoki-
netics and Adherence of Simple antiretroviral regimens), appropriate dosing of fixed-dose 
combination tablets, approved based on early pharmacokinetic data generated within 
the trial, was assessed. The tablets have higher nevirapine to lamivudine/stavudine dose 
ratio compared to adults FDCs. It is known that children, particularly the youngest, meta-
bolize nevirapine more rapidly than adults. In Chapter 5 (substudy of CHAPAS-1) we 
reported the exposure to nevirapine in 16 Zambian, HIV-infected infants weighing 3-6 
kg taking these paediatric fixed-dose combination tablets twice daily. The infants had 
plasma nevirapine concentrations that were slightly lower, but generally comparable with 
heavier children, and were higher than historical data. However, large interinfant varia-
bility (55%) led to a relatively high proportion of children, particularly those <5 months, 
with low nevirapine trough concentrations. Nevertheless, given fast growth rates after 
starting ART such that most infants spend only a short time in the lowest weight band, 
and the encouraging viral responses we observed at four weeks after ART initiation, 
WHO weight-band tables for nevirapine-containing fixed-dose combination tablets 
appear reasonable for HIV-infected infants weighing 3-6kg. 
WHO guidelines recommend nevirapine dose escalation (half dose for the first 14 days) 
when initiating ART to avoid toxicity from high initial nevirapine levels. Since young children 
metabolize nevirapine more rapidly, there is the potential for inadequate nevirapine plasma 
levels during dose escalation, which could result in slower viral load suppression or increased 
risk of later virological failure. In the subsequent chapter (Chapter 6; also a substudy of 
CHAPAS-1) the pharmacokinetics of nevirapine two weeks after nevirapine initiation with 
and without using a dose escalation strategy were evaluated in 162 Zambian HIV-infected 
infants/children. The relationship between starting dose and safety and efficacy was also 
assessed. Despite the relatively small sample size, with nevirapine dose-escalation at ART ini-
tiation more subtherapeutic nevirapine plasma concentrations 3-4 hours post-dose were ob-
served in children <2 years of age compared to older children. This finding is compatible with 
earlier studies describing more rapid nevirapine systemic clearance in younger than in older 
children. We also found that younger children had a low risk for rash with a full-dose initi-
ation strategy. To simplify ART initiation in young children and reduce the risk of suboptimal 
dosing, full-dose nevirapine at ART initiation should be considered for African HIV-infected 
children <2 years of age. Children >2 years of age could continue to receive dose-escalation 
to avoid the development of rash, or should have easy access to clinics to enable timely re-
view if rashes recur with temporary discontinuation and nevirapine re-initiation at half-dose.
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Paediatric dosing has not only been standardized with fixed-dose combination formula-
tions, but also by using simplified weight-band based dosing recommendations. However, 
these have typically been determined using extrapolation from licensed mg/kg or mg/m2 
doses, and require validation for optimal HIV treatment. Chapter 7 described actual efavi-
renz plasma exposure in a group of 41 HIV-infected Ugandan children aged between 3 and 
12 years treated following the 2006 efavirenz weight-band based dosing recommenda-
tions of WHO using full pharmacokinetic information. This was a substudy of the ARROW 
trial, an open-label randomized trial comparing routine laboratory (toxicity, CD4) versus 
clinically driven monitoring strategies, and also comparing three different first-line ART 
strategies in HIV-infected infants and children in Uganda and Zimbabwe (www.arrowtrial.
org). The children in this study had lower and highly intersubject variable pharmacokinetic 
parameters of efavirenz compared to historical data from adults. There were no statistically 
significant differences across weight-bands, suggesting no major effect of some using half 
tablets. Our findings in Chapter 7 suggest that children receiving efavirenz dosed according 
to 2006 WHO guidelines (or the licensed recommendations on which these were based) 
could be at a higher risk of virological failure, and that all pediatricians in resource-limited 
and resource-rich countries should move to the higher WHO 2010 guideline dosing as a 
matter of urgency. Nevertheless, doses in some weight-bands may need to be increased still 
further, and this also should be investigated promptly. 
There are numerous factors which may lead to interindividual variability in pharma- 
cokinetics, such as gender, age, body weight, non-compliance, and genetic factors. 
Chapter 8evaluated mid-dosing interval efavirenz plasma concentrations and the influence 
of CYP2B6 polymorphisms in relation to efficacy, tolerability, and adherence in 87 Rwandan 
HIV-infected children. We found a high level of intersubject variability in mid-dosing inter- 
val efavirenz plasma concentrations in Rwandan HIV-1 infected children when they were 
dosed according to the national guidelines. Only two-third of these children had efavirenz 
concentrations within the therapeutic range. High variability (i.e. 107%) resulted in 14% 
children with subtherapeutic levels and 20% with potentially toxic plasma levels. Although 
the difference was not significant in this small study, a higher proportion of virologic failure 
was observed in children with (sub)therapeutic efavirenz levels. Finally, we found that both 
adherence and CYP2B6-genetic polymorphisms were major factors influencing variability 
in mid-dosing interval plasma concentrations. Significantly higher efavirenz levels were cor-
related to children having specific CYP2B6 variants (516TT, 785GG and 983CC). 
In Chapter 9 (a further pharmacokinetic substudy of ARROW) we evaluated a different 
weight-band based dosing recommendation from WHO, for twice daily zidovudine, which 
has only been limitedly studied, to investigate whether this provides optimal exposure in 
Ugandan, HIV-infected children. Zidovudine is a common component of first-line paediatric 
ART, especially in resource-limited countries. Here, we found higher zidovudine exposure 
in Ugandan children aged 1-12 years dosed twice-daily according to WHO 2006 weight-
bands compared to that previously reported in adults receiving the standard dose of 300 
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mg zidovudine twice-daily. Exposure was also higher than in the only two previous 
paediatric zidovudine pharmacokinetic studies evaluating twice daily zidovudine, which 
used lower doses than our study. Subsequent 2010 WHO guidelines have further increased 
the recommended zidovudine dose for children, without new evidence, but reflecting 
concernsthat children had often been under-dosed with ART. Children dosed following 
WHO 2010 guidelines, younger children, and those with low weight-for-age are there-
fore likely to have even higher zidovudine exposure than that observed in Chapter 9 and 
substantially higher than previously reported in adults. Our findings suggest that this 
higher exposure could be associated with greater suppression of haemoglobin levels within 
the normal range and probably with no change in efficacy, since viral load suppression 
was already very good using WHO 2006 dosing. However, the impact on severe anaemia 
warrants further investigation, particularly with regards to current WHO 2010 dosing.
The final chapter before the General Discussion expanded on the scale-up of second-
line ART access. ART formulations suitable for children should ideally be pleasant- 
tasting, with no food restrictions, be heat-stable and require administration no more than 
twice-daily. The present accessible antiretroviral drug for second-line in resource-limited 
settings is ritonavir-boosted lopinavir. This drug is currently only available as syrup, which 
tastes bad, requires a stable cold chain and has a relatively short shelf-life, or as paediatric 
tablets, which are very hard, still relatively large, unscored and cannot be cut into pieces 
(as this significantly reduces bioavailability). The lopinavir tablets are difficult to be taken 
by children younger than 5-6 years old - in contrast to many of the FDCs discussed above 
which are dispersible, scored, and generally preferred by carers. A randomised pharma-
cokinetic bio-equivalence phase Ib trial (CHAPAS-2; Chapter 10) was designed to assess 
the pharmacokinetics and acceptability of ritonavir-boosted lopinavir in sprinkle and 
tablet formulations for treatment of HIV infected children in Africa. The inexpensive, 
novel, heat-stable, solid drug sprinkle formulation of LPV/r evaluated in the CHAPAS-2 
study has been shown to have generally acceptable pharmacokinetic profiles and to 
be pre-ferred by younger children and their carers compared to the currently available 
innovator syrup. The current WHO weight band dosing recommendations appear to be 
appropriate for use in the paediatric population.
In the General Discussion (Chapter 11) the challenges in translating our research 
findings into practice in resource-limited settings were discussed, focusing on antiretro- 
viral prophylaxis for pMTCT of HIV, HIV-treatment for children in resource-limited 
settings, research capacity development and the advantages of international collabora-
tion for clinical research. 
Clinical pharmacology studies are highly relevant for improving and expanding the roll-
out of HIV-treatment and clinical care in pregnant women and children in resource- 
limited settings. Conducting the VITA trials investigating the addition of simple strategies 
of enzyme inducers (a single-dose carbamazepine or seven days of phenytoin at labor 
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onset) to single-dose nevirapine for pMTCT in HIV-infected pregnant women has been 
challenging, but support from other African clinical research groups became extremely 
valuable in successfully completing the trial. 
Strategies, such as WHO’s option A (possibly with the addition of an enzyme inducer), 
should be used in pMTCT when WHO’s Option B/B+ is not available or unfeasible. However, 
it is hoped that the roll-out of Option B/B+ for pMTCT will be expanded soon to be globally 
accessible in order to meet one of the ambitious targets of UNAIDS/WHO to reduce the 
overall mother-to-child HIV transmission rate to <5% at the population level by the end 
of 2015.
In terms of optimising HIV treatment for children in resource-limited settings, more appro- 
priate pediatric drug formulations that are inexpensive and easily usable are urgently 
needed to widen global access to HIV-treatment for children. The WHO’s standardized 
dosing guidelines developed by the pediatric antiretroviral working group should be eval-
uated in the global goal to optimize treatment in resource-limited settings. Future trials 
should focus on inexpensive, new generation drugs with correct dosing guidelines and 
appropriate formulations for second-line and third-line treatment in children.
Research capacity development is essential in performing clinical trials and strengthening 
health systems in resource-limited settings. This thesis has shown that north-south and 
south-south collaboration plays an important role in exchanging knowledge about clin-
ical pharmacology studies. The next step for these developed research collaborations 
in Sub-Saharan Africa is to partner with less developed sites in the regions to facilitate 
training and to further expand research capacity.
More than twenty years ago, professor Chifumbe Chintu (one of the investigators of 
CHAPAS) with others from UTH, Lusaka, Zambia developed one of the first African-led, 
North-South collaborations in research for pediatric infectious diseases. They had a motto 
launched that also comprises the conclusion of this thesis: ‘Holding hands together and 
moving forward in the fight against HIV/AIDS in Africa.’
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HIV, het humaan immunodeficiëntie virus, is het virus dat AIDS, het Acquired Immune 
Deficiency Syndrome, veroorzaakt. Dit virus valt de afweercellen in het lichaam aan, ver-
menigvuldigt zich daar en vernietigt daarbij de afweercellen. Op die manier is het virus in 
staat het mechanisme uit te schakelen waarmee het lichaam zich beschermt tegen allerlei 
ziekteverwekkers, zoals bacteriën, schimmels en virussen. Die ziekteverwekkers worden 
normaal gesproken zonder problemen door het immuunsysteem vernietigd, maar kunnen 
nu een ziekmakende infectie veroorzaken. Het zijn in de meeste gevallen ook deze 
infecties waaraan een AIDS-patiënt overlijdt. 
HIV bevindt zich in bloed, sperma, voorvocht, vaginaal vocht en moedermelk. Als HIV in 
deze lichaamsvochten in contact komt met iemand anders’ bloedbaan of slijmvliezen, is 
er kans op een HIV-infectie, zoals bij onveilig seksueel contact, bij het inspuiten van drugs 
met gebruikte naalden of spuiten, een baby van een HIV-geïnfecteerde moeder, een 
bloedtransfusie of bij het prikken aan een naald met HIV-besmet bloed.
Sinds de ontdekking van HIV in het begin van de jaren tachtig, dat tegelijkertijd het begin 
was van deze grote epidemie, zijn er naar schatting 30 miljoen mensen gestorven aan 
HIV/AIDS. Op dit moment leven er maar liefst 34 miljoen mensen met HIV wereldwijd en 
daar komt elke 12 seconden een nieuwe patiënt bij. Sinds de komst van de HIV-remmers 
en betere wereldwijde beschikbaarheid van deze middelen is het welzijn en de levens-
verwachting van mensen met HIV/AIDS sterk verbeterd. Maar ondanks de vooruitgang 
die is geboekt met de bestrijding van deze ziekte in het laatste decennium, blijft de HIV-
epidemie één van de grootste problemen voor de wereldwijde volksgezondheid.
Het gebied in Afrika ten zuiden van de Sahara is de zwaarst getroffen regio in de wereld, 
waar 68% van alle mensen met HIV leven. In tegenstelling tot de meeste andere 
landen, waar homoseksuele mannen of drugsgebruikers het meeste risico lopen op 
besmetting, zijn het in het gebied in Afrika ten zuiden van de Sahara voornamelijk vrouwen die 
slachtoffer zijn geworden van de epidemie. Omdat ook veel vrouwen van vruchtbare 
leeftijd met HIV zijn besmet, worden er veel baby’s met HIV geboren. Alleen al in 2011 
hebben 330.000 kinderen wereldwijd een HIV-besmetting opgelopen (in 9 op de 10 
gevallen overgebracht door hun HIV-geïnfecteerde moeder) en 90% van die kinderen leeft 
in het gebied in Afrika ten zuiden van de Sahara. Een behandeling wordt meestal gestart 
met drie HIV-remmers en wordt ook wel antiretrovirale combinatietherapie genoemd. Helaas 
is deze antiretrovirale combinatie therapie nog steeds niet wereldwijd beschikbaar. Vanaf 
2002 zijn er in Afrika grootschalige HIV-behandelprogramma’s opgestart om de antiretro- 
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virale combinatietherapie zo snel mogelijk beschikbaar te krijgen voor iedereen die dat nodig 
heeft. Op advies van de Wereldgezondheidsorganisatie (WHO) worden in ontwikkelings- 
landen een beperkt aantal en goedkope HIV-remmers voorgeschreven en zo min mogelijk 
laboratorium tests gebruikt. Met deze benadering is inmiddels grote vooruitgang geboekt. 
Eind 2011 kreeg een recordaantal van 8 miljoen volwassenen en kinderen voor het eerst 
de levensreddende HIV-remmers, maar nog altijd is de helft van de mensen met HIV niet 
voorzien van behandeling, terwijl ze dat wel heel hard nodig hebben. Voor kinderen is de 
beschikbaarheid van HIV-remmers nog veel lager. Slechts 28% (dus minder dan een derde) 
van de kinderen wordt op dit moment behandeld.
HIV-behandeling voor zwangere vrouwen in Afrika
De kans van overdracht van HIV van een moeder op haar baby kan sterk worden verkleind 
door HIV-remmers te gebruiken tijdens de zwangerschap, de bevalling en de borstvoeding. 
In de westerse wereld wordt een HIV-geïnfecteerde vrouw tijdens haar zwangerschap zo 
snel mogelijk met antiretrovirale combinatietherapie van drie HIV-remmers behandeld 
om het virus zo goed mogelijk te onderdrukken. Op die manier wordt de kans van over-
dracht van HIV op de baby verminderd tot vrijwel 0. In Afrika zijn de middelen die we in de 
westerse wereld gebruiken niet overal beschikbaar. Vanaf 2000 adviseerde de WHO een 
simpele, goedkope, maar zeer effectieve methode: één dosis van het middel nevirapine, 
dat net voor de bevalling moet worden gegeven aan de moeder en na de bevalling aan 
het kind. Dit zorgt voor bijna een halvering aan HIV-besmettingen in de baby’s. Een nadeel 
echter is de ontwikkeling van resistentie, waardoor het middel bij een volgende bevalling 
of bij chronisch gebruik niet meer werkt. Eén dosis van het middel nevirapine alleen 
wordt daarom niet langer aanbevolen, maar nog wel als onderdeel van de antiretrovirale 
combinatietherapie. Deze simpele methoe van één dosis nevirapine zal dus langzaam 
verdwijnen, maar wordt in de praktijk doorgaans nog steeds gebruikt door duizenden 
zwangere vrouwen in ontwikkelingslanden. Dit gebeurt met name in de gebieden buiten 
de steden, waar antiretrovirale combinatietherapie helaas nog niet voorhanden is.
HIV-behandeling voor kinderen in Afrika
In de westerse wereld is de medische zorg voor kinderen met HIV/AIDS goed geregeld. De 
overdracht van HIV van moeder-op-kind kan bijna geheel voorkomen worden. Daarnaast 
worden baby's en kinderen goed onderzocht en kunnen ze een antiretrovirale combinatie-
therapie krijgen als ze dat nodig hebben. Doordat er in de westerse wereld relatief weinig 
kinderen met HIV leven, is er geen grote financiële stimulans voor grote farmaceutische 
bedrijven om medicijnen te ontwikkelen die specifiek geschikt zijn voor kinderen. De 
weinige die er zijn, zijn bovendien een stuk duurder dan de volwassen varianten. Kinderen 
vormen daarmee het buitenbeentje voor de ontwikkeling van betere en betaalbare HIV-
remmers, waardoor de beschikbaarheid van deze middelen voor deze kwetsbare groep 
patiënten achter blijft (met maar 28% van de kinderen die op dit moment behandeling 
krijgen). Inmiddels zijn er een aantal generieke farmaceutische bedrijven die het initiatief 
hebben genomen om dit onvervulde gat voor kinderen te dichten.
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Het doel van dit proefschrift is het verbeteren van de HIV-behandelingen voor HIV- 
geïnfecteerde zwangere vrouwen en kinderen in Afrika. Hiervoor hebben we de klinische 
farmacologie van HIV-remmers in deze kwetsbare groep Afrikaanse mensen bestudeerd. 
Met de klinische farmacologie wordt naar het effect gekeken van het menselijk lichaam 
op het geneesmiddel (ook wel farmacokinetiek genoemd) en wordt de relatie tussen de 
geneesmiddelconcentratie in het bloed en het effect op het menselijk lichaam (ook wel 
farmacodynamiek genoemd) onderzocht.
Het eerste deel van dit proefschrift beschrijft het onderzoek van simpele, beschikbare en 
betaalbare methoden voor de preventie van de moeder-op-kind-overdracht van HIV in 
het gebied in Afrika ten zuiden van de Sahara. Daarbij hebben we onderzoek gedaan bij 
zwangere vrouwen naar de toevoeging van een extra geneesmiddel, waardoor mogelijk 
minder resistentie ontstaat tegen het middel nevirapine. 
Het tweede deel van dit proefschrift gaat over het verbeteren van HIV-behandelingen voor 
kinderen in ontwikkelingslanden. Hiervoor hebben we nieuwe, geschikte HIV-genees- 
middelen geëvalueerd en hebben we gekeken of de doseringsrichtlijnen van de WHO goed 
zijn voor het gebruik van deze HIV-remmers voor kinderen in ontwikkelingslanden.
Deel I: Onderzoek in HIV-geïnfecteerde zwangere vrouwen
Zoals eerder beschreven, wordt één dosis van de HIV-remmer nevirapine net voor de 
bevalling doorgaans nog steeds gebruikt door duizenden HIV-geïnfecteerde zwangere 
vrouwen in ontwikkelingslanden, waar antiretrovirale combinatietherapie helaas nog 
niet voorhanden is. Nevirapine zorgt voor een snelle daling van het virus in het bloed, 
waardoor de kans wordt verkleind dat het kind besmet raakt met HIV. Een nadeel van 
nevirapine is het hoge risico op resistentie als het middel eenmalig wordt gegeven 
zonder andere middelen erbij. In Hoofdstuk 2 van dit proefschrift is een systematisch 
review met een meta-analyse (een beknopt overzicht van alle literatuur over dit onder-
werp) beschreven, waarin  het effect van de toevoeging van andere middelen op de 
nevirapine-resistentie is onderzocht. Er waren 18 onderzoeken gevonden, die naar dit 
vraagstuk hadden gekeken. Eén dosis van nevirapine alleen resulteerde in 31% resis-
tente moeders. Deze moeders kunnen mogelijk geen nevirapine meer gebruiken in een 
volgende zwangerschap, omdat het gewoonweg niet meer werkt. Daarnaast kunnen 
zij hun resistente virus overbrengen op anderen. Met toevoeging van een andere HIV-
remmer, zidovudine, zagen we bij 21% van de moeders resistentie ontstaan. Als er dan 
ook nog een week lang HIV-remmers na de bevalling worden toegevoegd aan die ene 
dosis nevirapine plus zidovudine verdwijnt het risico op resistentie bijna geheel. In ons 
onderzoek zagen we namelijk slechts 0.011% (1 op 10.000) resistente moeders. Als 
die HIV-remmers nog langer werden gegeven (20-30 dagen) leek het verschil nog iets 
kleiner, maar eigenlijk niet verschillend met 0.003%. De richtlijnen van de WHO bevelen 
bij gebrek aan antiretrovirale combinatietherapie aan om zidovudine plus één dosis 
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nevirapine net voor de bevalling te geven met nog een week lang HIV-remmers na de 
bevalling. Ons onderzoek bevestigd dat deze aanbeveling goed is met een daling naar 
slechts 0.011% resistente moeders.
In Hoofdstuk 3 en 4 zijn de VITA-onderzoeken beschreven. Deze onderzoeken zijn uitge-
voerd in HIV-geïnfecteerde zwangere vrouwen in Tanzania en Zambia. Hierbij hebben we 
een ander middel toegevoegd aan die ene dosis nevirapine, namelijk carbamazepine en 
fenytoine in een lage dosering. Deze middelen noemen wij enzyminductoren en zorgen 
voor een versnelde afbraak van nevirapine. In het algemeen wil je niet dat geneesmiddelen 
met elkaar een wisselwerking hebben, maar hier maken we er juist gebruik van. Als nevira-
pine sneller uit het bloed wordt geklaard, zal dat ook tot minder resistentie moeten leiden, 
maar dit was nog nooit eerder onderzocht in deze patiëntengroep. De vrouwen werden 
in twee groepen verdeeld. Groep 1 kreeg een dosis nevirapine en groep 2 kreeg een dosis 
nevirapine plus een enzyminductor voor de bevalling. Eén dosis van de enzyminductor, 
carbamazepine, zorgde voor een daling in nevirapine bloedspiegels van wel 36% (VITA-1). 
Ook zagen we minder resistentie in deze groep. In Hoofdstuk 4 (VITA-2) hebben we 
fenytoine erbij gegeven tot 7 dagen na de bevalling. Dit zorgde voor een 85% daling 
van de nevirapine bloedspiegels en we zagen ook een trend naar minder resistentie. De 
groepen waren helaas te klein om over resistentie een echte eerlijke uitspraak te kunnen 
doen. In beide onderzoeken bleken de middelen veilig en bleek nevirapine nog steeds 
even effectief tijdens de bevalling. Eén dosis nevirapine zou dus met een zevendaagse 
toevoeging van fenytoine een goed alternatief zijn, als antiretrovirale combinatietherapie 
niet beschikbaar is.
Deel II: Onderzoek in HIV-geïnfecteerde kinderen in Afrika
Adequate geneesmiddelconcentraties in het bloed zijn heel belangrijk bij de behandeling 
van HIV bij kinderen. Maar dat is makkelijker gezegd dan gedaan. Kinderen kunnen niet 
zomaar worden vergeleken met volwassenen. Het effect van het lichaam op de genees-
middelconcentraties in het bloed van kinderen is sterk variabel aangezien kinderen zich 
individueel ontwikkelen en groeien, totdat ze volwassen zijn.  
In Hoofdstuk 5 is een klein onderzoek beschreven van het grote CHAPAS-1 kinderonder-
zoek. In dit onderzoek zijn nieuw ontwikkelde kindertabletten onderzocht. Deze kinder-
tabletten bevatten drie middelen: nevirapine, lamivudine en stavudine. Nevirapine is een 
HIV-remmer die door kinderen, voornamelijk door de allerjongsten, sneller wordt afge-
broken in het lichaam dan door volwassenen. Daardoor vinden we vaak te lage nevira- 
pine concentraties in het bloed, terwijl de bloedspiegels van de andere twee middelen 
goed zijn. In de nieuwe kindertablet zit in verhouding meer nevirapine ten opzichte van 
de andere twee middelen en daarom verwachtten we betere nevirapine concentraties in 
het bloed van de kinderen te zien. We hebben de concentraties onderzocht in het bloed 
van 16 HIV-geïnfecteerde Zambiaanse baby’s/kinderen tussen de 3-6 kg. De nevira- 
pine concentraties bleken, vooral in de allerjongsten onder de 5 maanden, erg wisselend 
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en iets lager dan in oudere, zwaardere kinderen, waarin dit onderzoek al eerder was uit-
gevoerd. De kindjes zitten echter maar korte tijd in de gewichtsgroep 3-6 kg, ze groeien 
immers snel en krijgen daarna een hogere dosering. Daarnaast werd het virus wel 
voldoende onderdrukt, waardoor we vinden dat deze kindertabletten in deze dosering, 
geadviseerd door de WHO, acceptabel zijn voor Afrikaanse HIV-geïnfecteerde kinderen 
tussen de 3-6 kg.
De WHO beveelt bij het eerste gebruik van nevirapine aan om met een halve dosering te 
starten voor de eerste 14 dagen, waarna de volledige dosering kan worden gegeven. In 
het begin worden namelijk vaak hoge nevirapine concentraties in het bloed gemeten met 
nare bijwerkingen, zoals huiduitslag, tot gevolg. Omdat jonge kinderen de HIV-remmer 
nevirapine sneller afbreken in het lichaam dan volwassenen, zou het bij deze groep juist 
kunnen zijn dat ze helemaal geen te hoge nevirapine spiegels hebben in het begin met 
een volledige dosering. Een halve dosering in de eerste 14 dagen is dus misschien hele-
maal niet nodig, en zou misschien zelfs tot te lage bloedconcentraties kunnen leiden met 
een slechtere onderdrukking van HIV tot gevolg. In Hoofdstuk 6, ook een CHAPAS-1 
subonderzoek, is gekeken naar de nevirapine concentraties in het bloed van 162 HIV-
geïnfecteerde Zambiaanse kinderen tussen de 0-12 jaar. De kinderen waren verdeeld 
over twee groepen. De ene groep kreeg eerst de aanbevolen halve dosering nevirapine 
tijdens de eerste 14 dagen en de andere groep startte direct met de volledige nevirapine 
dosering. Twee weken na het starten van de nevirapine werden bloedspiegels gemeten. 
Zoals we hadden verwacht, zagen we lagere spiegels in de kinderen met de aanbevolen 
halve dosering. Met name bij veel kinderen jonger dan 2 jaar zagen we te lage nevira-
pine concentraties. Dat zou tot slechtere onderdrukking van HIV kunnen leiden, maar 
dat konden we helaas met dit onderzoek niet aantonen. Wel zagen we in de groep met 
heel jonge kinderen (onder de 2 jaar) die waren gestart  met een volledige dosering 
helemaal geen bijwerkingen, maar bij de oudere kinderen wel. Dit onderzoek heeft dus 
aangetoond dat bij kinderen onder de 2 jaar direct met een volledige dosis nevirapine 
kan worden gestart, omdat de kans op bijwerkingen veel kleiner is. Oudere kinderen 
zouden wel met een halve dosering moeten starten, zoals volwassen, vanwege deze bij- 
werkingen. Als oudere kinderen toch ook met een volledige dosering willen starten, 
omdat dat gewoonweg makkelijker is, moeten ze wel snel bij een kliniek kunnen komen, 
voor het geval dat ze toch huiduitslag krijgen.
In Hoofdstuk 7 en 8 hebben we onderzoek gedaan naar de doseringsrichtlijnen van de 
WHO en hebben we gekeken of deze goed zijn voor het gebruik van de HIV-remmer, 
efavirenz, voor kinderen in ontwikkelingslanden. Hoofdstuk 7 beschrijft de informatie 
die we uit de efavirenz concentraties uit het bloed hebben gekregen van 41 Oegandese 
HIV-geïnfecteerde kinderen tussen de 3-12 jaar. Deze kinderen werden nog gedoseerd 
volgens de richtlijnen van de WHO uit 2006. Dit was een subonderzoek van een groter 
onderzoek, dat ARROW heette. De kinderen in het onderzoek hadden lagere en veel 
meer wisselende efavirenz bloedspiegels dan bij volwassenen was gemeten. Onze 
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bevindingen geven duidelijk aan dat deze efavirenz doseringen uit 2006 kunnen leiden tot 
een slechtere onderdrukking van HIV. We geven dan ook aan als conclusie dat de kinder- 
artsen zo snel mogelijk naar de nieuwere richtlijnen van de WHO uit 2010 moeten over-
stappen. De efavirenz concentraties in het bloed van kinderen die gedoseerd worden met 
de nieuwe richtlijnen uit 2010 worden op dit moment onderzocht in een vervolgonderzoek.
In Hoofdstuk 8 is gekeken naar de factoren die de wisselende efavirenz bloedspiegels 
in kinderen verklaren. Het is bekend dat het geslacht, de leeftijd en het gewicht van een 
kind, maar ook bepaalde genen een rol kunnen spelen in de hoogte van de efavirenz 
bloedspiegels. Voor dit onderzoek zijn efavirenz concentraties gemeten in 87 Rwandese 
HIV-geïnfecteerde kinderen. De efavirenz concentraties in het bloed van deze kinderen 
wisselden enorm, wanneer ze volgens de richtlijnen van 2006 werden gedoseerd. Slechts 
twee van de drie kinderen had een goede efavirenz concentratie in het bloed, 14% van 
de kinderen had een te lage bloedspiegel met grotere kans op slechte onderdrukking van 
HIV en 20% had een te hoge spiegel met grote kans op bijwerkingen. Ook vonden we 
dat veranderingen in een bepaald gen (ook wel genetisch polymorphisme genoemd) en 
het trouw innemen van de HIV-remmer twee belangrijke factoren waren voor de variabele 
bloedspiegels in de kinderen. 
In Hoofdstuk 9 (een ander subonderzoek van ARROW) hebben we de doseringsrichtlijnen 
uit 2006 van de WHO voor het tweemaal daags gebruik van de HIV-remmer zidovudine 
bestudeerd. Zidovudine is een middel dat erg veel in kinderen in ontwikkelingslanden 
wordt gebruikt. In dit onderzoek vonden we hogere zidovudine concentraties in het bloed 
van de kinderen vergeleken met gemeten waarden in volwassenen. We hebben ook gezien 
dat deze hogere spiegels voor wat lagere hemoglobine spiegels kunnen zorgen. Dat kan 
leiden tot bloedarmoede. Inmiddels zijn de richtlijnen van de WHO voor zidovudine in 2010 
verder opgehoogd, omdat kinderen vaak met andere HIV-remmers ondergedoseerd 
worden (zoals de HIV-remmer efavirenz uit Hoofdstuk 7). Het risico op hoge zidovudine 
concentraties met de nieuwe richtlijnen uit 2010 is dus waarschijnlijk nog groter dan met 
die uit 2006. We denken dat dit geen verbetering van de onderdrukking van het virus 
oplevert, want dat was al erg goed. De impact die deze hogere doseringsrichtlijnen uit 2010 
voor zidovudine hebben op bloedarmoede wordt nog verder onderzocht.
Het laatste onderzoek uit dit proefschrift gaat over de uitbreiding van de beschikbaarheid 
van tweedelijns antiretrovirale combinatietherapie. Tweedelijns HIV-remmers worden voor-
geschreven als de standaard eerste-keus HIV-remmers niet meer gegeven kunnen worden, 
omdat ze bijwerkingen geven, niet meer werken (door resistentie) of wisselwerkingen 
geven met andere geneesmiddelen die de patiënt krijgt. Idealiter zouden HIV-remmers voor 
kinderen aangenaam moeten smaken, met of zonder eten ingenomen moeten kunnen 
worden en niet vaker dan tweemaal per dag gegeven moeten worden. De enige beschik-
bare tweedelijns HIV-remmer in ontwikkelingslanden is lopinavir/ritonavir. Dit middel is in 
tabletten beschikbaar, maar die mogen niet in stukjes gemalen worden, zoals wel in de 
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kindertabletten voor de onderzoeken in de Hoofdstukken 5-9 beschreven. Kinderen 
jonger dan 5-6 jaar zijn niet in staat deze lopinavir/ritonavir tabletten te slikken. Ook is lopinavir/ 
ritonavir in vloeibare vorm beschikbaar, maar het gebruik daarvan levert ook problemen 
op. De flessen zijn zwaar en lastig te vervoeren, moeten gekoeld worden bewaard (terwijl 
veel mensen in Afrika geen koelkast hebben) en hebben een korte houdbaarheidsdatum. 
Bovendien is het niet altijd even makkelijk om een kind zover te krijgen de drank door te 
slikken, omdat deze erg vies smaakt. In Hoofdstuk 10 zijn nieuw ontwikkelde kinder- 
tabletten en korreltjes van de HIV-remmer lopinavir/ritonavir vergeleken met de vies 
smakende drank die in Afrika beschikbaar is. De bloedspiegels van 77 Oegandese kinderen 
werden onderzocht en vergeleken. De lopinavir/ritonavir concentraties in het bloed van de 
kinderen die de korreltjes kregen bleken over het algemeen goed overeen te komen met de 
bloedspiegels van de kinderen die de drank of de nieuwe kindertablet kregen. Bovendien 
hadden de jonge kinderen en hun ouders ook een voorkeur voor de korreltjes boven de 
drank. Bovendien bleken de huidige doseringsrichtlijnen voor lopinavir/ritonavir van de WHO 
goed voor het gebruik in deze Afrikaanse kinderen. Het is te hopen dat de lopinavir/ritonavir 
korreltjes snel op de markt beschikbaar komen.
In de discussie van Hoofdstuk 11 zijn de belangrijkste bevindingen in bovengenoemde 
onderzoeken besproken. Onderzoek van de farmacologie van HIV-remmers is erg belang-
rijk in de uitbreiding van HIV-behandelingen en de medische zorg  voor zwangere vrouwen 
en kinderen in ontwikkelingslanden. Niet alleen om goede resultaten uit deze onderzoeken 
te halen, maar ook om kennis van het doen van onderzoek over te brengen naar de 
Afrikaanse teams, zodat ze later zelfstandig onderzoeken kunnen uitvoeren. In de VITA-
onderzoeken bleek ook dat de samenwerking tussen verschillende Afrikaanse onderzoeks-
groepen erg waardevol was. Hierdoor hebben we de VITA-onderzoeken tot een goed 
einde gebracht met mooie resultaten. Het is te hopen dat de HIV-behandelprogramma’s 
voor HIV-geïnfecteerde zwangere vrouwen zo goed en zo snel mogelijk wereldwijd worden 
uitgebreid voor de bescherming van de baby’s die nog geboren gaan worden.
Voor het verbeteren van de HIV-behandelingen voor HIV-geïnfecteerde kinderen in ont-
wikkelingslanden is het belangrijk dat er geschikte medicijnen voor kinderen beschikbaar 
komen. Daarbij moeten ook de doseringsrichtlijnen van de WHO goed geëvalueerd worden 
voor het gebruik van deze HIV-remmers voor kinderen. Daarnaast is het belangrijk dat 
de nieuwe geneesmiddelonderzoeken gedaan worden voor goedkope en tweedelijns 
(en derdelijns) HIV-remmers voor kinderen.
Meer dan 20 jaar geleden zette professor Chifumbe Chintu (één van de hoofdonder- 
zoekers van CHAPAS) samen met anderen een van de eerste samenwerkings- 
verbanden op tussen Afrika en voor het doen van onderzoek in kinderen met infectie- 
ziekten. Zij hadden een motto dat de belangrijkste conclusie van mijn proefschrift omvat: 
‘Holding hands together and moving forward in the fight against HIV/AIDS in Africa.’ 
‘De handen ineen slaan en vooruit gaan in de strijd tegen HIV/AIDS in Afrika.'
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Mijn Nijmeegse/Afrikaanse onderzoeksavontuur, dat begon in het najaar van 2008, loopt 
nu bijna ten einde. Ik kan wel zeggen dat het vijf bijzondere jaren waren, waarin ik veel, 
heel veel, heb geleerd, waarin ik nieuwe vrienden heb gemaakt, nieuwe werelddelen 
heb leren kennen en waarin ik ontzettend veel respect heb gekregen voor al die mensen 
die zich inzetten voor betere zorg en behandelingen voor die vreselijke ziekte HIV/AIDS.
Dit proefschrift is een resultaat van een succesvolle internationale samenwerking en was er 
niet geweest zonder de bijdrage van veel mensen. Ik wil graag bij enkelen van hen stilstaan. 
Mijn dank gaat allereerst uit naar alle kinderen en zwangere vrouwen, die zonder enig 
eigenbelang, trouw deelnamen en meewerkten aan de onderzoeken die in dit proef-
schrift zijn beschreven. Zonder hen waren deze onderzoeken onmogelijk geweest.
Professor David Burger, mijn promotor, beste David, mijn dank voor jou is werkelijk enorm 
groot. Jouw uitstekende begeleiding hebben me door lief en leed geholpen tijdens mijn 
promotietraject. Je agenda zit vaak boordevol, maar je maakt altijd tijd vrij als ik je nodig 
heb voor welke vraag dan ook. Dankjewel voor alles wat je me geleerd hebt de afgelopen 
jaren, voor al je geduld (dat ik soms behoorlijk op de proef heb gesteld), je betrokkenheid 
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